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 ABSTRACT 
The medical management of ulcerative colitis in children often requires 
aggressive pharmacological therapy or colonic resection. We hypothesized that synbiotic 
therapy, consisting of B. longum R0175 and inulin would improve symptoms and quality 
of life (QOL) in children diagnosed with ulcerative colitis.  
Consenting pediatric subjects (8-18 years; n = 9) with ulcerative colitis in 
remission were provided synbiotic therapy, (Probiotic: Bifidobacterium longum R0175 
2.0 x 1010 cfu/day; Prebiotic: 15 g/day of inulin) (n = 4) or placebo (maltodextrin + 
ascorbic acid capsule; 15 g/day of non-resistant maltodextrin) (n = 5) for ten months in a 
pilot study (Phase I). After ten months, the study was unblinded and synbiotic therapy 
was administered to eight pediatric subjects (Phase II). In attempt to increase sample 
size, three adult subjects with active UC were recruited and provided the synbiotic 
therapy (Phase III). In all phases of the research, QOL was measured using the Short 
Inflammatory Bowel Disease Questionnaire (SIBDQ). The SIBDQ was administered at 
baseline and every two months. Subjects kept a daily records of symptoms (stool 
consistency and frequency, presence of blood and mucous, presence of abdominal pain 
and overall feeling).   
Phase I QOL scores were significantly better for those receiving the synbiotic 
therapy versus the placebo (p = 0.014). Severe symptoms occurred in 60% of the control 
subjects, where as subjects receiving synbiotic therapy did not experience severe 
symptoms (p = 0.032). Phase II QOL scores were significantly better post-treatment 
with synbiotic therapy (p=0.034). One subject (steroid dependant) was able to wean off 
Prednisone® while receiving the synbiotic therapy; she remained in remission and was 
symptom free for over 26 months. In Phase III, synbiotic therapy did not induce 
remission in the adult subjects with active UC. No adverse effects were reported. 
Synbiotic therapy consisting of Bifidobacterium longum R0175 and inulin, when 
provided in addition to conventional treatment, appears to be a safe and effective 
strategy for managing pediatric ulcerative colitis in remission. Further clinical trials are 
warranted to confirm these preliminary results. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1 Background 
Ulcerative Colitis (UC) is an inflammatory bowel disease (IBD) characterized by 
intestinal inflammation and ulcerations within the mucosa of the colon (Friedman & 
Blumberg, 2005). The current hypothesis is that IBD is an inappropriate response to 
either the endogenous microbial flora within the intestine, with or without some 
component of autoimmunity (Friedman & Blumberg, 2005). Pathogenic bacteria have 
been suggested to evoke an inflammatory response in the gut mucosa (Cummings, 
McFarlane & McFarlane, 2003), that the mucosal immune system fails to control 
(Friedman & Blumberg, 2005). 
Children tend to have a high incidence of severe type of UC (Tomomosa et al., 
2004). The symptoms of UC are diarrhea, rectal bleeding, passage of mucus, tenesmus, 
abdominal pain, weight loss, lethargy and poor appetite (Wylie & Sarigol, 1998). 
 Synbiotic therapy is a novel treatment used to induce a favorable intestinal 
environment in the host (Gibson & Roberfroid, 1995) and aims to generate synergistic 
effects by combining prebiotic and probiotic treatments. Modulation of the bacteria in 
the colon, through the use of prebiotics and probiotics, may be useful in modifying the 
disease state (Furrie et al., 2005). Recent case reports have shown that synbiotic therapy 
significantly improved the intestinal bacteria (inducing domination of anaerobic bacteria 
and suppression of pathogenic bacteria), improved short chain fatty acids in the feces 
and improved nutritional status in seven patients with refractory enterocolitis (Kanamori 
et al., 2004). In a single short-term study, synbiotic therapy has been shown to improve 
inflammatory markers, reduce inflammation in the rectal mucosa and regenerate colonic 
epithelial tissue in patients with active UC (Furrie et al., 2005).  
 Hypotheses for the cause of the disease also center on initiation and perpetuation 
of mucosal damage by exogenous agents, such as bacterial sulfides (Roediger, Moore & 
Babidge, 1997). There is increasing evidence to suggest that hydrogen sulfide (H2S), 
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 produced by intestinal sulfate-reducing bacteria may be involved in the pathogenesis of 
chronic diseases such as UC (Roediger, Duncan, Kapaniris & Millard, 1993; Pitcher & 
Cummings, 1996). In vitro studies have demonstrated that when butyrate is selectively 
inhibited in the colonocytes by hydrogen sulfide, the colonocytes develop lesions that 
closely mirror biochemical lesions reported in UC (Roediger et al., 1993). High 
concentrations of hydrogen sulfide (Pitcher, Beatty & Cummings, 2000; Levine, Ellis, 
Furne, Springfield & Levitt, 1998) and sulfate reducing bacteria have been found in 
patients with active UC (Roediger et al., 1997). Patients with active UC have been found 
to have higher amounts of sulfate-reducing bacteria with clinically active disease 
compared with patients in remission (Ohge et al., 2005; Pitcher et al., 2000). Sulfate 
levels in western Canada are particularly high; out of 428 sampling locations across 
Alberta and Saskatchewan, 13% had sulfate concentrations of greater than 500 mg/L 
(Health Canada, 1994). 
 There is considerable evidence that inflammatory bowel disease (IBD) impairs 
health related quality of life (HRQOL) (Casellas, Lopez-Vivancos, Badia, Vilaseca, & 
Malagelada, 2001). Chronic gastrointestinal symptoms and required treatments of IBD 
impose psychological and social stresses on young patients. Response to treatment may 
not always mirror an improvement in well-being, thus there has been increasing 
emphasis on the assessment of HRQOL in patients with chronic diseases. The Short 
Inflammatory Bowel Disease Questionnaire (SIBDQ) has been developed and validated 
to assess HRQOL for patients with IBD (Irvine, Zhou, & Thompson, 1996; Jowett, Seal, 
Barton & Welfare, 2001). 
 
1.2 Purpose 
 Results of well-designed clinical trials indicate that probiotic or prebiotic therapy 
(used independently) may effectively maintain remission in UC (Haskey & Dahl, 2006). 
However, there is little evidence that examines the effect of synbiotic therapy in UC. 
Only one clinical has examined the effect of synbiotic therapy in adult patients with 
active UC (Furrie et al., 2005). To date, there have been no clinical trials that have 
examined the effect of synbiotic therapy in pediatric patients with UC.  
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 It is believed that supplementation with synbiotic therapy may be a safe and 
effective strategy to maintain remission in UC. Thus, it is necessary to evaluate the 
clinical efficacy and the effect on quality of life of synbiotic therapy (Probiotic: 
Bifidobacteria longum R0175; Prebiotic: inulin) in maintaining remission in UC 
patients. In addition, with the high levels of sulfate found in the water supply in 
Saskatchewan, there is value in examining whether low sulfate water will also benefit 
UC patients. 
 
1.3  Objectives  
 The objectives of the study are as follows: 
1. To determine if the consumption of inulin and Bifidobacterium longum 
R0175 will have an effect on quality of life and symptoms in subjects with 
UC. 
2. To determine if the consumption of the placebo will have an effect on 
quality of life and symptoms in subjects with UC. 
3. To compare the number of subjects experiencing a relapse of UC during 
the ten month period between the two treatment groups. 
4. To assess tolerance to the study medications (Bifidobacteria longum 
R0175 and inulin) and record adverse events. 
5. To assess compliance to the prescribed treatment protocol in the UC 
subjects. If compliance is an issue, possible solutions will be suggested. 
 
1.4  Hypotheses 
  The hypotheses of this study are as follows: 
1. Pediatric subjects with UC that are treated with the synbiotic therapy 
(Probiotic: Bifidobacteria longum R0175; Prebiotic: inulin) will 
experience improved of quality of life and reduced symptoms (abdominal 
pain, blood, mucous, stool frequency and stool consistency) compared to 
the pediatric subjects consuming the placebo.   
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 2. Pediatric subjects with UC that are treated with the synbiotic therapy 
will relapse less frequently than pediatric subjects with UC receiving the 
placebo. 
3. Synbiotic therapy will induce remission in both pediatric and adult 
subjects with active UC. 
 
1.5  Limitations 
 There are limitations associated with this clinical trial. The researchers did not 
feel it was ethical to pursue invasive medical procedures such as colonoscopy and 
biopsy in subjects of such a young age. Data collection was limited to non-invasive 
procedures such as self-reporting in the study diaries, thus endoscopic and histological 
findings were not collected. The data obtained from the study diaries was an expression 
of the subjects recording practices which may be inherently limited. The researchers did 
not examine the dietary habits of the subjects.  
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 CHAPTER 2 
LITERATURE REVIEW 
 
 
2.1 ULCERATIVE COLITIS 
2.1.1 Clinical Presentation 
 Ulcerative Colitis (UC) is one of two chronic inflammatory diseases of the 
gastrointestinal tract. In UC, the inflammatory response is limited to the mucosa and 
submucosa of the colon. It normally manifests in the rectum and spreads throughout the 
large intestine (Friedman & Blumberg, 2005). Symptoms of UC include diarrhea, rectal 
bleeding, passage of mucus, tenesmus, abdominal pain, weight loss, lethargy and poor 
appetite (Wylie & Sarigol, 1998). If UC is left untreated, it can lead to dehydration, 
malnutrition and anemia. Patients with UC may also present with extraintestinal 
manifestations, such as decreased linear growth velocity in pediatric patients, arthritis 
and skin lesions (Gremse & Crissinger, 2002). The severity of symptoms usually 
correlates with the severity of the disease.   
 
2.1.2 Epidemiology  
 There are a number of studies that describe the incidence of IBD in the world. 
The highest incidence rates for IBD have been reported in Northern Europe, the United 
Kingdom and North America (Loftus, 2004). However, incidence rates are increasing in 
other areas of the world.   
 Bernstein et al. (2006) recently studied the epidemiology of IBD in Canada. 
Bernstein et al. (2006) estimated that in the year 2000, approximately 81,000 Canadians 
were living with UC. The estimated incidence rate was 11.8/100,000 person-years and 
the prevalence was 194/100,000 for the adult population. The peak age of onset in the  
adult population is usually during the second and third decades of life. There are no 
differences in incidence for gender. There appears to be a difference in incidence rates of 
UC between urban and rural dwellers across Canada with a total urban: rural incidence 
rate ratio of 1.13 (Bernstein et al., 2006).  
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  Bernstein et al. (2006) reported that the incidence of pediatric UC is highest in 
Nova Scotia (5.7) and lowest in British Columbia (3.2). The incidence rate is higher for 
girls than boys (3.6). The prevalence of pediatric UC is highest in Alberta (30.7) and 
lowest in British Columbia (17.5). The incidence of pediatric UC in Saskatchewan was 
4.2/100,000 person-years and prevalence was 18.1/100,000. The age of onset of UC in 
pediatric patients is usually in late adolescence (Gremse & Crissinger, 2002). 
 
2.1.3 Etiology and Pathogenesis  
 The etiology and pathogenesis of UC is unknown (Chudleigh & Hunter, 2003; 
Gremse & Crissinger, 2002). The current hypothesis is that IBD is an inappropriate 
response to either the endogenous microbial flora within the intestine, with or without 
some component of autoimmunity (Friedman & Blumberg, 2005). It is believed that 
patients with IBD suffer from dysbiosis (Penner & Fedorak, 2005). Dysbiosis describes 
the abnormalities in intestinal bacterial content and host-bacterial interaction.  
 Current research is suggesting that IBD may also have an infectious etiology. 
Pathogenic bacteria may evoke an inflammatory response in the gut mucosa 
(Cummings, Macfarlane & Macfarlane, 2003), that the mucosal immune system fails to 
control (Friedman & Blumberg, 2005). The pathogenic bacteria involved in this process 
include species belonging to the genera Yersinia, Shigella, Salmonella, Campylobacter, 
Clostridium, Aeromonas and pathogenic Escherichia coli (Cummings et al., 2003; 
Steidler, 2001). These organisms are able to either penetrate the gut epithelium or 
proliferate the epithelial surface evoking the inflammatory response (Cummings et al., 
2003). 
 
2.1.4 Diagnostic Evaluation  
Combinations of laboratory, radiographic and endoscopic tests are used in the 
diagnosis of UC. Diagnostic tests for UC provide the evidence to confirm the diagnosis 
of UC and to rule out other gastrointestinal conditions that mirror UC.   
 Initial investigations in a patient with symptoms of UC involve excluding 
enteric infection through examination of the stool for bacterial and viral pathogens (e.g., 
Salmonella, Shigella, Campylobacter, Aeromonas, Plesiomonas, Yersinia, Escherichia 
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 coli 0157:H7, Clostridium Difficile or Entamoeba histolytica) (Bremner, Griffiths & 
Beattie, 2004; Chudleigh & Hunter, 2003). The symptoms of bacterial and parasitic 
gastroenteritis are very similar to those of UC (Chudleigh & Hunter, 2003).  
Routine laboratory investigations include complete blood count, serum chemistry 
profile (e.g., electrolytes, blood urea nitrogen, creatinine, albumin and liver enzymes), 
iron status and inflammatory markers (e.g., C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR), IgG and IgA antibodies) (Bremner, Griffiths & Beattie, 2004). 
Hypoalbuminemia, anemia, elevated CRP, elevated ESR, leukocytosis and 
thrombocytosis are often present in UC (Chudleigh & Hunter, 2003). Electrolyte 
disturbances are common when severe diarrhea is present. Iron-deficiency is associated 
with the loss of blood through stools.
Endoscopy is indicated in all cases of UC for diagnosis and to assess disease 
extent (Bremner, Griffiths & Beattie, 2004; Chudleigh & Hunter, 2003). Often distal 
gastrointestinal tract findings may be indistinguishable in UC and Crohn’s disease; 
therefore diagnostic testing of pediatric IBD includes evaluation of the proximal 
gastrointestinal tract with radiographs, small bowel follow through and 
esophagogastroduodenoscopy (Chudleigh & Hunter, 2003). The addition of proximal 
gastrointestinal endoscopy with biopsy improves the diagnostic accuracy. Crohn’s 
disease tends to involve the entire gastrointestinal tract and extends into the intestinal 
wall from the mucosa to the serosa. Histology is required to confirm the diagnosis and 
distinguish UC from Crohn’s disease and other gastrointestinal conditions (Bremner, 
Griffiths & Beatty, 2004). 
 
2.1.5 Measurements of Disease Activity in UC 
 Disease severity is assessed using symptomology, laboratory investigations and 
endoscopy. Multiple disease activity indices for UC have been devised, but none have 
been rigorously validated (Higgins, Schwartz, Mapili, & Zimmermann, 2005). Most 
clinical trials use multiple disease activity indices since there is no clear gold standard 
(Higgins, Schwartz, Mapili, & Krokos, et al., 2005). The medical management of UC is 
based on disease severity. 
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2.1.5.1 Truelove and Witts Classification of UC 
Truelove and Witts (1955) were the first to classify UC patients into three 
categories, those with mild, moderately and severe disease (Table 2.1). 
   
   Table 2.1 Truelove and Witts Classification of UC 
Disease Severity Symptoms 
Mild < 4 bowel movements/day 
Passage of blood in stool less than daily 
No systemic symptoms 
Moderate > 5 bowel movements/day with blood present 
Tenesmus, colicky pain, malaise 
Low grade or intermittent fever 
Abdominal tenderness in left lower quadrant 
Anemia, hypoalbuminemia, fecal leukocytes 
Severe > 6 bowel movements/day with blood present 
Abdominal tenderness, tachycardia 
Fever, weight loss, hypoalbuminemia 
    Adapted from Truelove SS, Witts LI. (1955). BMJ 2, 1041. 
  
 
 2.1.5.2 Powell-Tuck Activity Score 
 Powell-Tuck et al. (1978) developed the Powell-Tuck Activity Score for clinical 
trials of corticosteroid treatment to include a wider range of symptoms than Truelove 
and Witts classification of UC. The Powell-Tuck Activity Score includes endoscopy, a 
general health question and examination for abdominal tenderness (Table 2.2). A score 
of < 3.5 indicates that the patient is in remission (Higgins et al., 2005). The Powell-Tuck 
Activity Score is widely used but has never been validated (Higgins, Schwartz, Mapili & 
Krokos, et al., 2005). 
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      Table 2.2 Scoring System for the Powell-Tuck Activity Score 
Symptom Score 
Bowel frequency (day)  
   3-6 
   >6 
Stool consistency 
   formed 
   semi-formed 
   liquid 
Abdominal pain 
   before/after BM 
   prolonged 
Anorexia 
Nausea/Vomiting 
General Health 
   normal 
   slightly impaired 
   activities restricted 
   unable to work 
Extracolonic manifestations 
   one/mild 
   more than one/severe 
Abdominal tenderness 
   mild 
   marked 
   rebound 
Body temperature 
   <37.1 
   37.1-38 
   >38 
Blood in stool 
    trace 
    more than trace 
Sigmoidoscopy 
    non-hemorrhagic 
    friable 
   spontaneous bleed 
 
1 
2 
 
0 
1 
2 
 
1 
2 
1 
1 
 
0 
1 
2 
3 
 
1 
2 
 
1 
2 
3 
 
0 
1 
2 
 
1 
2 
 
0 
1 
2 
 
2.1.5.3 Ulcerative Colitis Disease Activity Index (UCDAI) 
 Sutherland et al. (1987) developed the UCDAI (Table 2.3). The UCDAI score is 
the sum score of four parameters, each scoring between 0 and 3, making 12 the worst 
score. According to the sum score, UC activity is classified as follows: sum score 0–2 
(no activity); 3–5 (mild activity); 6–8 (moderate activity); 9–12 (severe activity). A score 
of <2.5 indicates the patient is in remission (Higgins, Schwartz, Mapili & Krokos, et al., 
2005). 
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 Table 2.3 Ulcerative Colitis Disease Activity Index 
Variable Score 
Stool frequency (day) 
   normal 
   1-2 stools/day > normal 
   3-4 stools/day > normal 
    >4 stools/day > normal 
Rectal bleeding 
   none 
   streaks of blood 
   obvious blood 
   mostly blood 
Mucosal appearance 
   normal 
   mild friability 
   moderate friability 
   exudation, spontaneous bleeding 
Physician’s rating of the disease 
    normal 
    mild 
    moderate 
    severe 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
0 
1 
2 
3 
 
 
2.1.5.4 Seo index 
 In 1992, Seo et al. developed a numerical disease activity index for UC to 
correlate with Truelove and Witts’ classification (Table 2.4). The activity index (AI) is 
expressed as follows: AI = 60 x blood stool + 13 x bowel movements + 0.5 x ESR - 4 x 
Hb - 15 x albumin + 200. Index values below 150, values between 150 and 220, and 
values above 220 nearly corresponded to mild, moderate, and severe disease, 
respectively, in Truelove and Witts' classification. A score of <120 indicates the patient 
is in remission (Higgins, Schwartz, Mapili & Krokos, et al., 2005). 
 
 
 
 
 
 
 
 10
  
Table 2.4 Seo Activity Index 
Variable  Score Weighting 
Bloody stool 
Little or none 
Present 
Bowel movements/day 
≤ 4 
5-7 
≥ 8 
Erythrocyte sedimentation rate (mm/h) 
Hemoglobin (g/dl) 
Albumin (g/dl) 
Constant 
 
0 
1 
 
1 
2 
3 
 
 
x 60 
 
 
x 13 
 
 
 
x 0.5 
 
x - 4 
x -15 
200 
   
 
 2.1.5.5 Simple Clinical Colitis Activity Index (SCCAI) 
 Walmsley et al. (1998) developed the SCCAI, a survey of six questions that 
assesses the symptoms of UC (Table 2.5). Laboratory values and endoscopy are not 
always available for immediate evaluation; therefore the intent was to develop an index 
that could be scored immediately without the use of laboratory indices. The SCCAI has 
been validated against an established activity index (e.g., Powell-Tuck). The SCCAI is 
designed to be used as an initial assessment of outpatients, by non-specialist physicians 
and by patients themselves as guide to modify treatment or the need to seek further 
advice (Walmsley et al., 1998). A score of <2.5 indicates the patient is in remission 
(Higgins, Schwartz, Mapili & Krokos, et al., 2005). 
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 Table 2.5 Clinical Scoring System for the SCCAI 
Symptom Score 
Bowel frequency (day) 
   1-3 
   4-6 
   7-9 
   >9 
Bowel frequency (night) 
  1-3 
  4-6 
Urgency of defecation 
  Hurry 
  Immediately 
  Incontinence 
Blood in stool 
  Trace 
  Occasionally frank 
  Usually frank 
General Well Being 
  Very well 
  Slightly below par 
  Poor  
  Very poor 
  Terrible 
Extracolonic features 
 
0 
1 
2 
3 
 
1 
2 
 
1 
2 
3 
 
1 
2 
3 
 
0 
1 
2 
3 
4 
1 point per manifestation 
 
2.1.6 Current Medical Management of Ulcerative Colitis in Children  
Children with UC have a high incidence of severe type illness and even when it 
occurs mildly, it often progresses to one of the more severe forms of colitis (Tomomasa 
et al., 2004). In a review of 171 children, 43 percent had mild disease, 57 percent had 
disease that was moderate or severe (Hyams, 1994). Children require individualized 
treatment that takes numerous factors into account: the specific disease manifestations 
(e.g., location of inflammation in the intestines, duration, and prior response to therapy), 
the psychosocial adaptation of the child and family, and the child's age and size (Crohn’s 
and Colitis Foundation of America, 2006). Children are in a period of rapid growth, 
therefore long term treatment with steroids may inhibit growth and should be avoided as 
much as possible (Tomomasa et al., 2004). Children are also moving through a period of 
emotional development, therefore quality of life must also be carefully evaluated 
(Tomomasa et al., 2004; Bremner, Griffiths, & Beattie, 2004). In addition to 
pharmacological therapy, the consequences of UC on peer and family relationships, 
school attendance and emotional well-being should be included as part of the 
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 comprehensive management of this disorder (Chudleigh & Hunter, 2003). Since the 
etiology of UC is unknown, the goals of medical therapy in pediatric UC patients are to 
control symptoms, prevent relapses, maintain growth and promote pubertal development 
(Tomomasa et al., 2004; Chudleigh & Hunter, 2003). 
 The treatment approaches for children with UC are based on adult experience 
(Crohn’s and Colitis Foundation of America, 2006). Pharmacological therapy for UC 
involves suppression of the inflammatory processes in order to control symptoms and 
prevent relapses (Chudleigh & Hunter, 2003). The type of pharmacological agent used is 
determined by the severity of the disease and response to treatment (Chudleigh & 
Hunter, 2003). 5-Aminosalicylates (5-ASA) preparations, such as Sulfasalazine® and 
mesalamine are used to induce and maintain remission in pediatric UC patients, but 
corticosteroids such as Prednisone® are often prescribed in conjunction with 5-ASA 
compounds for patients with moderate to severe colitis (Chudleigh & Hunter, 2003). 
Corticosteroids are most effective in the treatment of active UC versus UC in remission 
(Steidler, 2001; Wyllie & Sarigol, 1998). Pediatric patients that do not respond to 5-
ASA and corticosteroids may be effectively treated with immunomodulatory therapy 
such as aziathioprine, mercaptopurine, methotrexate, cyclosporine or tacrolimus 
(Tomomasa et al., 2004; Chudleigh & Hunter, 2003). The pharmacological agents 
described have a number of side effects such as growth suppression, hypertension, 
decreased bone mineral density, cataracts, glaucoma, hyperglycemia, bone marrow 
suppression, increased risk of infection and increased risk for certain cancers (Wyllie & 
Sarigol, 1998). Unfortunately, pediatric patients with the more severe forms of UC often 
will have chronic intermittent symptoms and some will have continuous symptoms 
despite being in remission (Hyams et al., 1996). 
 Colonoscopy during follow-up can determine disease progression and assess 
response to treatment (Bremner, Griffiths & Beatty, 2004). It is used in children that 
have UC that is difficult to treat, as repeat endoscopy can help determine the subsequent 
treatment choice (Bremner, Griffiths & Beatty, 2004). If there is disease progression 
with the initial therapy, treatment can then be intensified. 
 A colectomy is used for patients where pharmacologic therapies have been 
unsuccessful or the unacceptable side effects of medications must be avoided. The 
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 primary benefit of a colectomy is the control of symptoms without the use of 
medications (Chudleigh & Hunter, 2003). A colectomy is curative for UC, although the 
postoperative complications can be problematic (Bremner et al., 2004). The most 
common complication of a colectomy is pouchitis, a non specific inflammation of the 
ileal reservoir (Mahadevan & Sandborn, 2003). Despite the complications associated 
with a colectomy, almost all children with severe UC report improved quality of life 
after colectomy (Tomomasa et al., 2004). 
  
2.1.7 Current Nutrition Management of Ulcerative Colitis in Children 
 Nutrition therapy plays an adjunctive role in the medical management of 
pediatric UC, as the success of nutrition as a primary therapy is limited (Kelly, 1999). 
The goals of nutrition therapy for pediatric UC are to correct specific nutrient 
deficiencies and prevent growth failure (Chudleigh & Hunter, 2003). The provision of 
adequate nutrition is essential to promotion of optimal healing.   
 In UC, undernutrition is often caused by a reduced intake of calories and protein, 
altered taste sensation, either from side-effects from medication, nutrient deficiencies or 
sitophobia in patients who associate food intake with diarrhea or abdominal pain 
(Oviedo & Farraye, 2001). Weight loss has been reported to be as high as 60% to 75% in 
patients with UC (Kelly, 1999). Iron deficiency anemia occurring from blood loss is 
reported in about 80% of UC patients (Kelly, 1999). Medications used in the therapy for 
UC are associated with the development of nutritional deficiencies (Oviedo & Farraye, 
2001). Sulfasalazine® contributes to folate malabsorption and corticosteroids suppress 
intestinal absorption of calcium.   
 Current practice recommends a daily multivitamin supplement, as well as folic 
acid supplementation (1 mg/day) in all patients with UC (Oviedo & Farraye, 2001). 
Adequate dietary calcium is encouraged. In patients with limited dietary intake of 
calcium, a calcium supplement is recommended. A vitamin D supplement at a minimum 
dose of 400 IU/day is suggested (Oviedo & Farraye, 2001). Oral nutrition supplements 
are often prescribed to assist patients in meeting protein and caloric needs. Nutrition 
support may be necessary for patients who cannot voluntarily increase their intake and 
who are unable to meet their nutrition requirements via oral intake. 
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  There is no specific diet for the prevention or management of UC at this time 
(Oviedo & Farraye, 2001). Individuals with UC are instructed to find out their tolerance 
to foods on a trial-and-error basis (Oviedo & Farraye, 2001). Enteral or parenteral 
therapy, in addition to corticosteroid therapy, does not appear to increase the remission 
rate or reduce the need for a colectomy in UC patients (Kelly, 1999; Chudleigh & 
Hunter, 2003). However, in growing children, treatment with nocturnal enteral feeding 
has been successful in circumventing weight loss and correcting body composition 
(Kelly, 1999). Exclusion diets do not prevent or induce remission in patients with UC 
(Oviedo & Farraye, 2001). At the present time, a low fibre diet is prescribed during 
periods of active inflammation. A high fibre diet, including sources of insoluble and 
soluble fibre may be prescribed during periods of remission (Gremse & Crissinger, 
2002).     
 
 
2.2 HEALTH RELATED QUALITY OF LIFE (HRQOL) 
2.2.1 Definition of Health Related Quality of Life 
Health related quality of life (HRQOL) has been defined as the functional effect 
of an illness and its consequent therapy upon a patient, as perceived by the patient 
(Schipper, Clinch & Olweny, 1996). Health status of patients with chronic disease 
should not only include assessment of disease activity, but should also investigate the 
psychological state, cultural influences, degree of social support, effects of  disease 
complications, previous surgery, and medication (Garrett, & Drossman, 1990). Changes 
induced by chronic diseases in different aspects of patients’ lives are reflected in 
impairment in HRQOL (Alcala, Casellas, Fontanet, Prieto & Malagelada, 2004).   
HRQOL is a term applied to a wide spectrum of both intangible and tangible 
parameters of perception and function in the physical, social and emotional domains 
(Irvine, 1993). The domains may range from negatively valued aspects of life, including 
death, to the more positively valued aspects of life such as happiness (Guyatt, Feeny & 
Patrick, 1993). Thus, patient perception of HRQOL is increasingly acknowledged to be a 
critical component in patient care (Alcala et al., 2004). UC, like many other chronic 
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 diseases, significantly impairs HRQOL. During relapses, the perception of health is 
markedly impaired for all dimensions of HRQOL (Casellas et al., 2001).  
 
2.2.2 Importance of Measuring HRQOL 
Traditional medical management and follow-up of patients with UC is based on 
clinical symptoms, laboratory tests, endoscopic and histological findings (Martin, Leone, 
Fries & Naccarato, 1995). These findings fail to recognize the subjective experiences of 
the patients. In UC, HRQOL has been found to be significantly altered not only when 
the disease is active but even when it is in clinical remission and laboratory and 
endoscopic findings are essentially normal (Martin et al., 1995). 
Clinicians and policymakers are recognizing the importance of measuring 
HRQOL in clinical medicine and research (Guyatt et al., 1993). Measurement of 
HRQOL can facilitate identification of patient needs, such as the necessity for psycho-
social support (Irvine, 1993; Martin et al., 1995). HRQOL instruments can be used to 
detect subtle differences in disease states (Irvine, 1993). For example, Jowett et al. 
(2001) established that the Short Inflammatory Bowel Disease Questionnaire (a HRQOL 
tool) was able to detect clinically important changes in disease activity in patients living 
with IBD. HRQOL tools can be used in clinical research to assess outcomes, for 
example assessing new drugs (versus placebo) or different choices of drugs (Levine, 
1993). HRQOL is recommended to be a required secondary outcome measure in clinical 
trials involving IBD (Sandborn et al., 2002). Finally, assessment of HRQOL provides a 
more in depth perspective of a patient’s total health status and may offer important 
information to the clinician that may have otherwise been overlooked by traditional 
measures (Hjortswang et al., 2003). Measurement of HRQOL ultimately leads to 
improved patient care. 
 2.2.2.1 HRQOL in Childhood and Adolescence  
 Measurement of HRQOL is more difficult in children and adolescents than in 
adults as physical, emotional and intellectual functions are constantly changing with 
normal development. Chronic and unpredictable gastrointestinal symptoms and required 
treatments impose psychological and social stresses on young patients (Griffiths et al., 
1999). Teenagers affected by growth stunting and delayed physical maturation are at 
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 increased risk for psychosocial trauma and social isolation (Griffiths et al., 1999). IBD 
triggers emotional responses such as unfairness and frustration, and children with UC 
report anger and embarrassment related to the disease (Griffiths et al., 1999). IBD has a 
major impact on HRQOL in both children and adolescents and is a crucial component of 
monitoring the impact chronic disease has on a child’s overall well-being. 
  
2.2.3 Validated Tools for Measuring HRQOL in UC 
 Several tools have been designed to measure HRQOL in UC, with most tools 
being subjective and quantitative (Levine, 1993). The most widely used and 
internationally accepted HRQOL questionnaires for use in IBD are the Inflammatory 
Bowel Disease Questionnaire (IBDQ), Short Inflammatory Bowel Disease 
Questionnaire (SIBDQ), the Rating Form of Inflammatory Bowel Disease Patient 
Concerns (RFIPC) and Short Form General Health Survey (SF-36). IMPACT is a newly 
developed HRQOL questionnaire designed for use in children with IBD. 
 2.2.3.1 Inflammatory Bowel Disease Questionnaire  
 The IBDQ is a 32 item questionnaire that evaluates bowel symptoms, social 
functions, worries and concerns related to IBD (Guyatt et al., 1989). Reponses are 
graded on a seven point Likert scale, ranging from one (represents the “worst” aspect) to 
seven (representing the “best” aspect). The sum score is the total of the individual scores 
and ranges from 32 to 224, with the lowest score representing the poorest quality of life. 
The 32 questions are divided into four domains: bowel symptoms (10 questions), 
systemic responses (5 questions), emotional functions (12 questions) and social 
functions (5 questions). The IBDQ has been translated and validated into other 
languages such as Dutch, Swedish, English, Greek, Chinese, Korean and Spanish 
(Russel, 1997; Hjortswang et al., 2001; Cheung, Garratt, Russell & Williams, 2000; 
Pallis, Vlachonikolis & Mouzas, 2001; Leong et al., 2003; Kim et al., 1999; Lopez-
Vivancos, Casellas, Badia, Vilaseca & Malagelada, 1999). The main drawback of the 
IBDQ is that it is very time consuming for practitioners to administer and interpret 
(Cassellas et al., 2004). The IBDQ is the most widely used tool to measure HRQOL in 
IBD and has repeatedly been validated in multiple settings, and it has become the gold 
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 standard for measurement of quality of life in UC (Higgins, Schwartz, Mapili & 
Zimmerman, 2005). 
 2.2.3.2 Short Inflammatory Bowel Disease Questionnaire  
 Irvine et al. (1996) developed a shortened version of the IBDQ which is called 
the SIBDQ (Appendix 5). The SIBDQ uses ten questions derived from the IBDQ. The 
ten questions are divided into four domains: bowel symptoms (3 questions), systemic 
responses (2 questions), emotional functions (3 questions) and social functions (2 
questions). Reponses are graded on a seven point Likert scale as described for the IBDQ. 
The total score ranges from 10 (worst health) to 70 (best health). The SIBDQ has been 
validated in UC (Irvine et al., 1996; Jowett et al., 2001). It is able to discriminate 
between both active and inactive disease (Irvine et al., 1996), as well as differentiate 
between different classes of disease activity (i.e., remission versus mild relapse) (Jowett 
et al., 2001). The SIBDQ is reproducible and consistent in a test-retest situation when 
the clinical situation remains changed, and is sensitive enough to respond to changes in 
disease activity for an individual (Jowett et al., 2001). Jowett et al. (2001) were able to 
demonstrate that a mean decrease of 11.8 points occurred for an individual when disease 
activity changed from remission to mild relapse or mild to moderate relapse. The 
SIBDQ is administered and scored quickly; therefore, it is ideal for use in clinical 
practice and in the research setting (Irvine et al., 1996). 
2.2.3.3 Rating Form of Inflammatory Bowel Disease Patient Concerns  
 Drossman et al. (1991) developed the Rating Form of Inflammatory Bowel 
Disease Patient Concerns (RFIPC) to evaluate the worries and concerns associated with 
IBD. The RFIPC is a self administered questionnaire containing 25 items of concern to 
IBD patients. It takes the form of ‘Because of your condition, how concerned are you 
with …?’. Each item is ranked from 0 to 100 (0= not at all, 100 = a great deal), on a 
visual analogue scale. The total score is calculated as an average of all concerns. The 
RFIPC has been validated for use in clinical care, as well as in research to evaluate the 
effects of interventions on IBD outcome.  
 2.2.3.4 Short Form General Health Survey  
 The SF-36 is a self-administered, widely used multipurpose survey of general 
health status developed by Ware and Sherbourne (1992). SF-36 is a 36 item health 
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 survey that consists of multi-item scales touching on eight aspects of health: physical 
functioning, role limitations due to physical health, bodily pain, general health, vitality, 
social functioning, limitations due to emotional problems and mental health (Ware & 
Sherbourne, 1992). For each question, raw scores are coded, summed and transformed 
into a scale ranging from 0 to 100 with higher scores representing better health states. It 
is has been shown to be reliable and valid in surveying HRQOL in patients with a 
variety of chronic diseases (McHorney, Ware & Raczek, 1993). SF-36 has been widely 
used in studies examining HRQOL in IBD patients. 
 2.2.3.5 IMPACT 
 IMPACT is described as a “disease specific HRQOL questionnaire developed for 
use in pediatric IBD” (Otley et al., 2002). The questionnaire is targeted to children and 
adolescents with IBD between the ages of 10 to 17 years. IMPACT is a self-
administered questionnaire that includes 36 questions encompassing six domains: bowel 
(6 concerns), body image (3 concerns), functional/social impairment (11 concerns), 
emotional impairment (11 concerns), tests/treatments (3 concerns) and systemic 
impairment (2 concerns) (Otley et al., 2002). A visual analogue scale is used for 
responses. A horizontal line is anchored by a range from worst (0 cm) to best function 
(10 cm) and patients are asked to mark where their feelings lie in response to each 
question. Each mark is measured and multiplied by .7 to give a maximal score of 7 per 
question, so the scores range from 0 to 231 with lower scores representing poor quality 
of life. IMPACT is designed as a descriptive tool to facilitate recognition of emotional 
and functional disability (Otley et al., 2002). This tool is also described as an evaluative 
tool that can be incorporated into clinical trials (Otley et al., 2002). Otley et al. (2002) 
reported that IMPACT is a valid and reliable reflection of HRQOL in older children 
(ages 10-17 years) with IBD.  
 IMPACT is a relatively new questionnaire available to researchers and clinicians. 
The first reported use of IMPACT in a clinical trial was in 2005 when Shepanski et al. 
studied the HRQOL in children and adolescents with IBD after attending a summer 
camp. Otley et al. (2006) used IMPACT to assess pediatric HRQOL during the first year 
after diagnosis. 
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 2.3 ORIGIN OF THE INTESTINAL MICROFLORA 
2.3.1 Development of Healthy Microflora 
The development of the human intestinal microflora is a complicated process 
involving the microflora of the parent and the infant’s immediate environment. The 
human fetus is sterile in utero, but during and after the birth process, the fetus is exposed 
to a variety of different species of microbes (Mackie, Sghir & Gaskins, 1999). It is well 
established that the type of birth delivery has a significant impact on the development of 
the intestinal microflora (Mackie, Sghir & Gaskins, 1999). Other factors that may 
contribute to the composition of the intestinal microflora are mother’s dietary intake or 
probiotic use, gestational age, primary source of nutrition (bottle or breast-fed), neonatal 
health, immunological status, gastrointestinal transit time, pH and stress (Kopp-
Hoolihan, 2001). 
 Dramatic differences have been noted in the microflora of infants born vaginally 
versus by Caesarean section. The newborn born vaginally first comes into with 
microflora in the birth canal. Studies have demonstrated that the gastric contents of 
newborns are very similar to that of the mother’s cervix (Brook, Barett, Brinkman, 
Martin & Finegold, 1979), implying that the mother’s microflora is passed to the infant. 
The microflora of infants born via Caesarean section is believed to be the result of 
exposure to environmental exposures from obstetrical equipment, air, hospital staff and 
other infants in the nursery (Lennox -King, O’Farrell, Bettelheim & Shooter, 1976). 
After birth, environmental, cutaneous and oral microbes will be passed from the mother 
to the infant through kissing, caressing and suckling (Mackie, Sghir & Gaskins, 1999). 
 Feeding practices have an impact on the composition of the intestinal microflora. 
The dominate organisms of formula fed infants are the Enterobacter species, where as 
the microflora of breast-fed infants is predominately Bifidobacteria (Mackie, Sghir & 
Gaskins, 1999). These differences are believed to be due to components in human milk 
(e.g., human milk oligosaccharides) that is currently not replicated in infant formulas 
(Mountzouris & Gibson, 2003). Following weaning and introduction of solids, the 
number and diversity of obligate anaerobes increases (Mackie, Sghir & Gaskins, 1999). 
By 24 months, the fecal microflora resembles that of an adult (Stark & Lee, 1982). Once 
the microflora is established, it is stable throughout life and it difficult to change 
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 permanently. It continues to be manipulated throughout life for short periods of time 
through a variety of factors such as the environment, diet (prebiotics and probiotics), 
antibiotic therapy and gastrointestinal illness.  
 
2.3.2 Microflora and Gastrointestinal Health 
The intestinal microflora plays a crucial role in the gastrointestinal health of the 
host, which may be both beneficial and harmful to health. For example, specific strains 
of the healthy gut microflora, such as Bifidobacterium and Lactobacillus species have 
anti-inflammatory capabilities that prevent the colonization of the intestine by 
pathogenic strains of bacteria which are beneficial to health. Pathogenic bacteria (e.g., 
Clostridium difficile) may invade the intestinal microflora causing gastrointestinal illness 
which is harmful to health. The concept of manipulating the gastrointestinal microflora 
to prevent or treat illness is currently being promoted. Temporary alterations of the 
gastrointestinal flora can be achieved through the addition of prebiotics and probiotics in 
the diet. The addition of probiotics to dairy products and prebiotics to various food 
sources are just some examples. 
 
2.4 PREBIOTICS  
2.4.1 Definition 
 Prebiotics are defined as non-digestible food ingredients (dietary fibre) that 
beneficially affect the host by selectively stimulating the growth and/or activity of one of 
more limited number of bacteria in the colon and thus improve host health (Gibson & 
Roberfroid, 1995). For a food ingredient to be considered a prebiotic, it must meet 
several criteria. These criteria include: it must neither be hydrolyzed, nor absorbed in the 
upper part of the gastrointestinal tract; be selectively fermented by one or a limited 
number of potentially beneficial bacteria in the intestine; and is able to alter the colonic 
microflora towards a healthier composition (Gibson & Roberfroid, 1995).   
   
2.4.2 Types of Prebiotics 
 All prebiotics are described as short-chain carbohydrates with a degree of 
polymerization (DP) of between 2 and 60 units and are not digested by human or animal 
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 digestive enzymes (Roberfroid, 2002). They are classified as dietary fibre and are widely 
used in a variety of food products. Lactulose, oligofructose (FOS), galacto-
oligosaccharides, inulin, psyllium and germinated barley foodstuff are examples of 
prebiotics that have been demonstrated to selectively foster the growth of the 
Bifidobacterium and Lactobacillus species in the colons of healthy subjects (Kanauchi, 
Mitsuyama, Araki & Andoh, 2003). Prebiotics have also been shown to stimulate the 
production of lactate and short chain fatty acids (SCFA's), acetate, propionate and 
butyrate as end products of prebiotic fermentation (Delzenne, 2003). Recent data 
obtained from FOS intake indicate that the dose and duration of intake, the place where 
fermentation occurs (proximal or distal colon), are important factors influencing the 
prebiotic effect – namely the increase in Bifidobacteria (Delzenne, 2003).   
 
2.4.3 Inulin and Fructooligosaccharides (FOS) 
 The most well studied prebiotics are inulin and FOS. Inulin is a term applied to a 
heterogeneous blend of fructose polymers found widely distributed in nature as plant 
storage carbohydrates (Niness, 1999). A product with a DP from 2 to ≥60 is labelled as 
inulin (Roberfroid, 2001). Oligofructose or FOS is a subgroup of inulin, consisting of 
polymers with a DP of ≤10 units.   
 Inulin and FOS are present as plant storage carbohydrates in fruit and vegetables 
such as wheat, onion, banana, garlic, chicory, endive, Jerusalem artichoke and leek (Van 
Loo, Coussement, De Leenheer, Hoebregs & Smits, 1995). Human milk contains 
approximately 5-10 g/L of oligosaccharides (Bode, 2006). The inulin commercially 
available is synthesized from chicory root. The average daily consumption of inulin and 
FOS in Europe ranges between 3-11 g/day and 3-10 g/day in the American diet (Van 
Loo et al., 1995).   
 2.4.3.1 Chemical Structure of Inulin and FOS 
 Inulin is not simply one molecule; it is a polydisperse of ß (2-1) linkages (Phelps, 
1965). The fructose units in the mixture of linear fructose polymers and oligomers are 
each linked by ß (2-1) bonds. The ß (2-1) bonds give inulin and FOS unique properties. 
These linkages prevent inulin from being digested like a typical carbohydrate and are 
 22
 responsible for it reduced caloric value and dietary fibre effects (Niness, 1999). Figure 
2.1 shows an example of the chemical structure of inulin (Stevens, 2006). 
 
Figure 2.1 Chemical Structure of Inulin (Stevens, 2006) 
 
  
 2.4.3.2   Functional Properties of Inulin and FOS 
 The differences in chain length between inulin and oligosaccharides account for 
their distinct differences in functional properties. Inulin has a longer chain length than 
FOS; therefore inulin can form microcrystals when sheared in water or milk. These 
crystals create a smooth creamy texture and provide a fat-like mouth feel. Because of 
these characteristics, inulin has been used a fat-replacement in baked goods, fillings, 
dairy products, frozen desserts and dressings (Niness, 1999).   
 FOS is composed of short chain oligomers and possesses functional properties 
similar to sugar or glucose syrup. FOS acts in much the same way sugar does in baked 
goods, but it has fewer calories and enriches the product with fibre. FOS contributes 
body to dairy products, depresses the freezing point in frozen desserts, provides 
crispness to low-fat cookies and acts as a binder in granola bars (Niness, 1999). FOS is 
often added to yogurt to capitalize on the prebiotic effect, which may serve to enhance 
the action of the probiotic cultures typically added to yogurt (Niness, 1999).  
 Both inulin and FOS are used worldwide to add fibre to food products (Niness, 
1999). Unlike other fibre, they add no “off flavours” and do not increase viscosity of the 
food product. These properties allow the formulation of high fibre foods that look and 
taste like standard food formulations. 
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  2.4.3.3   Nutritional Properties of Inulin and FOS 
 Inulin has been used in other countries to replace fat, sugar and calories in food 
products such as ice cream, dairy products, candy and baked goods. Inulin has a lower 
caloric value as compared to other forms of carbohydrates due to the ß (2-1) linkages 
(Niness, 1999). The ß (2-1) bonds render inulin non-digestible by human enzymes, thus 
inulin can pass through the mouth, stomach and small intestine without being 
metabolized. All ingested inulin or FOS enters the colon where it fermented by the 
colonic microflora. The energy derived from the fermentation is largely a result of the 
production of SCFA and lactate, which are metabolized and contribute 1.5 kcal/gram of 
useful energy (Niness 1999). 
 Another important attribute of inulin is its action as a dietary fibre. Inulin and 
FOS influence intestinal function by increasing stool frequency (Gibson, Beatty, Wang 
& Cummings, 1995), increasing stool weight (Gibson et al., 1995) and decreasing fecal 
pH (Gibson & Roberfroid, 1995), which has been linked to suppression in the 
production of putrefactive substances in the colon. 
 
2.4.4 Prebiotic Effects of Inulin and FOS  
 2.4.4.1 Bifidus Stimulation   
 The ultimate aim of supplementation of the human diet with prebiotics is the 
beneficial management of the gut microbiota (Kolida, Tuohy & Gibson, 2002). As 
mentioned previously, inulin escapes digestion in the upper part of the gastrointestinal 
tract and reaches the colon virtually intact. Once the inulin enters the colon, the resident 
bacteria namely Bifidobacteria and Lactobacilli, ferment the prebiotic.     
  The most well known actions of inulin are to stimulate the growth of 
Bifidobacteria. Health benefits ascribed to Bifidobacteria include the following: 
inhibiting the growth of harmful bacteria, stimulating components of the immune 
system, aiding in the synthesis of certain ions, synthesis of B vitamins, prevention of 
osteoporosis and cancer prevention (Niness 1999; Kolida et al., 2002). The bifidogenic 
effect of inulin and FOS has been well proven in both in vitro and in vivo (Gibson & 
Roberfroid, 1995; Delzenne 2003; Van Loo et al., 1995; Niness 1999; Gibson et al., 
1995, Kolida et al., 2002; Kruse, Kleesen & Blaut, 1999). Dramatic positive shifts in the 
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 microflora have shown through in vivo human studies at doses of inulin between 5 and 
20 g/day over a 15 day period (Gibson et al., 1995; Wang & Gibson, 1993). Table 2.6 
summarizes the in vivo human studies published to date that determine the bifidogenic 
effect of inulin and FOS.  
 
Table 2.6 Summary of Human Studies that Provide Statistically Significant 
Evidence for the Bifidogenic Effect of Inulin and FOS 
 
Reference Prebiotic Mode of study Evidence of prebiotic effect 
Kruse et al. 
1999 
Inulin 8 healthy humans Increase in Bifidobacteria 
Bouhnik et al. 
1999 
FOS 40 healthy humans Increase in Bifidobacteria at 10 
g/day 
Gibson et al. 
1995 
FOS and 
Inulin 
8 healthy humans 15 g of inulin/day led to 
Bifidobacteria becoming 
predominant in feces 
Kleessen et 
al. 1997 
Inulin and 
lactose 
20 five elderly 
constipated patients 
Increase in Bifidobacteria, 
decrease in putrefactive bacteria 
Tuohy et al. 
2001 
FOS 31 healthy humans Increase in Bifidobacteria at FOS 
supplemented at 6.6 g/day 
Buddington et 
al. 1996 
FOS 12 healthy humans Increase in Bifidobacteria, no 
change in total bacteria levels 
 
 Kruse et al. (1999) studied the effect of inulin on fecal flora composition in eight 
healthy living subjects. Subjects consumed a typical Western diet (45% energy as fat, 
40% energy as carbohydrate) followed by a fat reduced diet (30% energy as fat, 55% 
energy as carbohydrate) for a period of 64 days. Inulin was used as the fat replacement 
(maximum inulin consumed was 34 g/day). The control subjects consumed an identical 
diet but inulin was not used as fat replacement. A significant increase in Bifidobacterial 
populations was observed. Inulin significantly increased Bifidobacteria from 9.8 to 11.0 
log10 /gram of dry feces. 
 Bouhnik et al. (1999) assessed the tolerance and threshold dose of FOS in 40 
healthy human subjects. The researchers found that fecal Bifidobacteria counts increased 
in seven days. The optimal dose for promoting bifidogenesis without significant side 
effects was 10 g/day of FOS.  
 Gibson & Wang (1995) studied the selective stimulation of Bifidobacteria by 
inulin and FOS in a 45-day study of eight healthy subjects. The subjects were fed control 
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 diet of 15 g of sucrose for the first 15 days followed by 15 g of FOS for the next 15 
days. Four subjects went on to receive 15 g of inulin for the final 15 days of the study. 
Both FOS and inulin significantly increased Bifidobacteria. Bacteriodes, clostridia and 
fusobacteria decreased when fed FOS, where as gram-positive cocci decreased when the 
subjects received the inulin. 
 Kleessen et al. (1997) studied the effects of lactose and inulin on the bowel 
habits of elderly constipated patients. Groups of 15 patients received lactose and groups 
of 10 patients received inulin for 19 days. The dosages of the lactose and inulin were 
initiated at 20 g/day and gradually increased to 40 g/day. Inulin increased Bifidobacteria 
significantly from 7.9 to 9.2 log10/g dry feces and decreased enterococci and 
enterobacteria frequency. 
 Tuohy et al. (2001) completed a double-blind, placebo controlled crossover trial 
using 31 healthy volunteers. Thirty-one volunteers consumed daily either three 
experimental biscuits (providing 6.6 g of FOS/day) or three placebo biscuits for a 21 day 
crossover period. Bifidobacteria significantly increased with the biscuits supplemented 
with the FOS. The researchers also found that Bifidobacterial numbers returned to pre-
treatment levels within seven days, following discontinuation of the biscuits containing 
the FOS.   
 Buddington et al. (1996) studied the influence of FOS on the fecal flora in 12 
healthy humans. The subjects were fed a control diet for 42 days of 4 g of FOS/day 
between days 7 and 32. Increases in fecal Bifidobacteria were noted when the subjects 
were on the control diet, with the highest density of Bifidobacteria occurring when the 
diet was supplemented with FOS.   
 On the basis of the results of well-designed human studies, it can be concluded 
that inulin administered at 5-15 g/day for a few weeks can change the composition of the 
fecal bacteria, especially the Bifidobacteria. 
 2.4.4.2 Fermentation   
 Carbohydrates such as inulin or FOS that reach the proximal colon are highly 
fermented. Inulin and FOS are so highly fermented that studies have been unable to 
recover any of these products in the feces (Cummings & Macfarlane, 2002). The lower 
DP oligomers (i.e., FOS) are believed to be fermented in the proximal colon and the 
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 longer chain prebiotics (i.e., inulin) are fermented more distally in the colon (Kolida et 
al., 2002).   
 Fermentation of carbohydrates by colonic microflora is an anaerobic process 
producing gas (CO2, H2 and CH4), short chain fatty acids (SCFA) and lactic acid 
(Cummings & Macfarlane, 2002). Lactic acid is further metabolized into SCFA. These 
gases are utilized by fecal bacteria, absorbed then excreted in breath or excreted in 
stools. The majority of SCFA are absorbed and only very small fraction is found in the 
stool. SCFA are an important source of energy for bacteria such as Bifidobacteria and 
Lactobacilli.      
 The SCFA have important effects on the intestinal tract. It is largely accepted 
that butyrate plays an essential role in maintaining colonic mucosa integrity by acting on 
epithelial cell metabolism, proliferation and differentiation (Cherbut, 2002). While 
prebiotics have been shown to be a source of SCFA both in vivo and in vitro in animals, 
in vivo studies in humans have been inconclusive (Gibson, Beatty et al., 1995; Kleessen 
et al., 1997; Cummings & Mcfarlane, 2002). Inulin and FOS are known to produce 
butyrate and therefore, may modulate intestinal barrier function (Cherbut, 2002). This 
hypothesis still needs to be tested in humans. However, short-chain FOS, known to 
produce substantial amounts of butyrate in the colon, has been shown to increase 
mucosal crypt height and epithelial cell density in neonatal pigs (Delzenne, 2003). 
Further studies in humans are needed to identify the exact mechanism of fermentation on 
mucosal cells.    
 2.4.4.3 Fecal bulking effect 
 Carbohydrates that reach the bowel have a mild laxative effect. The clearest 
demonstration of a mild laxative effect is in the controlled diet study completed by 
Gibson et al. (1995), which showed 15 g/day of inulin and FOS increased stool output. 
Dahl et al. (2005) confirmed that inulin fortification (13 g/day) produces significant 
fecal bulking in institutionalized individuals. In addition, inulin has been shown to 
stimulate bowel movements and increase stool frequency, in elderly constipated patients 
(Kleessen et al. 1997). Other human experiments using inulin and FOS have shown not 
been able to demonstrate an increase in stool output, but the studies did not control for 
diet, which would mask the small effects. Inulin and FOS are likely mild laxatives, but 
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 because the effect is small it is difficult to detect except in carefully controlled studies 
(Cummings & Macfarlane, 2002). 
 
2.4.5 Safety of Prebiotics 
 Inulin and FOS are present in the daily diet of many of the world’s population 
(Van Loo et al., 1995). Up to 20 g/day/person may be ingested through the normal diet 
without noticeable side effects (Coussement, 1999). Historical literature provides no 
specific reports doubting the safety of inulin containing vegetables (Coussement, 1999). 
In fact, many inulin-containing vegetables (e.g., chicory, garlic and leek) have been 
noted to have beneficial effects on health. 
 The long history of mankind’s safe use of inulin-containing foods is reflected by 
the fact that very little formal toxicity testing in laboratory animals has been reported 
(Coussement, 1999). Numerous publications in peer-reviewed clinical journals 
document careful studies with inulin and FOS in healthy subjects and patients with 
chronic diseases (Roberfroid, Gibson & Delzenne, 1993). The studies of subjects with 
various disease conditions and of differing ages provide additional assurance of the 
safety of inulin and FOS.   
 2.4.5.1 Tolerance 
 Tolerance of a nondigestible fibre is determined by the osmotic effect and the 
fermentation effect. The osmotic effect leads to an increased presence of water in the 
colon. Smaller molecules like sorbitol exert a higher osmotic pressure and bring more 
water into the colon (Roberfroid et al., 1993). The fermentation effect is caused by the 
production of fermentation products, mainly SCFAs and gases. Slow fermenting 
products such as inulin are easier to tolerate than FOS (Roberfroid et al., 1993).   
 It is difficult to determine the tolerance of fibre for an individual, as individuals 
have different tolerance and intestinal acceptability levels. For example, diarrhea is a 
symptom of poor tolerance, but soft stools may be acceptable or even a desired outcome. 
Flatulence is even more difficult to measure objectively, as what is acceptable for one 
person may be intolerable for another.   
 An approach, based on personal judgement of discomfort, was designed by 
Orafti et al. to determine the tolerance level of fermented carbohydrates such as inulin 
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 and FOS (Roberfroid et al., 1993). A food is considered unacceptable, if it causes one or 
more of the following symptoms: too much flatulence, too much intestinal pressure, too 
much intestinal noise, too much intestinal cramping or diarrhea as observed by the 
individual (Roberfroid et al., 1993). The no observed adverse effect level (NOAEL) for 
inulin is proposed to be 30 g/day (Roberfroid et al., 1993). Orafti’s tests and experience 
show that regarding the sensitivity to (totally) fermentable carbohydrates, three 
categories of people can be distinguished: 1) nonsensitive persons can consume 30 g/day 
without the undesirable actions described above; 2) sensitive persons can consume 10 
g/day without undesirable actions but might experience undesirable reactions with 20 
g/day; 3) very sensitive persons can experience undesirable reactions at doses of ≤10 
g/day (Roberfroid et al., 1993). The values reported are based on adult volunteers. Little 
or no information is available concerning the acceptability of indigestible carbohydrates 
for children. A test with FOS completed by Cadranel et al. (1995) showed that daily 
doses of 3, 6, 9 g of FOS in drinks or confectionary products cause no significant 
undesirable effects in children aged 10 to 13 years of age (Roberfroid et al., 1993). 
 Inulin appears to be better tolerated than FOS. Inulin has rarely been shown to 
cause diarrhea (Roberfroid et al., 1993). The values that can be recommended as 
formulation doses for inulin, based on both tests with volunteers and the experience of 
the food industry are 10 g/day (Roberfroid et al., 1993), a value significantly less than 
the proposed NOAEL of 30 g/day.   
 
2.4.6     Prebiotics and Infant Nutrition and Health 
 In the newborn breast-fed infant, a stable microflora is developed in the colon 
within five days of birth. Breast-fed infants are known to have a gastrointestinal flora 
that is dominated by Bifidobacteria and Lactobacilli. Although breast-fed infants and 
formula fed infants have a similar gastrointestinal flora at days three and four of life, 
there is a substantial difference in colonic flora after several weeks of life, which is 
dependant on mode of feeding (Harmsen et al., 2000). Bifidobacteria become 
predominant in breast-fed infants, but the formula fed infant’s colonic flora is dominated 
by anaerobic bacteria such as bacteroides (Harmsen et al., 2000). More importantly, the 
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 numbers of pathogenic bacteria such as clostridium and coliform are higher in infants 
receiving formula.    
 The mechanism that appears to play a role in the promotion of growth of 
Bifidobacteria in the colon of breast-fed infants are the oligosaccharides found in human 
milk. Human milk oligosaccharides are the third most abundant solid constituents of 
human milk (Picciano, 2001). Human milk oligosaccharides are postulated to play an 
immuno-protective role in the infant. Research is only beginning to understand the 
defense mechanisms of human milk oligosaccharides and its role in infant health. There 
is substantial evidence suggesting that oligosaccharide secretion in mother’s milk is a 
very complex, variable and dynamic process (Harmsen et al., 2000). Cow’s milk and 
infant formula have very low levels of oligosaccharides.   
 The addition of prebiotics (e.g., inulin, FOS and galacto-oligosaccharides) to 
infant formula stimulates the growth of Bifidobacteria and plays an immuno-protective 
role in the infant (Boehm et al., 2002; Vandenplas, 2002). Supplementation of a preterm 
formula with a mixture of FOS and galacto-oligosaccharides has been shown to 
stimulate the growth of Bifidobacteria and results in stool frequency and consistency 
similar to preterm infants fed human milk (Boehm et al., 2002). Similar results have 
been observed in term infants fed a combination of galacto-oligosaccharides and FOS 
versus standard infant formula (Hansjorg et al., 2003). The infants fed the formula 
containing the nondigestible oligosaccharides had higher numbers of Bifidobacteria 
compared with infants fed standard infant formula. 
 FOS supplementation may have potential immunomodulatory activity in the 
infant, although research is very preliminary. Infant cereal supplemented with FOS has 
been shown to decrease the occurrence of febrile illness, associated with diarrhea or 
respiratory illness (Saavedra & Tshernia, 2002). An additional study observed improved 
humoral immune response to measles vaccine in infants receiving infant cereal 
containing FOS (Firmansyah et al., 2001). The mechanisms of the observed clinical 
benefit have yet to be defined, but it is becoming apparent that modifications in 
intestinal flora by ingestion of prebiotics may yield immunological benefits (Saavedra & 
Tshernia, 2002).   
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 2.4.7 Prebiotics and Gastrointestinal Disease 
 2.4.7.1 Inflammatory Bowel Disease 
 The effect of inulin has been tested in the rat model of distal colitis induced by 
dextran sulphate sodium, which histologically resembles human UC (Videla et al., 
2001). Oral inulin prevented mucosal inflammation, as demonstrated by lower colonic 
lesion scores and the release of fewer inflammatory mediators in test rats as compared 
with controls (Videla et al., 2001). 
 Several small scale studies of prebiotics have been reported in UC patients 
(Table 2.7). Inulin has been tested in patients with ileal pouch-anal anastomosis. 
Compared with placebo, three weeks of dietary supplementation with 24 g of inulin 
increased butyrate concentrations, lowered pH, decreased numbers of Bacteriodes 
fragilis, and diminished concentrations of secondary bile acids in feces (Welters et al., 
2002). This was endoscopically and histologically accompanied by a reduction of 
inflammation of the mucosa of the ileal reservoirs.   
 A multi-center open trial, completed over 24 weeks, has suggested that 
administration of 20-30 g/day of germinated barley foodstuff (GBF), provided in 
addition to base line therapy may be useful in the induction and maintenance of clinical 
remission in patients with mild to moderately active UC (Kanauchi et al., 2003). Patients 
consuming GBF showed significant decrease in clinical activity index scores and 
increased fecal concentrations of Bifidobacteria.  
 A 24-week trial found that psyllium was superior to the placebo in alleviating the 
gastrointestinal symptoms of patients with UC in remission (Hallert et al., 1991). In a 
randomized control trial, psyllium was equivalent to mesalamine, a commonly 
prescribed anti-inflammatory agent in maintaining remission in UC (Fernandez- Banares 
et al., 1994).  
 Hallert et al (2003) investigated the effects of oat bran on remission rates in 
patients with UC. This pilot study involved adding 60 g of oat bran, corresponding to 20 
g of oat fibre, to the daily diet of 22 patients. During the intervention, the fecal butyrate 
concentrations increased significantly and reduced symptomology in patients reporting 
abdominal pain and reflux. 
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  Davies et al. (1978) studies the effect of a high fibre diet on remission rates in 
UC patients in remission taking sulfasalazine® (SAS). The increased fibre was in the 
form of whole wheat bread, vegetables and a supplement of 25 g/day of bran. Fifteen 
patients continued on SAS and a regular diet and 20 patients were provided a high fibre 
diet and the SAS was stopped. The relapse rate of the high fibre group was 75% and 
20% relapse rate with the patients that remained on the SAS. This study demonstrates 
that not all types of dietary fibre will have a prebiotic effect on the intestinal mucosa. It 
appears that only specific prebiotics play a role in maintaining remission in UC.      
 The human studies mentioned above, support the idea that prebiotics may 
prevent intestinal inflammation. More clinical trials with larger populations are 
necessary to demonstrate the effectiveness of prebiotics in the prevention of 
inflammation in IBD.  
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 Table 2.7 Evidence for the Prebiotic Effect in Ulcerative Colitis 
Authors Prebiotic Dosage 
(g/day) 
Mode of 
study 
Length of 
treatment 
Evidence for 
prebiotic effect 
Welters et 
al., (2002) 
Inulin 24 g/day 20 patients 
with ileal 
pouch-anal 
anastomosis 
3 weeks Increased butyrate 
concentrations, 
lowered pH, 
decreased numbers of 
Bacteriodes fragilis, 
and diminished 
concentrations of 
secondary bile acids 
in feces. 
Kanauchi et 
al., (2003) 
Germinated 
barley food 
stuff (GBF) 
20-30 g/day 
in addition to 
standard 
medical 
therapy 
18 patients 
with 
moderately 
active UC 
4 weeks Patients consuming 
GBF showed 
significant decrease 
in clinical activity 
scores, increased 
concentration of 
Bifidobacteria in 
stool. 
Hallert et 
al., (1991) 
Psyllium Group A: 20 
g/day 
psyllium 
Group B: 
1.5g/day 
mesalamine 
Group C: 20 
g/day 
psyllium and 
1.5 g/day 
mesalamine  
105 patients 
with UC in 
remission 
24 weeks Decreased symptoms 
of UC, increase in 
Bifidobacteria and 
decrease in free water 
in the stool. 
Hallert et 
al., (2003) 
Oat bran 60 g/day 22 patients 
with  UC in 
remission 
12 weeks Increased butyrate 
concentrations, 
significant 
improvement in 
symptoms. 
 
 2.4.7.2 Colon Cancer 
 Experimental observations have suggested that prebiotics may play a protective 
role in the development of colon cancer. Recent research in experimental animal models 
has revealed that inulin has significant anticarcinogenic properties (Pool-Zobel & 
Cherbut 2003; Marteau & Boutron-Ruault, 2002). Inulin acts chemopreventively by 
reducing the incidence of tumours in the colon (Pool-Zobel & Cherbut, 2003). The 
effects may be due to the stimulation of the Bifidobacteria, which themselves have been 
shown to be antigentoxic in the colon (Pool-Zobel & Cherbut, 2003). Fermentation 
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 products, such as the short chain fatty acids may also contribute to the protective effects 
(Marteau & Boutron-Ruault, 2002). The experimental evidence from animal studies 
strongly supports the possibility that inulin will contribute to reducing colon cancer risk 
in humans (Pool-Zobel & Cherbut, 2003). Clinical and epidemiological studies in 
humans are currently in progress to evaluate the relevance of prebiotics in reducing 
colon cancer risk (Van Loo, Clune , Bennett, & Collins, 2005). 
 2.4.7.3 Bowel Habits 
 All carbohydrates that reach the large intestine have a mild laxative effect. Non-
digestible carbohydrates with a low molecular weight exhibit a positive effect on 
intestinal transit in constipated patients (Marteau & Boutron-Ruault, 2002). The clearest 
demonstration of a mild laxative effect of prebiotics is in a controlled diet study which 
showed that 15 g of FOS increased stool output significantly from 136 to 154 g/day 
(Gibson, Beatty et al., 1995). In studies reporting only qualitative data, FOS or inulin 
‘improved constipation’ in small groups of hospitalized patients (Kleesen et al., 1997; 
Hidaka & Hirayama, 1991). Inulin and FOS are likely laxative but because the effects 
are small, it is difficult to detect except in carefully controlled studies (Cummings & 
Macfarlane, 2002). 
 2.4.7.4 Traveller’s Diarrhea 
 Traveller’s diarrhea remains a common problem for those journeying overseas 
for either business of holidays. It is particularly frequent on visitors to Central America, 
the Far East, India and parts of Asia. Current estimates are that 60 million travellers 
from the West visit high-risk areas annually and of these, 30-50% had episodes of 
diarrhea (Cummings & Macfarlane, 2002). A diet controlled study showed that 
administering 10 g of FOS daily failed to prevent traveller’s diarrhea in 244 healthy 
subjects travelling to high and medium risk destinations for traveller’s diarrhea 
(Cummings, Christie & Cole, 2001). There are multiple causes for diarrhea in travellers, 
such as exposure to different foods, increased alcohol consumption and pathogens that 
affect the small bowel versus the large bowel (Cummings & Macfarlane, 2002). The 
wide variety of etiologies of traveller’s diarrhea may be some of the reasons non-
digestible carbohydrates failed to show beneficial effects in prevention of traveller’s 
diarrhea.     
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  2.4.7.5 Antibiotic-Associated Diarrhea (AAD) 
 The incidence of diarrhea following antibiotic use is particularly high with 
Clostridium difficile disease being most common (Aslam, Hamill & Musher, 2005). 
Antibiotic-Associated Diarrhea (AAD) is the result of disrupted microflora and most 
often occurs two to eight weeks after antibiotic use and is associated with age, health 
status, hospitalization and exposure to nosocomial pathogens (McFarlane, 1998). 
Oligofructose is metabolized by Bifidobacteria resulting in a marked increase in 
numbers of Bifidobacteria in healthy volunteers, thereby decreasing Clostridia species 
(Gibson, Beatty et al., 1995). Lewis et al. (2005) provided 12 g of oligofructose or 
placebo (sucrose) daily to 435 elderly patients along with their prescribed antibiotics. 
Stools were cultured for Bifidobacteria, C. Difficile and anaerobes. Oligofructose was 
well tolerated by the patients and concentration of fecal Bifidobacteria was significantly 
higher in the patients receiving oligofructose versus the placebo group (p<0.001). Stool 
form and consistency was not altered with the oligofructose supplementation nor was the 
incidence of diarrhea reduced. Lewis et al. (2005) concluded that oligofructose had no 
effect on the prevention AAD.  
 Lewis, Burmeister, & Brazier (2005) provided 142 inpatients diagnosed with C. 
difficile toxin-associated diarrhea with 12 g of oligofructose or placebo for 30 days in 
addition to antibiotic therapy. Compared to baseline stool culture, oligofructose resulted 
in increased fecal concentrations of Bifidobacteria (p<0.0001). Patients taking the 
oligofructose were less likely to develop a relapse of diarrhea than those taking the 
placebo (8.3% oligofructose vs. 34.3% of placebo; p<0.001). Lewis, Burmeister and 
Brazier (2005) concluded that oligofructose appears to be effective in preventing relapse 
of C. difficile-associated diarrhea. 
 2.4.7.6 Necrotizing Enterocolitis (NEC) 
 Necrotizing Enterocolitis (NEC) is an acquired disease, primarily of very low 
birth weight infants (<1500 g at birth), which is characterized by mucosal or intestinal 
necrosis in the terminal ileum, with the colon and the proximal small bowel involved 
less frequently (Beers & Berkow, 2005). NEC is a serious gastrointestinal disease of 
unknown etiology (Lin et al., 2005). Despite advances in neonatal practice, NEC 
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 remains a major cause of gastrointestinal issues in premature infants and the first cause 
of death in extremely premature infants (Butel, Waligora-Dupreit & Szylit, 2002).  
 The pathophysiology of NEC still remains to be elucidated, but immaturity of the 
gut, enteral feeding and bacterial colonization are all thought to be involved (Butel et al., 
2002). Butel et al. (2002) have suggested that a delayed colonization by Bifidobacteria 
promotes colonization of potentially pathogenic bacteria which may contribute to the 
development of NEC. It is now being postulated that modulating the microbiota of the 
intestine by prebiotics, may play a role in prevention of NEC. A study by Butel et al. 
(2002) using gnotobiotic quails as an experimental model of NEC revealed that 
oligofructose dietary supplementation was shown to increase Bifidobacteria level and 
decrease pathogenic bacteria. Oligofructose acted as an anti-infective agent and 
decreased the occurrence and severity of intestinal lesions associated with NEC. The 
researchers concluded that the addition of oligofructose to pre-term milk may maintain 
colonization of Bifidobacteria and play a role in the prevention of NEC. Studies in 
human neonates have yet to be completed.      
 
 
2.5 PROBIOTICS  
2.5.1 Definition 
A probiotic has been defined as a preparation of a product containing viable, 
defined microorganisms in sufficient numbers, which alter the microflora in a 
compartment of the host and by that exert beneficial effects in the host (Schrezenmeir & 
De Vrese, 2001). In order for microorganisms to belong to the probiotic group they must 
meet several criteria. These criteria include: be able to withstand and survive the effect 
of gastric acid, biliary secretions and pancreatic secretions in order to reach the small 
and large intestines; be non-pathogenic and non-toxic; remain viable during transport 
and storage; exert beneficial effects on the host; stabilize the intestinal microflora; 
adhere to the intestinal epithelial cell lining; and produce antimicrobial substances 
towards pathogens (Tomasik & Tomasik, 2003). 
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 2.5.2 Types of Probiotics  
The most well-studied probiotic species belong to the Lactobacillus and 
Bifidobacterium species. Table 2.8 lists some of the commercially available probiotics 
that have been added to foods (e.g., yogurt or fermented milk products) or concentrated 
in supplements intended for human consumption. 
 
Table 2.8 Summary of the Probiotic Species Studied for Clinical Use 
Lactobacillus 
Species 
L. acidophilus, L. bulgaricus, L. casei, L. fermentum, L. gasseri, L. 
johnsonii, L. lactis, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. 
salivations 
Bifidobacteria 
Species 
B. bifidum, B. breve, B. lactis, B. longum 
Saccharomyces 
Species 
S. boulardii 
Escherichia 
coli  Species 
E. coli Nissle 1917 
Enterococcus 
Species 
E. faecium 
Streptococcus 
Species 
S. thermophilus 
 
Lactobacilli are non-spore-forming bacteria that ferment glucose into lactate, 
(Attisha & Clark, 1995). The most common application of Lactobacillus is industrial, 
specifically for the production of dairy products (Kopp-Hoolihan, 2001). Because of 
their ability to derive lactic acid from glucose, these bacteria create an acidic 
environment which inhibits growth of many bacterial species (Attisha & Clark, 1995). 
This genus also contains several bacteria that make up part of the natural flora of the 
human gastrointestinal tract (Linskens, Huijsdens, Savelkoul, Vandenbroucke-Grauls & 
Meuwissen, 2001). Lactobacillus is generally harmless to humans, rarely inciting 
harmful infections or diseases (Salminen & Donohue, 1996). Lactobacillus GG (LGG) is 
the most well studied probiotic (Salminen & Donohue, 1996). The clinical potential has 
been documented in several diarrheal diseases such as C. difficile-associated diarrhea, 
antibiotic-associated diarrhea, infectious diarrhea, atopic eczema and IBD (Schultz, 
Scholmerich & Rath, 2003).  
     Bifidobacteria are a major group of saccharolytic bacteria found in the large 
intestine (Teitelbaum & Walker, 2002). Members of the genus Bifidobacterium are 
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 anaerobic, gram-positive bacilli rarely associated with infection (Makelainen, Tahvonen, 
Salminen & Ouwehand, 2003). Bifidobacterium accounts for 25% of the bacteria in the 
adult colon and 95% of the bacteria in the breastfed newborn (Teitelbaum & Walker, 
2002).  
Saccharomyces boulardii is a yeast preparation that has been shown to inhibit the 
growth of pathogenic bacteria both in vitro and in vivo (Teitelbaum & Walker, 2002). It 
lives at an optimum temperature of 37◦C, and has been shown to resist digestion and thus 
reaches the colon in a viable state (Teitelbaum & Walker, 2002). S. boulardii has also 
been found to be unaffected by antibiotic therapy (Teitelbaum & Walker, 2002).  
    
2.5.3 Efficacy of Probiotics 
Studies on lactose intolerance, diarrhea and colon cancer show that a daily dose 
of 109 to 1010 (one to ten billion) colony forming units (cfu) of viable bacteria are 
needed for any measurable effect on health (Sanders, Walker, Walker, Aoyama & 
Klaenhammer, 1996). Effects of consuming lower levels have not been documented in 
research studies. It is believed that probiotics do not permanently adhere to the intestinal 
cells, but exert their effects as they metabolize and grow. Goldin et al. (1992) found that 
when LGG supplementation was stopped, the LGG disappeared from the feces of 67% 
of the volunteers within 7 days. Thus, daily consumption of probiotic is the best way to 
maintain the probiotic effects (Kopp-Hoolihan, 2001). 
In the future, probiotics are to be regulated by the Natural Health Products 
Directorate (NHPD) under the direction of the Health Products and Food Branch of 
Health Canada. At the present time, the concentration of probiotics in food and 
supplements varies tremendously between products (Kopp-Hoolihan, 2001). It is up to 
manufacturers to disclose the probiotic content of their products. With the 
implementation of the NHPD requirements for probiotic concentration and viable 
counts, at the time of consumption, will become standardized for these products. 
The shelf-life, for refrigerated products containing probiotics, ranges from 3-6 
weeks (Kopp-Hoolihan, 2001). The shelf-life of dried supplements is about 12 months. 
However, the viable counts may drop off significantly during this time (Kopp-Hoolihan, 
2001).          
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 2.5.4 Safety of Probiotics 
 The majority of scientific studies completed to date have described a good 
tolerance to probiotic preparations and the absence of significant adverse effects. 
Although most commercially available probiotic strains are considered to be safe, there 
are concerns with their use in particular patient populations. 
 The most important area of concern is the risk of developing sepsis following 
supplementation with probiotics. Several reports have directly linked cases of sepsis to 
ingestion of probiotics (Boyle, Robins-Browne & Tang, 2006). Bacterial sepsis, 
endocarditis and liver abscess have been reported in both adults and children. Rautio et 
al. (1999) report a case of an elderly woman with Diabetes Mellitus (Type 2, non-insulin 
dependant) who developed liver abscess and pneumonia following daily 
supplementation with LGG. Endocarditis developed in a 67-year old-man with mitral 
regurgitation following a dental extraction who was taking the probiotic L. rhamnosus 
(Mackay, Taylor, Kibbler & Hamilton-Miller, 1999). Bacterial sepsis has been reported 
in three premature infants with short bowel syndrome taking LGG supplements (Kunz, 
Noel & Fairchok, 2004; De Groote, Frank, Dowell, Glode & Pace, 2005). S. Boulardii 
related fungemia is the most commonly described risk factor of probiotic therapy. Boyle 
et al. (2006) reviewed over 19 cases of S. Boulardii related fungemia in both adults and 
children with a variety of medical conditions. 
  Bifidobacteria are generally recognized as safe for human consumption, based on 
their wide use in fermented dairy products (Makelainen et al., 2003). Furthermore, 
Bifidobacteria are the major component of intestinal microbiota. To date, there have 
been no case reports in the literature linking Bifidobacteria to infectious disease. 
Makelainen et al. (2003) assessed the tolerance and safety of two B. longum strains in 39 
healthy adults between the ages of 19 and 60. The subjects were randomly assigned into 
two groups, each of which received two capsules daily containing 109 cfu of B. longum 
strains (46 and 2C) or a placebo (maltodextrin) for three weeks. No side effects were 
reported and no undesirable changes in immune parameters were discovered. 
Makelainen et al. (2003) concluded that the two B. longum strains (46 and 2C) were well 
tolerated by the subjects and are safe for human consumption.              
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  All cases of bacteremia and fungemia related to administration of probiotics have 
occurred in individuals who were immunocompromised or had an underlying chronic 
disease or debilitation (Boyle et al., 2006). Many cases of probiotic sepsis involved 
patients who had underlying intestinal pathology (e.g., short bowel syndrome or 
diarrhea) which increases the risk for bacterial translocation. Tube feeding or the 
presence of a central venous catheter is also a common finding in cases of probiotic 
sepsis. Premature infants are at increased risk for bacteremia. No reports of sepsis have 
occurred in healthy individuals. Boyle et al. (2006) propose that the following risk 
factors merit caution in using probiotics: 1) immune compromise or premature infants, 
2) central venous catheter, 3) administration of probiotic via jejunostomy, 4) 
concomitant administration of broad spectrum antibiotics to which probiotic is resistant, 
5) probiotics with properties of high mucosal adhesion or known pathogenicity and 6) 
cardiac valve disease. Thus, most Lactobacilli and Bifidobacteria used in the food 
industry and in clinical trials appear to be safe for the general adult and pediatric 
populations.  
 
2.5.5 Mechanisms of Action of Probiotic Bacteria 
 Several mechanisms of action have been postulated to influence the effectiveness 
of probiotics in IBD. The mode of action of probiotic strains is likely to be multifactoral 
and strain specific. Some of the postulated mechanisms include suppression of growth or 
epithelial binding/invasion of pathogenic enteric bacteria, improvement of epithelial and 
mucous barrier function or engagement in immunomodulatory activities (Sartor, 2004).  
 The concept of microbiological balance existing in the intestine, involving 
competition between probiotic and pathogenic bacteria for specific binding sites on 
intestinal epithelial cells has been well established (Fedorak & Madsen, 2004). Probiotic 
bacteria have been shown to colonize the gut during therapy to induce specific pH and 
other chemical changes in the lumen, which may directly inhibit the growth of the 
pathogenic bacteria (Hart, Stagg & Kamm, 2003). Suppression of growth and function 
of pathogenic bacteria has been attributed to decreases in luminal pH via production of 
organic acids, secretion of bactericidal proteins and prevention of epithelial adherence 
(Sartor, 2004). 
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  Intestinal epithelial cells produce mucin genes (i.e., MUC2 and MUC3) which 
bind to pathogens, inhibiting invasion into the epithelial cell (Chang et al., 1994). Mack 
et al. (1999) reported that patients with IBD have reduced numbers of goblet cells at the 
sites of inflammatory lesions. In addition, the mucins present at the inflamed sites have 
reduced ability to bind pathogenic bacteria. Mack et al (1999) demonstrated in vitro that 
probiotics L. plantarum and L. rhamnosus GG inhibit the adherence of pathogenic E.coli 
to intestinal epithelial receptors through the increased expression of intestinal mucin 
genes, MUC2 and MUC3.    
 Probiotics have the ability to produce antimicrobial compounds called 
bacteriocins which have an antagonistic effect against pathogens (Flynn et al., 2002). 
Bacteriocins are bioactive peptides synthesized by probiotic bacteria that have a 
bactericidal effect or bacteriostatic effect on other closely related species (Flynn et al., 
2002). Bifidobacterium strains synthesize a broad range of bacteriocin-like inhibitory 
compounds that play a key role in the inhibition of pathogens (Collado, Hernandez & 
Sanz, 2005). 
 Probiotic bacteria have been shown to enhance gut epithelial and mucosal barrier 
function. Bacteria pathogens exert their detrimental effects by disrupting the barrier 
functions of mucosal cells, thereby increasing pathogen invasion (Madsen et al., 2001). 
Specifically, pathogenic bacteria disrupt the protein phosphorylation of claudin and 
occludin causing mucosal injury and subsequent pathogen invasion (Resta-Lenert & 
Barrett, 2003). When human intestinal cells are pretreated with two probiotic strains 
(e.g., L. acidophilus and S. thermophilus) invasion of the pathogenic bacteria 
enteroinvasive Escherichia coli was prevented (Resta-Lenert & Barrett, 2003). The 
mechanism of action is suggested to be that probiotics have the ability to modify tight 
junctions and the cytoskeleton in the epithelial cells, which interferes with pathogen 
adhesion and invasion.  
 Probiotic bacteria have been found to interact with epithelial and immune cells in 
the gastrointestinal tract altering immune function (Fedorak & Madsen, 2004). A variety 
of probiotic strains have the ability to block cytokine production by the intestinal 
epithelial cells (Fedorak & Madsen, 2004). The murine interleukin-10 (IL-10) deficient 
mouse colitis model has provided great insight into the role of probiotics as a treatment 
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 modality for IBD. Mice that lack IL-10 develop lesions that closely mirror the lesions 
found in IBD when infected with pathogenic bacteria. Madsen et al. (2001) were the first 
to demonstrate that administration of L. reuteri into the lower gastrointestinal tracts of 
IL-10 deficient mice prevented the development of colitis in these animals. The 
mechanism of action is believed to be the replenishment of IL-10 by the probiotic 
bacteria, indicating the importance of IL-10 in controlling intestinal inflammation. Pena 
et al. (2005) pretreated IL-10 deficient mice with L. reuteri and L. paracasei and then 
challenged the mice with pathogenic bacteria (Helicobacter hepaticus). This group 
found that the pro-inflammatory cytokines (IL-12 and tumor necrosis factor-α) were 
lowered in the probiotic-treated mice, thus showing the important role probiotics play in 
immunomodulatory activities. 
 It remains to be established which particular mechanism of action will relate to 
the treatment of IBD. Significant advances continue to be made in the understanding of 
these complex mechanisms. However, future research will need to determine whether 
probiotic bacteria exert their beneficial effects through a single versus multiple 
mechanisms of action. 
 
2.5.6 Probiotic Use in Gastrointestinal Diseases 
 The use of probiotics as therapeutic agents for gastrointestinal disease is rapidly 
moving into mainstream medical management. Probiotic therapy has been investigated 
for its effectiveness against a range of gastrointestinal disorders such as IBD (i.e., UC, 
Crohn’s disease and pouchitis), diarrhea, irritable bowel syndrome (IBS), H. pylori 
infection, lactose intolerance and necrotizing enterocolitis. Most of the probiotic agents 
currently being examined appear to be safe, with no adverse effects noted in thousands 
of subjects involved in clinical research (Saavedra, 2001).  
 2.5.6.1 Ulcerative Colitis  
 Preliminary controlled clinical data suggests that Escherichia coli Nissle 1917, 
VSL#3®, Bifidobacteria and S. boulardii may be beneficial in the management of UC. 
The majority of clinical trials that have assessed the efficacy of probiotics in UC have 
focused on the maintenance of remission. Table 2.9 summarizes the randomized control 
trials that support the use of probiotics in UC.   
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  Clinical studies have demonstrated that Escherichia coli Nissle 1917 is as 
effective as mesalazine in maintaining remission in UC. The first study completed by 
Kruis, Schulze, et al. (1997) studied 120 patients with UC in remission in a multicenter, 
double-blind, double-dummy study. For 12 weeks, patients received either 1.5 g of 
mesalazine daily or 5.0 x 1010 cfu/day of the viable E.coli strain Nissle 1917. Relapse 
rates were 11.3% for subjects receiving mesalazine and 16% for subjects receiving the 
E.coli Nissle 1917 (NS). Kruis, Fric, et al. (2004) completed a larger trial with 327 
patients with UC in remission. The subjects were randomized to receive 5.0 x 1010 
cfu/day of E.coli Nissle 1917 or 1.5 g/day of mesalazine for one year. Relapse rates were 
36.4% patients in the E.coli Nissle 1917 group and 33.9% in the mesalazine group 
(p=0.003), which suggests equivalence between E.coli Nissle 1917 and mesalazine in 
maintaining remission in UC. 
 Rembacken, Snelling, Hawkey, Chalmers and Axon (1999) performed a single 
center, randomized, double dummy study in 120 patients with active UC. In the initial 
phase of the study, patients were randomized to receive 2.4 g daily of mesalazine or 1.00 
x 1011 cfu/day of E.coli Nissle 1917 in attempt to induce remission. All patients received 
standard medical therapy (e.g., hydrocortisone enemas or oral Prednisone®) together 
with a one week course of oral gentamicin at entry into the study. Patients that were in 
remission within three months entered a follow-up phase of the study. The patients were 
randomized to receive 1200 mg/day of mesalazine or 5.0 x 1010cfu/day of E.coli Nissle 
1917 for one year. Initially, 75% of patients in the mesalazine group attained remission 
versus 68% in the E.coli group (p=0.0508). During the one year follow-up, relapse 
occurred in 73% of patients in the mesalazine group versus 67% in the E. coli group 
(NS). Rembacken et al. (1999) concluded that treatment with E.coli Nissle 1917 is 
equivalent to mesalazine in maintaining remission of UC. 
 Tursi et al. (2004) compared the efficacy and safety of a low dose of balsalazide 
(2.25 g/day) plus VSL#3® (9.0 x 1012 cfu/day) with balsalazide alone (4.5g/day) and 
with mesalazine (2.4 mg/day) in 90 patients with mild-moderate UC. All patients were 
randomly assigned to treatment groups with the duration of the treatment being eight 
weeks. The efficacy of the treatment was assessed by symptoms, endoscopic appearance 
and histological evaluation. The remission rate was 80% for the balsalazide/VSL#3® 
 43
 group, 77% for the balsalazide group and 53% for the mesalazine group (p<.02). 
Balsalazide plus VSL#3® was found to be significantly superior to balsalazide and to 
mesalazine in obtaining remission, it had better tolerance and was also superior in 
improving the clinical parameters evaluated. 
 Twenty patients with UC in remission, who were intolerant or allergic to 5-ASA, 
were treated with two doses of 3 g of VSL#3® (3.0 x 1012 cfu/day) for one year (Venturi 
et al., 1999). After 12 months of treatment, 75% of the patients were still in remission. 
Fecal concentrations of S. salivarius ssp. thermophilus, lactobacilli and Bifidobacteria 
increased significantly from baseline level (p<.05) and fecal pH was significantly 
reduced (p<.05). These results indicate that VSL#3® was able to colonize the intestine 
and may be useful in maintaining remission in UC patients.  
 In an open-label study, 24 patients with mild to moderate UC completed a four 
week course of S. boulardii (750 mg/day) while receiving maintenance treatment with 
mesalazine (3 g/day) (Guslandi, Giollo & Testoni, 2003). During this four week pilot 
study, 71% of the patients attained clinical remission, which was confirmed 
endoscopically. 
 Ishikawa et al. (2003) provided 100 ml/day of a fermented milk product 
containing live strains of B. bifidum, B. breve and L. acidophilus (1.0 x 1010 cfu/100 ml) 
for one year to patients in an unblinded, randomized control study. Patients had been 
diagnosed with UC at least one year previously and were in remission. Standard 
treatment for UC was provided as usual using salazosulfapyridine, mesalazine and 
steroids. Twenty-one subjects were assigned to either the bifido-fermented milk group 
(n=11) or the control group (n=10). During the one year study duration, exacerbation of 
UC symptoms was seen in three out of the 11 subjects in the bifido-fermented group 
versus nine out of ten subjects in the control group. A significant reduction in 
cumulative exacerbation rates was seen in the group consuming the bifido-fermented 
milk in addition to the standard medical therapy (p = 0.0184).  
 Kato et al. (2004) conducted a randomized placebo controlled study in 20 
subjects with mild to moderate, active UC. A fermented milk product containing live 
strains of B. bifidum, B. breve and L. acidophilus (1.0 x 1010 cfu/100 ml) was provided 
for 12 weeks along with conventional treatment (e.g., 5-ASA or sulfasalazine). The 
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 subjects treated with bifido-fermented milk (BFM) had a 70% response to treatment 
with 40% achieving remission, where as 33% of the placebo group had a response to 
treatment with only 33% achieving clinical remission. Clinical activity index scores 
were significantly lower in the BFM group versus placebo (p<0.05). Increases in fecal 
butyrate, propionate and other short chain fatty acids were also noted to be higher in the 
BFM group. The researchers concluded that supplementation with BFM along with 
conventional treatment is a safe and effective way to manage active UC. 
 Bibiloni et al. (2005) recently published the results of an open-label trial in 
patients with active UC not responding to conventional therapy. Thirty-two patients 
completed six weeks of treatment with VSL#3® (3.6 x 1012 cfu/day). Intention to treat 
analysis revealed that VSL#3® resulted in combined induction remission/response rate in 
77% of the patients. No adverse effects were reported. 
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 Table 2.9 Efficacy of Probiotic Therapy in the Management of Ulcerative Colitis  
Author Probiotic Dosage 
(cfu/day)
Mode of  
Study 
Length of 
Treatment
(weeks) 
Evidence of 
Probiotic Effect 
Bibiloni et 
al. (2005) 
VSL#3® 3.6 x 
1012
32 patients 
with active 
UC 
6 weeks Combined induction 
of remission/response 
rate in 77% of 
patients, probiotic 
species reached target 
site. 
Kato et al. 
(2004) 
Bifidobacteria-
fermented 
milk 
1.0 x 
1010
20 patients 
with mild- 
moderate  
active UC 
12 weeks Improved clinical 
activity index scores, 
endoscopic activity 
index, histological 
scores and increases 
in fecal SCFA.  
Tursi et al. 
(2004) 
VSL#3® 9.0 x 
1012
90 patients 
with mild-
moderate  
active UC 
8 weeks VSL#3®/balsalazide 
combination was 
superior to balsalazide 
or mesalazine alone in 
inducing remission. 
Kruis et al. 
(2004) 
E. coli Nissle 
1917 
5-50 x 
109
327 
patients 
with UC in 
remission 
12 months Maintenance of 
remission in UC (as 
effective as 
mesalazine). 
Guslandi et 
al.(2003) 
S. boulardii 750 
mg/day 
24 patients 
with mild 
moderate  
active UC 
4 weeks 17/24 patients attained 
clinical remission, 
confirmed 
endoscopically. 
Ishikawa et 
al. (2003) 
B. breve, B. 
bifidum and L. 
acidophilus 
1.0 x 
1010
21 
subjects  
with UC in 
remission 
12 months Significant reduction 
in the exacerbation 
rates seen in the 
probiotic group. 
Venturi et 
al. (1999) 
VSL#3® 3.0 x 
1012
20 patients 
with UC in 
remission, 
intolerant 
to  
5-ASA 
12 months VSL#3® colonized the 
intestine and fecal PH 
reduced, useful in 
maintaining remission 
in UC. 
Rembacken 
et al. 
(1999) 
E. coli Nissle 
1917 
Initial: 
1.0 x 
1011 
Follow-
up: 5 x 
1010
120 
patients 
with  
active UC 
Initial: 12 
weeks 
Follow-up: 
12 months 
 Maintenance of 
remission in UC (as 
effective as 
mesalazine). 
Kruis et al. 
(1997) 
E. coli Nissle 
1917 
5.0 x 
1010  
120 
patients 
with UC in 
remission 
12 weeks Maintenance of 
remission in UC  
(as effective as 
mesalazine) 
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  2.5.6.2 Crohn’s Disease 
 There are limited numbers of randomized control trials using probiotics in 
Crohn’s disease. The studies completed to date have examined the effectiveness of 
LGG, E. coli Nissle 1917 and S. boulardii in the management of Crohn’s disease.  
 In 1997, Malchow conducted a double-blind pilot study that tested the effects of 
E. coli Nissle 1917 on efficacy and tolerance in maintaining remission in 28 patients 
with active colonic Crohn’s disease. All patients received 60 mg of Prednisolone® and 
then were randomized to receive either E. coli Nissle 1917 (5 x 1010 viable 
bacteria/capsule) or placebo for one year. In both groups, the Prednisolone® was tapered 
according to protocol. All patients receiving prednisolone and E.coli Nissle 1917 were 
able to discontinue steroids six months into the trial, where as only a few patients in the 
placebo group could stop the Prednisolone® completely. In the group receiving the 
E.coli Nissle 1917, 33.3% had a relapse over the one year of treatment period compared 
to 63.6% in the placebo group. Malchow (1997) concluded that the intake of 
Prednisolone® was reduced by the adjuvant application of the E.coli Nissle 1917 in 
patients with colonic Crohn’s disease. 
 In an open trial conducted by Guslandi et al. (2000), 32 patients with Crohn’s 
disease in clinical remission were randomly treated with mesalamine (3g/day) or 
mesalamine (2 g/day) plus S. boulardii (1 g/day) for six months. Clinical relapse was 
observed in 37.5% patients on mesalamine alone versus 6.25% patients receiving 
mesalamine plus S. boulardii (p=0.04). Relapse was assessed using the Crohn’s Disease 
Activity Index (CDAI). All patients completed the study without reporting side effects. 
Gupta et al. (2000) conducted a pilot trial in four children with active Crohn’s 
disease to investigate the effect LGG supplementation on clinical outcome. The patients 
received LGG therapy (1010cfu/ twice daily) in conjunction with their current therapy of 
Prednisone® and immunomodulatory agents. There was significant clinical improvement 
in all four subjects, as evidenced by reduced disease activity scores, improved intestinal 
permeability and a reduction in steroid dose.  
 Prantera et al. (2002) completed a single center, randomized, double-blind, and 
placebo-controlled trial in 45 patients. The study examined the effect of LGG in 
preventing postoperative endoscopic recurrence following intestinal resection in Crohn’s 
 47
 disease. Each patient was randomly allocated to receive 1.2 x 1010cfu/day of LGG or a 
placebo for one year. After 52 weeks of treatment, 83.3% of patients receiving the LGG 
versus 89.4% of patients receiving the placebo remained in remission (p=0.894). Of the 
patients in remission, 60% of the patients in the probiotic treated group had recurrent 
endoscopic lesions compared with 35.3% in the placebo (p=0.0297). The patients 
receiving the LGG also had more severe endoscopic recurrence as compared to placebo. 
The authors concluded that LGG did not reduce the recurrence of lesions nor decrease 
the severity of recurrent lesions. 
 Shultz et al. (2004) enrolled 11 patients with moderate to active Crohn’s disease 
in a randomized, double-blind, placebo controlled trial. All patients were started on oral 
antibiotic treatment for two weeks and started on a tapering steroid regime. Following 
week one, the patients were randomized to receive either LGG (2 x 109 cfu/day) or a 
placebo for six months. Five out of 11 patients completed the trial with two patients in 
each group sustaining remission. Four patients in the treatment group and five patients in 
the placebo group reached remission during the tapering period. The mean time to 
relapse was 16 ± 4 weeks in LGG group and 12 ± 4.3 weeks in the placebo group 
(p=0.05). The researchers could not demonstrate a benefit of LGG in inducing remission 
or maintaining remission in Crohn’s disease.  
 Bousvaros et al. (2005) conducted a randomized, placebo controlled trial with 
LGG in 75 pediatric patients with Crohn’s disease in remission. The probiotic therapy 
was provided in addition to standard medical therapy for two years. Median time to 
relapse in the LGG was 9.8 months and 11.0 months in the placebo group (p=0.24). The 
study was stopped early as the interim analysis showed lack of efficacy. Bousvaros et al. 
(2005) concluded that LGG does not prolong time to relapse over standard medical 
therapy.   
 2.5.6.3 Pouchitis    
 Pouchitis is a non-specific inflammation of the ileal reservoir following surgical 
creation of an ileoanal pouch anal anastomosis following resection of the colon 
(Sandborn, 1994). It is manifested clinically by abdominal pain, diarrhea, urgency, rectal 
bleeding and sometimes systemic features such as fever (Sandborn, 1994). The overall 
prevalence of pouchitis is approximately 50% at ten years follow-up (Tamboli, 
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 Caucheteux, Cortot, Colombel & Desreumaux, 2003). The cause of pouchitis has not 
been clearly established, but the literature suggests that the intestinal flora may be 
disrupted. Pouchitis has been associated with reduced counts of Lactobacilli and 
Bifidobacteria found within the pouch (Gosselink et al., 2004). 
 A systematic review was completed by Sandborn et al. (1998) to determine the 
effectiveness of a variety of medical therapies for inducing or maintaining remission in 
pouchitis. The review included the oral probiotic therapy VSL#3® as a potential 
treatment for pouchitis. At that time, Sandborn et al. (1998) concluded that probiotic 
therapies appear to be efficacious, but selection, dose and duration of therapy remain 
empiric.   
 Gionchetti et al. (2000) conducted a randomized, double-blind, placebo 
controlled trial in 40 subjects with chronic active pouchitis, defined as having at least 
three relapses per year. The subjects were induced into clinical remission after one 
month of antibiotic treatment with ciprofloxacin and rifaximin and then randomized to 
receive VSL#3® (1.8 x 1013 cfu/day) or placebo for nine months. Of the 20 patients who 
received the placebo, 100% relapsed within the nine month period. Of the subjects that 
received the VSL#3®, 85% remained in remission for the nine months (p<0.001). This 
was the first control trial suggesting that probiotics may play a therapeutic role in the 
management of pouchitis.   
 Gionchetti et al. (2003) used VSL#3® (9.0 x 1011 cfu/day) to prevent pouchitis in 
another double-blind, randomized control trial. Following ileostomy closure, 40 patients 
were randomized to receive either VSL#3® or placebo for one year. Pouchitis occurred 
in 40% of the placebo group versus 10% of the VSL#3® group (p<.05). Health related 
quality of life was significantly improved in the probiotic group (p< 0.001).  
 In an open label study, Laake et al. (2003) provided a fermented milk product 
(Cultura®; 500ml) containing 108cfu/ml of Lactobacilli and Bifidobacteria to ten 
patients with IPAA. The primary aim of the study was to determine if inflammation of 
the pouch reservoir is affected by four weeks of treatment with probiotics. Seven out of 
ten patients had reduced macroscopic inflammation in the pouch mucosa after probiotic 
treatment, but histologically the mucosa did not change significantly.    
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  Kuisma et al. (2003) completed a double-blind randomized control trial using L. 
rhamnosus GG to determine the efficacy of a single strain probiotic as a primary therapy 
for pouchitis and its effect on the microflora in the pouch. Twenty patients with history 
of pouchitis were randomized to receive supplements of L. rhamnosus GG (1.0-2.0 x 
1010 cfu/day) or a placebo twice daily for three months. No differences in clinical, 
endoscopic or histological scores were found between baseline and at completion of the 
study following supplementation with L. rhamnosus GG (p=0.97). As a primary therapy, 
L. rhamnosus GG was not effective for the clinical improvement of pouch inflammation. 
L. rhamnosus GG was effective in increasing the ratio of total fecal lactobacilli to total 
fecal anaerobes (p=0.03), but only 40% of patients were colonized with L. rhamnosus 
GG.  
 A subsequent study completed by Gosselink et al. (2004) used a fermented dairy 
product containing L. rhamnosus GG (1.4 x 1010 cfu/day) to delay the onset of pouchitis. 
Episodes of pouchitis were observed less frequently in the patients treated with L. 
rhamnosus GG than in the control group (p=0.011). The first onset of pouchitis was also 
delayed up to three years when a daily dose of the L. rhamnosus GG was provided. The 
authors concluded that daily intake of L. rhamnosus GG when provided as part of a 
fermented product is not only effective in delaying episodes of pouchitis but it is less 
expensive than VSL#3®. 
 Mimura et al. (2004) published results of a multicenter, randomized, placebo-
control trial using the probiotic mixture VSL#3® in 36 patients with recurrent or 
refractory pouchitis, defined as at least two relapses per year. Patients were induced into 
remission by providing four weeks of combined metronidazole and ciprofloxacin and 
then randomized to receive VSL#3® (6.0 x 1011 cfu/day) or placebo once daily for one 
year or until relapse. Remission was maintained at one year in 85% of patients receiving 
VSL#3® and in 6% patients receiving the placebo (p<0.0001). Quality of life scores 
remained high in the VSL#3® group (p=0.3), but deteriorated in the placebo group 
(p<0.0005). 
 Shen et al. (2005) studied 31 patients with antibiotic-dependent pouchitis were 
treated with VSL#3® (6.0 x 1011 cfu/day) for eight months. All patients received a two 
week course of ciproflaxicin or metronizazole prior to starting the VSL#3® therapy. At 
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 eight months follow-up, six patients remained on VSL#3® therapy, where as 23 patients 
discontinued the VSL#3® prior to the eight months because of recurrence of symptoms. 
The endoscopic scores of the six patients that remained on the VSL#3® were not 
significantly different from baseline (p=0.27), suggesting that VSL#3® may reduce 
symptoms of pouchitis but improve endoscopic scores to a lesser degree.  
 2.5.6.4 Irritable Bowel Syndrome (IBS) 
 Irritable bowel syndrome (IBS) is a motility disorder involving the entire 
gastrointestinal tract, causing recurring upper and lower GI symptoms, including 
variable degrees of abdominal pain, constipation and/or diarrhea, and abdominal 
bloating (Beers & Berkow, 2005). 
L. plantarum 299v (5 x 107 cfu/ml) provided in a fruit drink called Pro Viva® 
(Probi AB, Ltd. Sweden) has been studied in IBS with conflicting results (Sen et al., 
2002; Niedzielin, Kordecki & Birkenfeld, 2001; Nobaek , Johansson, Molin, Ahrne & 
Jeppsson, 2000). Sen et al. (2002) administered L. plantarum 299v (125 ml/day) or 
placebo for four weeks in a crossover design. No improvement was noted in symptoms 
or colonic fermentation following administration of the probiotic. Nobaek et al. (2000) 
reported a significant reduction in flatulence and abdominal pain in the patients 
receiving the L. plantarum 299v (400 ml/day) compared with the placebo group. 
Similarly, Neidzielin et al. (2001) found patients treated with L. plantarum 299v (400 
ml/day) had improvement in IBS symptoms and resolution of abdominal pain compared 
with placebo. A trend towards normalization of stool frequency was noted in patients 
with constipation treated with L. plantarum 299v. 
VSL#3® has been used to improve specific symptoms of IBS in two open label 
and two randomized control trials. Kim et al. (2003) provided VSL#3® (9.0 x 1011 
cfu/day) to patients with diarrhea-predominant IBS for eight weeks. An improvement 
was noted in abdominal bloating with VSL#3®, with no effect on other symptoms. A 
subsequent study examining patients with IBS with excess bloating, demonstrated that 
VSL#3® (9.0 x 1011 cfu/day) significantly reduced flatulence and delayed colonic transit, 
but had no effect on abdominal bloating (Kim et al., 2005). Two uncontrolled studies 
using VSL#3® noted clinical improvement related to changes in fecal bacterial flora and 
fecal biochemistry following probiotic administration in patients with diarrhea-
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 predominant IBS (Bazzocchi, Gionchetti, Almerigi, Amadini, & Campieri, 2002; 
Brigidi, Vitali,  Swennen, Bazzocchi  & Matteuzzi, 2001).  
L. casei strain GG (LGG) has been tested in two randomized control trials in 
both adults and children with IBS (Bausserman & Michail, 2005; O’Sullivan & 
O’Morain, 2000). In the study involving adults, LGG (1010 cfu/day) did not improve 
symptoms of bloating, pain or urgency in IBS patients with bloating related symptoms 
(O’Sullivan & O’Morain, 2000). The study involving children with IBS showed similar 
results to the adult study. LGG (1010 cfu/day) did not improve abdominal pain or other 
gastrointestinal symptoms (Bausserman & Michail, 2005).  
More recently, Niv et al. (2005) administered L. reuteri ATCC 55730 (2.0 x 108 
cfu/day for six months) to patients with all types of IBS (constipation-predominant, 
diarrhea-predominant and mixed types) in a double-blind randomized control trial. 
Patients in both the placebo and treatment groups improved with no significant 
differences between the two groups, demonstrating a strong placebo effect. The authors 
concluded that L. reuteri 55730 did not show improvement in any IBS symptoms. The 
lack of uniformity in the subjects may have accounted for the lack of effect.   
A long term, controlled trial using L. rhamnosus GG, L. rhamnosus LC705, B. 
breve Bb99 and Propionibacterium freudenreichii ssp. shermanii JS (8-9 x 109 cfu/day x 
6 months) demonstrated that the probiotic mixture improved abdominal pain, distention, 
flatulence and borborygmi (Kajander, Hatakka, Poussa , Farkkila & Korpela, 2005). A 
trend toward increased stool frequency was noted in the probiotic group with IBS 
(constipation-predominant and mixed type). 
Preliminary data using a combination of L. plantarum LP01 and B. breve BR0 (5 
x 109 cfu/day) or L. plantarum LP01 and L. acidophilus LAO 2 (5 x 109 cfu/day) for 
four weeks in a randomized control trial showed both reduction in abdominal pain scores 
and severity of the pain in the probiotic treated groups versus placebo (Saggioro, 2004). 
Overall symptom scores (included constipation, diarrhea, abdominal pain, bloating, 
flatulence, nausea, dyspepsia and cephalae) also improved in IBS patients receiving the 
probiotics. 
Seventy-five subjects with IBS (all types of IBS included) were randomized to 
receive a malted milk drink containing the probiotic preparations L. salivarius 
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 UCC/1331 or  B. infantis 35624 (1 x1010 cfu) or placebo for eight weeks (O'Mahony et 
al., 2005). Patients receiving the B. infantis 35624 experienced a greater reduction in 
symptoms (e.g., abdominal pain, bloating/distention and bowel movement difficulty) as 
compared to placebo and the L. salivarius UCC/1331 group. There was a trend towards 
improved quality of life scores in the patients receiving the probiotics.  
 2.5.6.5 Lactose Intolerance 
 Individuals with low levels of the lactase enzyme have limited ability to digest 
lactose, which can result in intestinal distress or lactose intolerance. Symptoms of 
lactose intolerance include loose stools, abdominal bloating, pain, flatulence and nausea 
after eating a lactose containing food (Haubrich, Schaffner & Berk, 1995). Probiotics are 
believed to adhere to the intestinal lining and digest dietary lactose, alleviating the 
symptoms of lactose intolerance (Levri, Ketvertis, Deramo, Merenstein & D’Amico, 
2005).  
 A recent systematic review investigating the effectiveness of probiotics in 
reducing symptoms of lactose intolerance (Levri et al., 2005), included seven 
randomized placebo controlled studies with the majority of studies using the probiotic 
strain L. acidophilus. Five of seven studies yielded negative results, one positive results 
and one reported both positive and negative outcomes. The authors concluded that 
probiotics do not reduce lactose intolerance. However some individuals will have 
symptoms eliminated for unknown reasons. A small pilot study using the multi-strain 
probiotic VSL#3® in ten patients with lactose intolerance, failed to demonstrate 
improvement in clinical symptoms and H2 excretion (Yesovitch, Cohen & Szilagyi, 
2004).   
 2.5.6.6 Diarrhea  
 The strongest evidence for the use of probiotics in gastrointestinal illness has 
been in the treatment of diarrhea. The efficacy of the probiotic against diarrheal illness 
depends on the type of diarrhea and differs between infectious, antibiotic-associated, C. 
difficile-associated and traveller’s diarrhea.     
 2.5.6.6.1 Acute Infectious Diarrhea in Children 
 The most well established benefit of using probiotics has been in the 
management of acute pediatric diarrheal disease. A number of randomized, placebo-
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 controlled trials have been completed in both the United States and Europe, which have 
evaluated several strains of probiotics in the treatment of acute diarrhea in children. Two 
meta-analyses of published controlled clinical trials of probiotic therapy in children with 
acute-onset diarrhea have been completed to date (Huang, Bousvarous, Lee, Diaz & 
Davidson, 2002; Van Niel, Feudtner, Garrison;Christakis, 2002).  Huang et al. (2002) 
included 18 randomized control trials of probiotic therapy in healthy children < 5 years 
of age with acute onset diarrhea. Co-administration of probiotics with oral rehydration 
therapy was found to reduce the duration of diarrhea by approximately one day in favor 
of the probiotic-treated subjects (95% confidence interval -1.1 days to -0.6 days, 
p<0.001). Further subanalyses limited to hospitalized children, double-blind trials and 
studies using Lactobacilli resulted in similar pooled estimates (-0.6 to -1.2 days, 
p<0.001). Van Niel et al. (2002) completed meta-analyses of nine randomized, placebo-
controlled studies examining the effect of Lactobacillus on the duration of diarrhea and 
diarrhea frequency. All subjects in the nine studies received oral rehydration therapy in 
addition to the Lactobacillus therapy. The Lactobacillus therapy reduced the duration of 
the diarrhea by 0.7 days (95% confidence interval: -0.3 to 1.2 days) compared with 
controls. Lactobacillus GG therapy appeared to have a greater reduction in the duration 
of diarrhea (a reduction of 1.2 days; 95% confidence interval: -1.6 to -0.08 days, 
p<0.001). A reduction in diarrhea frequency by 1.6 stools on the second day of treatment 
with Lactobacillus was also noted (95% confidence interval: 0.7-2.6 fewer stools).  
 2.5.6.6.2 Clostridium Difficile-Associated Diarrhea  
 Clostridium difficile is a gram-positive, anaerobic bacillus that colonizes the 
human large intestine and produces at least two exotoxins: Toxin A (endotoxin) and 
Toxin B (cytotoxin) (Beers & Berkow, 2005). Colonization by this organism and 
subsequent infection occur in response to disruption of the stability of the microflora, 
usually following antibiotic therapy (Plummer, Weaver, Harris, Dee & Hunter, 2004). 
Clostridium difficile-associated diarrhea is one of the most common causes of infectious 
diarrhea in hospitalized patients (Plummer et al., 2004).   
 A recent meta-analysis examined the effectiveness of probiotics in the treatment 
of Clostridium difficile-associated diarrhea (McFarland, 2006).  McFarland (2006) 
included six randomized control trials which used a variety of probiotic preparations (L. 
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 rhamnosus GG, L. plantarum 299v, S. boulardii or LABB (L. acidophilus and B. 
bifidum), dosages (mean 5 x 1010 cfu/day) and duration (median 3 weeks). From the six 
randomized control trials examined, probiotics showed significant efficacy for reducing 
recurrences of Clostridium difficile-associated diarrhea (RR=0.59, 95% confidence 
interval: 0.41, 0.85, p<0.005). Two trials reported a 33% reduction in Clostridium 
difficile-associated diarrhea recurrences in the probiotic treated group compared with the 
placebo group. Five of the six randomized control trials used standard antibiotics (e.g., 
vancomycin or metronidazole) in combination with probiotic therapy. S. boulardii was 
the only probiotic preparation that showed significant efficacy in reducing the 
recurrences of Clostridium difficile-associated diarrhea. Further studies need to focus on 
expanding the types and dosages of probiotic, as well as provide sufficient power to 
detect a significant. 
 2.5.6.6.3 Antibiotic-Associated Diarrhea (AAD)  
 Six meta-analyses have evaluated the efficacy of probiotics in prevention of 
AAD (Cremonini et al., 2002; D’Souza, Rajkumar, Cooke & Bulpitt, 2002; Szajewska & 
Mrukowicz, 2005; McFarland, 2006; Sazawal, Hiremath, Shingra, Malik, Deb & Black, 
2006; Johnston, Supina & Vohra, 2006). The meta-analyses included studies completed 
in both children and adults. 
 Cremonini et al. (2002) analyzed seven randomized, placebo-controlled trials, 
with a minimum of two weeks of follow-up with administration of either Lactobacillus 
ssp. or S. boulardii. A total of 881 patients were included in the seven trials. Cremoni et 
al. (2002) found that supplementation with probiotic therapy resulted in a combined 
relative risk reduction of 0.3966 (95% confidence interval: 0.27, 0.57).  
 D’Souza et al. (2002) examined nine randomized, double-blind, placebo-
controlled trials that looked at prevention of AAD. The study regimens used probiotics 
combined with one antibiotic or a variety of antibiotics. The probiotic strains used in the 
trials were S. boulardii, Lactobacilli spp., Bifidobacteria spp., E. faecium or a 
combination of probiotic strains. The odds ratio in favor of the probiotic treatment in 
preventing AAD was 0.37 (95% confidence interval: 0.26, 0.53). Six studies showed a 
significant benefit of probiotic treatment compared with placebo (p<0.05). The authors 
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 concluded that Lactobacilli spp.and S. boulardii have the greatest potential to prevent 
AAD.  
 Szajewska and Mrukowicz (2005) evaluated the effectiveness of S. boulardii in 
preventing AAD in children and adults. Five randomized control trials (1076 
participants) were analyzed and found that treatment with S. boulardii compared with 
placebo reduced the risk of AAD from 17.2% to 6.7% (RR: 0.43; 95% CI: 0.23-0.78). 
The number needed to treat to prevent one case of antibiotic-associated diarrhea was 10 
(95% CI: 7-16). 
 The largest meta-analysis completed to date, examining the efficacy of probiotics 
in the prevention of AAD involved 25 randomized control trials (2,810 patients) 
(McFarland, 2006). Of the 16 trials that involved adults, 44% (7) showed significant 
efficacy for probiotics and 67% (6) of the trials that involved children had significant 
efficacy. The combined efficacy shows that probiotics have a significant protective 
effect for AAD. The relative risk reduction for AAD was 0.43 (95% confidence interval: 
0.31, 0.58 p<0.001). A variety of probiotic strains were assessed in this meta-analysis, 
but two single probiotic strains (S. boulardii and L. rhamnosus GG), as well as mixtures 
of two different strains of probiotics significantly reduced the development of AAD. 
Daily dosages ranged from 107 to 1011 and duration of treatment ranged from five days 
to eight weeks. High daily dosages of probiotic (≥1010/day) were associated with 
significant efficacy for reducing the incidence of AAD; where as duration of probiotic 
administered did not significantly differ between the trials.  
 Sazawal et al. (2006) pooled 19 trials with data on AAD and found similar 
results to previously published meta-analyses. Probiotics reduced the incidence of AAD 
by 52% (95% confidence interval, 35, 65% p<0.001).  
 Johnston et al. (2006) evaluated the potential effectiveness of probiotics in 
preventing AAD in pediatric patients less than 19 years of age (n=707 patients). Pooled 
results yielded favorable results for the efficacy of probiotics (RR: 0.43; 95% CI: 0.25-
0.75); treatment of six patients should prevent one case of diarrhea. These findings are 
consistent with D’ Souza et al. (2002) and Cremonini et al. (2002). 
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  2.5.6.6.4 Traveller’s Diarrhea 
 Probiotics have been used as prophylaxis in traveller’s diarrhea in an attempt to 
colonize the gut with beneficial bacteria that compete with pathogenic bacteria for 
nutrients and binding sites in the gastrointestinal tract. 
 Sazawal et al. (2006) completed a meta-analysis of six randomized control trials 
which examined the efficacy of probiotics in the prevention of traveller’s diarrhea. The 
probiotics used in these trials included L. rhamnosus GG, S. boulardii, L. fermentum 
KLD and L. acidophilus. Of the six trials, three had positive point estimates but did not 
achieve statistical significance. Probiotics reduced the incidence of traveller’s diarrhea 
by 8% (95% confidence interval: -6%, 21%; p=0.235). 
 2.5.6.7 Necrotizing Enterocolitis (NEC)  
 The pathogenesis of NEC may be related to the colonization of pathogenic 
bacteria in the bowel leading to development of an abnormal fecal flora, which in turn 
causes mucosal injury or bowel necrosis (Bin-Nun et al., 2005). Probiotics may protect 
against NEC by altering the intestinal microbial flora from one that contains harmful 
bacteria to one that is beneficial to the host (Lin et al., 2005). Bifidobacteria and 
Lactobacilli are the two most common species of probiotic bacteria found in the 
intestinal lumen of healthy infants, therefore have been the most studied in NEC (Dani, 
Biadaioli, Bertini, Martelli, & Rubaltelli, 2002, Hoyas, 1999, Lin et al., 2005; Bin Nun 
et al., 2005). 
 In an open label study, Hoyos (1999) provided daily doses of 2.5 x 108 live L. 
acidophilus and 2.5 x 108  live B. infantis to 1237 newborns admitted to a neonatal 
intensive care unit over a one-year period. The newborns received the probiotics during 
their entire length of stay; 1282 patients hospitalized in the previous year were used as 
the control group. In the control group there were 85 cases of NEC compared to 34 cases 
in the probiotic fed group (p<.0002). There were 35 NEC associated fatalities in the 
control group compared to 14 NEC associated fatalities in the probiotic fed group 
(p<0.005). The results showed a significant reduction in the incidence of NEC and NEC 
associated deaths in the infants treated with probiotics versus the controls.   
 A multicenter, double-blind, prospective study randomized 585 patients born <33 
weeks gestation or at a birth weight of < 1500 g to receive Lactobacillus GG (6 x 109 
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 cfu/day) or placebo once daily until discharge (Dani et al., 2002). The investigators were 
evaluating the effectiveness of Lactobacillus GG supplementation in reducing the 
incidence of NEC. The incidence of NEC was 1.4% in the probiotic fed group versus 
2.8% in the placebo, these difference were not significant. Dani et al. (2002) concluded 
that Lactobacillus GG did not reduce the incidence of NEC. 
 A prospective, masked, randomized control trial of 367 very low birth weight 
(VLBW) infants who survived greater than seven days were randomized to receive 
either breastmilk supplemented with probiotics (L. acidophilus and B. infantis; dosage 
2.0 x 106 cfu/day) or breastmilk alone from the start of feeds until the time of discharge 
(Lin et al., 2005). The incidence of death or NEC was significantly lower in the 
probiotic fed group (5%) versus the control group (12.8%) (p=0.009). The incidence of 
NEC was lower in the probiotic fed group (1.1%) versus the control group (5.3%) 
(p<0.05). There were six cases of severe NEC in the control group, but no cases in the 
probiotic fed group. Lin et al. (2005) concluded that L. acidophilus and B. infantis 
reduces the severity and incidence of NEC in VLBW infants.     
 In a double-blind study, 145 VLBW infants were randomized to receive either 
placebo or a probiotic mixture of B. infantis, S. thermophilus and B. Bifidus (109 
cfu/day) from the initiation of feeds until discharge (Bin-nun et al., 2005). The incidence 
of NEC was significantly reduced in the probiotic supplemented group (4%) versus the 
control group (16.4%) (p<0.05). NEC was also less severe in the probiotic supplemented 
group. All NEC related deaths occurred in the control group, where as there was no NEC 
related deaths in the probiotic supplemented group. A trend towards improved weight 
gain was noted in the probiotic supplemented group but the results were not significant.  
 2.5.6.8 Helicobacter pylori Gastritis 
 Scientific studies have suggested a role for probiotics in the treatment and 
prevention of Helicobacter pylori. Helicobacter pylori is a gram-negative bacteria that 
specifically colonizes the gastric mucosa, inducing a chronic and, in most people, 
asymptomatic gastritis (Marshall, 1994). It is currently recognized as an etiologic agent 
of gastroduodenal ulcer and a risk factor for the development of gastric lymphoma or 
adenocarcinoma (Marshall, 1994). Some strains of Lactobacillus and Bifidobacterium 
have been shown to exert bacteriostatic or bactericidal effects against H. pylori through 
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 the release of bacteriocins or organic acids in both in vitro and in vivo models 
(Gotteland, Brunser & Cruchet, 2006; Cruchet, Obregon, Salazar, Diaz & Gotteland, 
2003). Probiotics also have a possible role in stabilization of the gastric barrier function 
and decreasing mucosal inflammation in the gastric mucosa (Gotteland et al., 2006).  
 Gotteland et al. (2006) recently conducted a systematic review of the clinical 
trials using probiotics in adults and children colonized with H. pylori. The authors 
concluded that probiotics as a single therapy do not appear to eradicate H. pylori but 
may maintain lower levels of this pathogen (Gotteland et al., 2006). The probiotic strains 
L. johnsonii (Pantoflickova et al., 2003), L. gasseri (Sakamoto et al., 2001), L. casei 
(Tursi, Brandimarte, Giorgetti & Modeo, 2004) and Clostridium butyricum (Shimbo et 
al., 2005) appear to be most promising in reducing the density of colonization of H. 
pylori. When probiotics are administered in combination with antibiotics, probiotics may 
increase eradication rate and decrease adverse effects associated with antibiotic therapy 
(Gotteland et al., 2006). The probiotic strains L. acidophilus alone (Canducci et al., 
2000) and the mixture of L. acidophilus and B. lactis (Sheu et al., 2002) when provided 
in combination with antibiotic therapy appear to improve eradication of H. pylori.  
 
 
2.6 SYNBIOTIC  
2.6.1 Definition 
 Synbiotic refers to a mixture of prebiotics and probiotics that beneficially affect 
the host by improving the survival and implantation of live microbial dietary 
supplements in the gastrointestinal tract by selectively stimulating the growth and/or by 
activating the metabolism of one or a limited number of health-promoting bacteria, and 
thus improving host welfare (Gibson & Roberfroid, 1995). Synbiotic therapy aims to 
generate synergistic effects by combining prebiotic and probiotic treatments and is 
predicted to be effective against diseases caused by abnormal gastrointestinal flora 
(Kanamori et al., 2004). A product containing the prebiotic inulin and the probiotic 
Bifidobacteria fulfill the synbiotic definition (Schrezenmeir & De Vrese, 2001). 
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 2.6.2 Synbiotic Therapy in Gastrointestinal Disease 
 Synbiotic therapy is a potent new strategy used to treat various intestinal diseases 
such as IBD, diarrhea, short bowel syndrome, malignant colonic disease and viral and 
bacterial infections. 
2.6.2.1 Ulcerative Colitis 
 Furrie et al. (2005) developed a synbiotic therapy to treat UC patients with active 
disease. The probiotic B. longum (2 x1011 cfu/day) and a prebiotic (Synergy 1), made up 
of inulin-oligofructose (12 g/day), were administered to 18 patients with active UC for a 
period of one month. The study was a double-blind, randomized control trial. Furrie et 
al. (2005) demonstrated that the synbiotic therapy resulted in improvements in 
inflammatory markers, reduced inflammation in the rectal mucosa and regeneration of 
epithelial tissue in patients with active UC. Furrie et al. (2005) concluded that the short 
term synbiotic therapy for active UC resulted in improvement of the full clinical 
appearance of chronic inflammation.  
2.6.2.2 Diarrhea 
 The concurrent administration of L. rhamnosus, dietary fibre and micronutrients 
has shown significant effects on duration of diarrhea (Ahmad, Widjala, Firmansyah, 
Gliwitzki & Suhardjo, 2000). In a double-blind, randomized control trial, 58 children 
with acute gastroenteritis were randomized to receive a low lactose formula with or 
without the L. rhamnosus and oligofructose. Ahmad et al. (2000) reported that the 
duration of diarrhea was significantly reduced in the supplemented group (1.63 versus 
2.45 days). A trend toward a reduction in stool output was noted in the supplemented 
group but the results were not statistically significant.  
2.6.2.3 Short Bowel Syndrome 
 Short bowel syndrome refers to patients that have undergone massive bowel 
resection. An inadequate absorptive surface often results in severe malnutrition and 
bacterial overgrowth of the intestine (Beers & Berkow, 2005). Regulation of intestinal 
bacterial overgrowth in patients with short bowel syndrome is necessary to maximize the 
absorptive capacity of the intestine (Kanamori, Hashizume, Sugiyama, Morotomi & 
Yuki, 2001). Typically patients with bacterial overgrowth are treated with antibiotics, 
but an alternative strategy of applying prebiotics and probiotics has been reported. 
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  Kanamori et al. (2001) administered synbiotic therapy to a four year old girl 
suffering from bacterial growth as a result of short bowel syndrome. The synbiotic 
therapy L. casei, B. breve and galactooligosaccharides and were administered for two 
years. In this case report, the patient’s intestinal absorptive capacity and motility 
improved. After two years, the patient’s fecal bacterial flora was anaerobic dominant 
and the pathogenic bacteria (e.g., E. coli and Candida) were suppressed.     
 Refractory enterocolitis is a serious problem in pediatric surgical patients 
suffering from short bowel syndrome (Kanamori et al., 2004). Large amounts of 
pathogenic bacteria have been found in the bacterial flora of patients with refractory 
enterocolitis (Kanamori et al., 2004). Seven malnourished patients with chronic 
refractory enterocolitis, as a result of short bowel syndrome, received synbiotic therapy 
(e.g., B. breve, L. casei and galactooligosaccharides) for over one year (Kanamori et al., 
2004). The synbiotic therapy improved the intestinal bacterial flora by inducing the 
domination of anaerobic bacteria and suppressed the growth of pathogenic bacteria. 
Short chain fatty acids were also significantly increased in the feces.    
2.6.2.4 Colon Cancer 
 There are currently no published human clinical trials that examine the efficacy 
of probiotic preparations on colon cancer risk or colon cancer suppression. Evidence is 
primarily from animal and in vitro studies. However, there is an ongoing clinical trial 
involving eight research centers in Europe called the SYNCAN project. The SYNCAN 
project will examine the effects of a synbiotic preparation on colon cancer risk 
biomarkers in humans (Van Loo et al., 2005) This study is a 12 week randomized, 
double-blind, placebo-controlled trial of a food supplement containing Lactobacillus 
GG, B. Bb-12 and Raftilose Synergy 1 in adenoma patients. Colonic mucosal markers, 
fecal water markers and immunological markers are being measured. To date, results 
from the human intervention study have not been published.  
 2.6.2.5 Helicobacter Pylori Gastritis 
 One randomized control trial has examined the effect of a synbiotic on H. pylori 
eradication in children (Gotteland, Poliak, Cruchet, & Brunser, 2005). L. acidophilus LB 
or S. Boulardii plus inulin were compared with standard antibiotic treatment in182 
children colonized with H. pylori. Gotteland et al. (2005) reported that H. pylori was 
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 eradicated in 66% receiving antibiotics, 12% receiving the synbiotic and 6.5% of the 
children receiving the L. acidophilus LB. 
  
 
2.7 HYDROGEN SULFIDE 
2.7.1 Introduction 
There is growing evidence to suggest that hydrogen sulfide may play a role in 
initiation and perpetuation of mucosal damage in the colon (Figure 2.2) (Roediger, 
Moore & Babidge, 1997). Hydrogen sulfide is produced in the colonic contents by the 
action of sulfate-reducing bacteria (SRB) on dietary sulfate and sulfur amino acids 
(Jorgensen & Mortensen, 2001). SRB use sulfate as terminal electron acceptor in the 
electron transport chain for the dissimilation of short chain fatty acids or molecular 
hydrogen which are produced during colonic fermentation (Gibson, 1990). Hydrogen 
sulfide is the end product of bacterial sulfate respiration. It has been shown that patients 
with UC have significantly higher concentrations of sulfate reducing bacteria (Roediger 
et al., 1997) and luminal concentrations of luminal hydrogen sulfide (Pitcher, Beatty & 
Cummings, 2000) as compared to healthy controls. Thus, a role for colonic sulfide in the 
pathogenesis and treatment of UC has emerged (Roediger et al., 1997).  
 
Figure 2.2 Possible Mechanism for Pathogenesis of Hydrogen Sulfide in UC 
Dietary 
sulfate 
 
2.7.2 Impaired Colonic Epithelial Cell Metabolism in UC 
Roediger (1980) investigated the metabolism of butyrate in isolated colonic 
epithelial cells in a group of patients with both active and quiescent UC. Roediger 
(1980) found that in both acute and quiescent UC, oxidation of butyrate was 
significantly lower in UC tissues than in the control tissues, and the decrease correlated 
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 with the state of the disease. The diminished oxidation of butyrate was suggested to be 
due to a metabolic defect in the mucosa which explained the characteristic distribution 
of colitis in the colon of patients with UC (Roediger, 1980). The most compelling 
evidence to support this theory is derived from animal models. Rectal instillation of 
sodium 2-bromo-octanoate in rats, a potent inhibitor of butyrate oxidation, produces 
histological, clinical and biochemical lesions of acute UC similar to those found in UC 
in man (Roediger & Nance, 1986). In animal models, fecal concentrations of SCFAs in 
the colon parallel the severity of the lesions in UC (Stonerook, Tefend, Sharma, Peck, & 
Wood,  1996). Stonerook et al. (1996) found that in the cotton-top tamarin model of 
colitis, tamarins with moderate or severe colitis had significantly reduced levels of fecal 
SCFAs and progressive inflammation in a pattern similar to human colitis (Stonerook et 
al., 1996). Observations in vivo, in patients with active UC, show significantly lower 
butyrate oxidation than healthy controls (Den Hond et al., 1998). Den Hond et al. (1998) 
found that oxidation of butyrate was not decreased in most of the patients with UC in 
remission. Data (both in vivo and in vitro) supports the role of impaired colonic 
epithelial cell metabolism in the pathogenesis of UC. 
 
2.7.3 Hydrogen Sulfide and Colonic Epithelial Cell Metabolism 
Although some sulfur containing compounds are required for the production of 
butyrate, higher concentrations result in toxic effects. There is increasing evidence to 
suggest that excess hydrogen sulfide impairs the oxidation of butyrate in colonocytes 
(Roediger, Duncan, Kanpaniris, & Milliard, 1993). Roediger et al. (1993) demonstrated 
that when human colonocytes are exposed to hydrogen sulfide, fatty acid oxidation was 
impaired leading to similar metabolic abnormalities observed in active UC. Ohge et al. 
(2005) demonstrated that patients with ongoing pouchitis released significantly more 
hydrogen sulfide in the pouch contents than patients with inactive disease. Hydrogen 
sulfide in the feces of UC patients has been found to be elevated 3-4 fold compared to 
feces of healthy controls (Levine, Ellis, Furne, Springfield, & Levitt, 1998). Patients 
with active UC have also been found to have higher amounts of SRB with clinically 
active disease compared with patients in remission (Ohge et al., 2005; Pitcher et al., 
2000). Pitcher et al. (2000) demonstrated that SRB were almost three log values higher 
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 in feces of active UC patients as compared to quiescent UC and total viable counts 
correlated with clinical severity grade. 5-aminosalicylic acid (5-ASA), a common drug 
used to treat UC, has been shown to significantly suppress hydrogen sulfide production, 
by reducing the fermentative production of sulfide from sulfur amino acids (Pitcher et al, 
2000). Fecal sulfide levels of UC patients receiving 5-ASA have been found to be 
significantly lower than those patients not receiving 5-ASA (Pitcher et al., 2000). 
The finding that the feces of patients with UC tend to have higher SRB and 
higher levels of hydrogen sulfide may provide valuable insight into the pathogenesis of 
UC. 
 
2.7.4 Nutrition Sources of Sulfate 
 Intestinal sulfate is derived from exogenous sources, namely sulfate in drinking 
water and sulfur-containing foods (Roediger et al., 1997). Much of the sulfate derived 
from foods is from preservatives. Diets rich in dried fruits, Brassica vegetables, sausages 
and beer contain substantial sulfate concentrations (Florin et al., 1993). Sulfate is also 
derived from the sulfur containing amino acids.  Neither an Estimated Average 
Requirement (and thus a Recommended Dietary Allowance) nor an Adequate Intake for 
sulfate has been established (Institute of Medicine, 2004). 
 Sulfate is also commonly found in drinking water. Health concerns regarding 
sulfate in drinking water have been raised because of reports that diarrhea may be 
associated with the ingestion of water containing high levels of sulfate (Government of 
Saskatchewan [GOS], 2003 & United States Environmental Protection Agency, 1994).  
The laxative effect is often observed in water containing over 500 mg/L of sulfate (GOS, 
2003). Sulfate levels in central Canada are particularly high, out of 428 sampling 
locations across Alberta and Saskatchewan, 13% had sulfate concentrations of greater 
than 500 mg/L (Health Canada, 1994). In Saskatchewan, median levels of sulfate 
concentrations of drinking water range from 3 to 2170 mg/L when derived from private 
wells (Health Canada, 1994). The Saskatchewan Drinking Water Quality Standards and 
Objectives has established an aesthetic objective of less than 500 mg/L of sulfate in 
drinking water based on the potential for laxative effects (GOS, 2003). 
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 2.8 MALTODEXTRINS 
2.8.1 Introduction 
Maltodextrins used commercially, are derived from corn, potato and rice 
starches. They represent a mixture of saccharides with varying molecular weights 
between oligosaccharides and polysaccharides. Maltodextrins are available as dried 
white powders or in concentrated liquid forms. Maltodextrins are water soluble and have 
very little taste.   
 
2.8.2 Properties of Maltodextrins 
Maltodextrins are defined as hydrolysis products of starches with a dextrose 
equivalent (DE) of less than 20 (Wang & Wang, 2000). DE value is a measure of the 
total reducing power of all sugars present relative to glucose which has a DE of 100 
(Wang & Wang, 2000). A high DE value means that the product has been subjected to a 
greater degree of hydrolysis. Variations in DE values results in maltodextrins with 
varying physiochemical properties (Chronakis, 1998). Hygroscopicity, solubility, 
osmolality and their effectiveness to reduce the freezing point increase with increasing 
DE. Viscosity and cohesiveness increase as the DE decreases (Chronakis, 1998). 
Hydrolysis products with a DE greater than 20 are considered syrups. 
Maltodextrins contain linear amylase and branched amylopectin degradation 
products (Chronakis, 1998). α-Amylase employed in starch hydrolysis cleaves the α-1-4 
linkages of the starch molecule at random with little to no effect on the α-1-6 linkages 
(Wang & Wang, 2000). Thus, maltodextrin contains α-D-glucopyranosyl residues joined 
by α-1-4 linkages to give linear chains with a degree of α-1-4 with α-1-6 linked or α-1-6 
linked branch points (Chronakis, 1998). They have the same general formula as other 
carbohydrates but are of shorter chain length. Maltodextrins are easily digestible, being 
absorbed as rapidly as glucose. 
Resistant maltodextrins (RMD) are produced from hydrolysis and subsequent 
enzymatic treatment of starch to purposefully convert a portion of the normal α-1-4 
glucose linkages to random 1-2, 1-3, and 1-4 alpha or beta linkages (Matsutani America, 
2006). The human digestive system effectively digests only α-1-4 linkages; therefore the 
other linkages render the molecules resistant to digestion. 
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2.8.3 Food Applications of Maltodextrins 
Maltodextrins are used in the food industry as food additives. They have the 
ability to absorb waters and form gels, therefore are used as texture modifiers and as fat 
substitutes. (Chronakis, 1998). Some of the main food applications of maltodextrins are 
in salad dressings, rehydration drinks, dairy products, baked goods and in 
confectioneries (Chronakis, 1998). One of the most novel applications of maltodextrin is 
its recent use as a dietary fibre. Fibersol-2® is a maltodextrin, resistant to human 
digestion (i.e., resistant maltodextrin) which is currently being added to a variety of food 
products in Europe, Japan and the USA to increase dietary fibre content (Matsutani 
America, 2006) and for its demonstrated prebiotic effects. 
 
 
2.9 SUMMARY OF THE LITERATURE 
Human studies support the idea that prebiotics and probiotics modify disease 
states, such as UC by altering bacterial composition, immune status and inflammation. 
Until recently, prebiotic and probiotics were considered alternative medicine, but there is 
now increasing scientific evidence to support the use of both prebiotics and probiotics in 
the management of UC.  
 Four randomized control trials and one open label trial have demonstrated that 
when probiotics are provided in addition to standard medications, remission was not 
only achieved faster, but endoscopic and histological scores were significantly 
improved. A variety of probiotic preparations and dosages have been studied, with 
limited adverse effects reported. More research is needed to determine the optimal strain 
and dosage of probiotics needed for both active UC and UC in remission.  
 Prebiotics offer an exciting potential treatment for patients with UC. The 
rationale for stimulating the growth of Bifidobacteria and Lactobacillus is uncontested. 
To date there have been no published studies that have used inulin or FOS in 
maintaining or inducing remission in UC. Administration of prebiotics seems to be a 
safe, physiological and could be considered as prophylactic therapy for those individuals 
living with bowel diseases. Although this therapy appears promising, more clinical trials 
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 need to be completed to firmly establish the efficacy of prebiotics in the management of 
UC.    
Synbiotic therapy is the most recent novel idea used to induce favorable 
intestinal environments in the host (Gibson & Roberfroid, 1995). Scientific research in 
the area of synbiotic therapy and UC is limited to one open label trial, but it appears to 
be a promising supportive therapy. More long-term, large scale clinical trials are needed 
using synbiotics. 
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 CHAPTER 3 
RESEARCH METHODS 
 
 
3.1 Study Design 
 The study was initially approved as a single center, randomized, double-blind, 
placebo controlled study examining the effect of B. longum R0175 and inulin on 
maintaining remission in pediatric UC. The study was to be completed over a period of 
12 months. Ten months into the study, a novel report by Furrie et al. (2005) was 
published. Furrie et al. (2005) indicated that treatment with synbiotic therapy using both 
B. longum and inulin resulted in clinical improvement of chronic inflammation in adults 
with active UC. This finding, along with the observation that some subjects in our study 
were clinically well and some subjects were doing quite poorly (as indicated by low 
quality of life scores and the presence of severe symptoms), the latter potentially 
receiving the placebo, prompted us to ask the Biomedical Research Ethics Board at the 
University of Saskatchewan for guidance. The Biomedical Research Ethics Board 
indicated that the study must be unblinded. The remainder of the study was conducted as 
an open label trial. The single center, randomized, double-blind, placebo controlled 
study is called Phase I – Pediatric Pilot Study. Phase II – Pediatric Case Series is the 
open label portion of the study. Phase III - Adult Case Series was completed as an open 
label study.  
 
3.2 Recruitment 
 Pediatric subjects were recruited through a pediatrician in the Saskatoon Health 
Region that specializes in gastroenterology. The pediatrician provided the names of 
potential subjects to the research coordinator. Chart reviews were completed to 
determine the subjects that were eligible for the study. The parent or caregiver of each 
eligible subject was contacted by telephone where a brief description of the study was 
provided (Appendix 1.1). If the parent or caregiver and eligible subject showed interest 
in participating in the study, a meeting was organized to discuss the study in further 
detail. 
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  In order to increase the sample size, pediatricians from three pediatric hospitals 
in Western Canada (Winnipeg Children’s Hospital, Stollery Children’s Hospital and 
Regina General Hospital) were asked to participate in the study. A letter describing the 
study was sent to each of the pediatricians (Appendix 1.2). A follow-up phone call or e-
mail was completed within two weeks of sending the initial letter to ensure the 
pediatricians received the letter and to discuss potential participation in the study. The 
pediatric gastroenterologists from Winnipeg Children’s Hospital and Stollery Children’s 
Hospital reported being unable to participate; in one case, a group was currently running 
a probiotic trial in UC subjects and could not run another trial concurrently. A 
pediatrician at Regina General Hospital was contacted and expressed interest in 
participating in the trial. A meeting was organized to discuss further details of the study. 
The pediatrician had two pediatric patients that were eligible to participate in the study. 
One of the two patients was already involved in the study. The pediatrician indicated 
that he would discuss the study with the remaining patient and provide the family with 
study coordinator’s contact information. The family did not contact the research 
coordinator. 
 Due to the lack of success in recruiting pediatric subjects, the decision was made 
to expand the recruitment demographic to include adult subjects between the ages of 19 
to 40 years from the Saskatoon Health Region. Three adult gastroenterologists and one 
surgeon (involved with patients with UC) from the Saskatoon Health Region were 
contacted by letter to participate in the study (Appendix 1.3). All four physicians 
expressed interest in participating in the study. Meetings were held with all four 
physicians. Two of the four physicians decided to participate in the study. The 
physicians forwarded the names of the eligible subjects to the research coordinator.
  
3.3 Phase I – Pediatric Pilot Study 
3.3.1 Participants 
 Eligible subjects were between the ages of 8 and 18 years of age and had been 
diagnosed with UC in remission, defined as the absence of visible blood in the stools 
and less than two bowel movements per day. The initial diagnosis of UC had to have 
been confirmed by endoscopic and histological examination. Corticosteroid therapy was 
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 allowed up to two weeks prior to study initiation. Subjects were excluded if they had a 
non-intact colon (colectomy) or were considered to be immunocompromised by the 
attending physician. 
Approval for the study was granted by the Biomedical Research Ethics Board of 
the University of Saskatchewan, Saskatoon, Saskatchewan (Appendix 2.1 and 2.2). 
Written and informed consent was obtained from both the caregiver and the child before 
participation (Appendix 3.1.1 and 3.1.2).  
 
3.3.2 Study Medication 
 Institut Rosell (Montreal, QC, Canada) provided the placebo capsule 
(maltodextrin and ascorbic acid) and the probiotic (B. longum R0175 in maltodextrin 
and ascorbic acid, 2.0 x 1010 cfu/capsule). The placebo capsule and probiotic capsule 
were packaged in a laminate foil envelope (45 capsules per envelope). Although the 
probiotic was a freeze-dried formulation, it was advised by the Institut Rosell to keep the 
probiotic refrigerated. All stock was stored at four degrees and all subjects were 
instructed to store the laminate foil envelope at refrigeration temperature. 
 Sensus America LLC (Monmouth Junction, NJ, USA) supplied the inulin 
(Fruitafit® CLR).  Fruitafit® CLR is a mixture of both short and long chain 
oligosaccharides. Fifteen grams of inulin was weighed out on an electronic scale and 
placed in a sachet. Corn Products International, Inc. (Casco Incorporated, Etobicoke, 
Ontario, Canada) provided the maltodextrin (Casco, Globe Plus, 18 DE - Maltodextrin). 
Fifteen grams of maltodextrin was weighed out on an electronic scale and placed in a 
sachet. The weighing of the maltodextrin and the inulin was completed by a summer 
student. Taste and smell of the active treatment and placebo were not readily 
identifiable. 
 Every three months, the study medications were delivered via courier to the 
homes of the study participants in a cooled container for both the placebo and treatment 
groups.  
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 3.3.3 Randomization of Subjects 
 Phase I of the trial was designed as a randomized double-blind, placebo control 
trial. Eligible subjects were randomly allocated to the control group (15 g/day of non-
resistant maltodextrin, and a control capsule of maltodextrin and ascorbic acid) or the 
treatment group [15 g/day of inulin (Fruitafit® CLR, Sensus America LLC., Monmouth 
Junction, NJ, USA) and B. longum R0175 (Institut Rosell, Montreal, QC, Canada) at a 
dosage of 2.0 x 1010 cfu/capsule] for ten months or until relapse. Treatment allocation 
was performed by a staff member of the Department of Applied Microbiology and Food 
Science, University of Saskatchewan. The group assignment was not revealed to the 
research coordinator, physician, subjects or families.    
 
3.3.4 Study Protocol 
 At study entry, subjects and families were counseled regarding the study 
protocol. Subjects were instructed to consume one capsule containing the probiotic 
supplement (B. longum R0175 and 15 g of powdered inulin) or the placebo capsule and 
15 g of maltodextrin daily. The powder was to be mixed with hot or cold beverages. The 
capsules were to be swallowed. 
 Standard pharmacologic therapy for UC continued to be provided as per the 
attending physician. No dietary alterations were recommended except that all subjects 
were encouraged to avoid high sulfate water sources and bottled water use was 
encouraged. All subjects were instructed to avoid additional probiotic supplements 
during the study period. 
 Subjects were provided with a study diary and asked to keep a daily record of 
clinical symptoms. Clinical symptoms included stool consistency (loose or formed), 
stool frequency (number in 24 hours), blood or mucous (present or not), abdominal pain 
(present or not) and overall feeling (well or not) for the duration of the study (Appendix 
4). The study diary also recorded whether the subjects consumed the pill, powder and 
used bottled water.  
 Health-related quality of life was assessed using the Short Inflammatory Bowel 
Disease Questionnaire (SIBDQ) (Irvine et al., 1996) at study entry and every two 
months for ten months or until relapse (Appendix 5). The SIBDQ is a validated 
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 questionnaire for use in IBD that considers bowel, systemic and emotional symptoms, as 
well as social function. The score ranges from 10 (worst quality of life) to 70 (best 
quality of life). The SIBDQ was administered either in person or over the telephone. 
Prior to administering the SIBDQ to the child, verbal consent was requested from the 
parents (Appendix 3.2). 
 Chart reviews were undertaken at study initiation, at six months and at the end of 
the study. The following data was collected: current age, sex, age at diagnosis, age at 
randomization, location of disease, medical history, current medications, current status, 
date of last remission, length of last remission, birth place, parent’s birth place, current 
dwelling (urban/rural) and drinking water source (Appendix 6).  
 An exacerbation of UC was defined as a drop in SIBDQ score of ≥11.8 points 
(Jowett et al. 2001), with the presence of blood or mucous in the stool or admission to 
hospital for management of UC. 
 Compliance to the study protocol was assessed by examining the study diary, as 
well as questioning the subjects. 
 
3.4 Phase II – Pediatric Case Series 
Following completion of Phase I of the study, all subjects involved in the pilot 
study were provided the synbiotic therapy (B. longum R0175 and 15 g of powdered 
inulin). All subjects followed the study protocol as described in Section 3.3.4 for Phase I 
– Pediatric Pilot Study. 
Ethical approval to extend the study beyond one year was completed and 
approved by the Biomedical Research Ethics Board of the University of Saskatchewan 
(Appendix 2.3). 
 
3.5 Phase III – Adult Case Series 
 Eligible subjects were between the ages of 19 and 40 years of age. Eligibility 
criteria were a firmly established diagnosis of UC obtained by endoscopic and 
histological examination. Subjects could be in remission or have active UC. Exclusion 
criteria were extensive bowel surgery, non-intact colon (colectomy), existing or intended 
pregnancy, existing cardiac, renal or hepatic disease and diabetes. Immunocompromised 
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 subjects were excluded from the study. Corticosteroids were allowed up to two weeks 
prior to the study. Concurrent pharmacologic treatment continued as per the attending 
physician. 
Ethical approval to include the extended age group and subjects with active UC 
was completed and approved by the Biomedical Research Ethics Board of the University 
of Saskatchewan (Appendix 2.4). 
 
3.5.1  Study Design  
Phase III was designed as an open label case series, where all subjects received 
the treatment (15 g/day of inulin and B. longum R0175 - 2.0 x 1010 cfu/capsule) for up to 
12 months or until relapse. All subjects followed the study protocol as described in 
Section 3.3.4 for Phase I – Pediatric Pilot Study. In addition, the SIBDQ was 
administered on two occasions (over a period of one month) prior to starting the 
synbiotic therapy in order to obtain baseline quality of life data.  
 
3.6 Safety Assessment 
 Subjects recorded all adverse symptoms (e.g., flatulence, bloating, etc.) related to 
the study medication in the study diary. Severe adverse events (e.g., sepsis, etc.) related 
to the study medication were to be reported to the research coordinator as soon as 
possible. 
 
3.7 Data Analysis 
3.7.1 Sample Size Calculation 
 In studies of IBD, clinical investigators suggest a 25% response in the placebo 
group and 75% response in the treatment group, and such a difference is relevant from a 
clinical point of view (Gionchetti et al., 2000). For α = 0.05 (two tailed test) and β = 
0.20, a sample size of more than 19 patients per group is required in order to achieve a 
normal distribution. 
 
3.7.2 Statistical Analysis    
 All statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS© Version 14.0 for Windows, Chicago Illinois). Since the results of the 
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 study do not follow a normal distribution, non-parametric tests were used to analyze the 
data. A P-value of <0.05 (two sided) was considered to be statistically significant.  
 
3.7.3 Demographic Data 
 Demographic and clinical characteristics for both the placebo and synbiotic 
groups (Phase I subjects) were calculated as median values with a range following 
randomization. Sex of the subjects (male versus female) was tabulated. Comparisons 
between the placebo and synbiotic group were made using the Mann-Whitney U test and 
Chi-squared test (for nominal data). 
  The demographic and clinical characteristics are profiled for each subject that 
participated in Phase II of the study.  
 
3.7.4 Quality of Life Scores 
 The SIBDQ consists of ten questions with responses to each question graded on a 
seven point Likert scale. Each question scores between a range of one (represents the 
“worst” aspect) to seven (representing the “best” aspect). The response category “All of 
the time” was assigned a score of one, “Most of the time” a score of two, “A good bit of 
the time” as score of three, “Some of the time” a score of four, “A little of the time” a 
score of five, “Hardly any of time” a score of six and “None of the time” as score of 
seven. The sum score was totaled for all the individual questions contained in the 
SIBDQ (higher scores indicate better quality of life). The SIBDQ has its own 
standardized scoring system which is based on the IBDQ-36. 
 The ten questions on the SIBDQ are clustered into four dimensions of quality of 
life: systemic domain (two questions), emotional domain (three questions), bowel 
domain (three questions) and social domain (two questions). The dimensional score was 
the sum of the scores of the items included in each domain. 
 Comparison of the total SIBDQ scores at baseline with month ten or at relapse 
were made between the placebo group and synbiotic group using the Mann-Whitney U 
test. The Wilcoxon signed-rank test was used to determine differences between SIBDQ 
scores within the placebo and synbiotic groups. Dimensional SIBDQ scores are 
presented as median values. Differences were assessed using the Mann-Whitney U test, 
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 when more than two groups were compared the Kruskal-Wallis test was used; if 
statistically significant, the variable that differed from the others was identified using the 
Bonferroni test.  
 Comparisons of the total SIBDQ scores pre-treatment and post-treatment for 
Phase II were completed using the Wilcoxon signed-rank test. Comparisons of the 
SIBDQ scores within subjects were completed using the Friedman Test. 
 
3.7.5 Symptoms 
 Stool consistency (loose or formed), stool frequency (number in 24 hours), blood 
or mucus (present or not), abdominal pain (present or not) and overall feeling (well or 
not) were labeled, coded and entered into a spreadsheet. The mean values with the 
standard deviation were derived for both the synbiotic and placebo groups. Comparisons 
between the placebo and synbiotic group were made using the Mann-Whitney U test. 
 Phase II symptom data were presented as the mean value. Symptom scores pre-
treatment and post-treatment were compared using the Wilcoxon signed-rank test. 
 
3.7.6 Phase III – Adult Case Series Analyses 
 Phase III subjects are described in this thesis as case reports. 
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 CHAPTER 4 
RESULTS 
 
 
4.1 PEDIATRIC PILOT STUDY 
4.1.1 Baseline Characteristics of the Subjects 
 Of the 14 subjects invited to participate in the study, consent was obtained from 
10 subjects. The reasons for refusal to participate were as follows: three subjects were 
not interested in participating in the trial and one subject did not show up for the study 
meeting on two separate occasions. In addition to the 14 subjects initially contacted to 
participate in the study, an eight year old child with moderately severe UC unable to be 
weaned off Prednisone® consented to participate in the study. Due to the severity of her 
disease and steroid-dependency, she was included as an open-label case study. 
 Two subjects enrolled in the study, but discontinued within two weeks of 
orientation to the study. One subject withdrew following the orientation to the study due 
to worsening of symptoms and a reason for the second subject’s withdrawal from the 
study was not provided. Both subjects withdrew from the study prior to starting the 
study medications. Appendix 7 depicts a visual schematic of the recruitment process for 
the study. 
 The baseline characteristics of the subjects are shown in Table 4.1. There were 
no significant differences observed between the two groups at study entry. 
 
 
 
 
 
 
 
 
 
 
 76
 Table 4.1 Baseline Characteristics of the Pediatric Study Subjects (Phase I –  
Pediatric Pilot Study) 
 
 Synbiotic 
 (n=4)A
Placebo 
(n=5) 
 
P* 
Median age (years) 12.6 (8.9-17) 12.6 (11.4-18.4) 0.539 
Gender  
   Male 
   Female 
 
1 
3 
 
3 
2 
 
 
0.520 
Age at diagnosis 
(years) 
10.9 (7.9-12.4) 11.7 (10.7-15.4) 0.140 
Duration of disease 
(months) 
25 (4-65) 20 (9-36) 0.712 
Time since last 
relapse (months) 
6 (1-64) 8 (5-36) 0.537 
Disease extent 
   Total/subtotal 
   Left-sided 
   Proctosigmoid 
 
3 
1 
0 
 
2 
1 
2 
 
Medications† 
   Prednisone®
   Pentasa®
   Salofalk®
   Sulfasalazine®
   None 
 
1 
1 
0 
3 
0 
 
0 
1 
1 
2 
1 
 
AOpen label case included 
†UC related drugs only 
*P values were determined using the Mann-Whitney U test or Chi-square test. P <0.05 were considered to 
be significant. 
Values are presented as median with the range. 
 
4.1.2 Clinical Course 
 As shown in Appendix 8.1, three out of four subjects (cases 6, 7 and 9) in the 
synbiotic group were still in remission at ten months. The subjects in the synbiotic group 
did not experience severe symptoms. Severe symptoms were defined as the presence of 
blood or mucous in the stool or presence of abdominal pain. Case 9 (open-label case 
study) was a nine year old female with moderate to severe UC who was corticosteroid-
dependant (40 mg/day). Prior attempts at weaning corticosteroids resulted in return of 
severe symptoms. Following 43 days of synbiotic therapy, Case 9 was able to wean off 
corticosteroids and remain in remission. Case 8 dropped out of the study after two 
months without a reason being provided. 
Of the five subjects receiving the placebo, three subjects experienced a severe 
relapse of UC (Cases 1, 2 and 5). Case 5 was admitted to hospital within 55 days of 
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 starting the study with severe diarrhea, rectal bleeding and abdominal pain. Case 2 did 
not report severe symptoms in the study diary, but relapsed and was admitted to hospital 
within 134 days of study initiation. By the end of ten months, Case 1 experienced blood 
or mucous in the stool on a daily basis and quality of life scores dropped 23 points. Four 
out of five subjects in the placebo group reported the presence of severe symptoms in 
their study diaries (Cases 1, 3, 4 and 5).   
 
4.1.3 Quality of Life 
 As presented in Figure 4.2, in the four subjects receiving the synbiotic therapy, 
SIBDQ scores were high at study entry (median 63.5 points) and at ten months increased 
even further (median 67.5 points); this difference was not statistically significant (p = 
0.109). In the five subjects receiving the placebo, the SIBDQ scores dropped from a 
median of 54 points to a median of 48 points at the time of relapse or ten months (p = 
0.345). Comparing the two groups, there was no significant differences at study entry 
(synbiotic v placebo: median 63.5 points v 54 points; p = 0.140) but the groups differed 
significantly at the time of relapse or ten months (median 67.5 v 48; p = 0.014). 
 
Figure 4.1 SIBDQ Scores at Study Entry and at Ten Months or Time of Relapse for 
Synbiotic Therapy (n = 4) and Placebo Groups (n = 5) (*p = 0.014) 
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coxon-signed rank test.  P <0.05 were 
 The results of the dimensional scores of the SIBDQ at ten months or time of 
relapse for the synbiotic and placebo groups are shown in Figure 4.3. Distribution of the 
dimensions for the synbiotic and placebo groups differed significantly from each other 
(p = 0.011). There was a greater preservation of the social dimension as compared to the 
bowel, systemic and emotional dimensions (p = 0.016). In the placebo group, the lowest 
dimension of the SIBDQ was the emotional impact (p=0.018). The latter finding 
suggests that the emotional dimension is the most affected in UC. 
 
Figure 4.2 Median Values of SIBDQ Scores by Dimension at Ten Months or Time 
of Relapse for Synbiotic and Placebo Groups 
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*P values were determined using the Kruskal-Wallis test.  P <0.05 were considered to be significant. 
 
4.1.4 Symptoms 
 Stool frequency, days with formed stool and days without abdominal pain were 
not significantly different between the two groups (Table 4.2). There was a significant 
difference in days without blood or mucous in the stool (p = 0.032) and days feeling well 
(p = 0.014) in the subjects receiving the synbiotic therapy versus the placebo. 
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 Table 4.2 Comparison of Bowel Function and Symptom Scores of Synbiotic Group 
and Placebo Group at the End of Phase I - Pediatric Pilot Study 
 
Between groups (post-treatment) 
 
 Synbiotic Therapy 
(n=4)A
Placebo  
(n=5) 
P* 
Stool frequency 
(#/day) 
1.5 ± 0.4 2.2 ± 2.4 0.624 
Days with formed 
stool (%) 
61.4 ± 46.5 61.3 ± 38.0 0.806 
Days without 
abdominal pain (%) 
97.3 ± 4.9 89.1 ± 14.9 0.213 
Days without blood or 
mucous in the stool 
(%) 
100 ± 0 71.6 ± 41.9 0.032* 
Days feeling well (%) 99.3 ± 0.9 63.4 ± 34.4 0.014* 
AOpen label case included in synbiotic group. 
*P values were determined using the Mann-Whitney U test. P <0.05 were considered to be significant. 
Values are presented as mean ± standard deviation. 
 
4.1.5 Compliance 
The mean compliance rate in the synbiotic group was 93.1% for the probiotic 
capsules and 92.2% for the inulin. The mean compliance rate in the placebo group was 
90.4% for the placebo capsule and 84.3% for the maltodextrin powder. There were no 
significant differences detected between the two groups in consumption of powder (p = 
0.389) or the capsules (p = 0.431). Some subjects disliked the taste of the beverages 
when mixed with the inulin or maltodextrin.  
 Low sulfate water was consumed 98.4% of the time in the synbiotic group and 
79.9% of the time in the placebo group. The large difference in consumption of low 
sulfate water is because one subject in the placebo group did not use low sulfate water 
on a regular basis. The two groups were not significantly different from each other (p = 
0.110). 
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 4.1.6 Safety  
 No side effects were reported in the subjects receiving neither the treatment nor 
the placebo. No adverse effects occurred as a result of the study medications. 
 
4.2 PEDIATRIC CASE SERIES 
4.2.1 Subject Characteristics 
Following completion of Phase 1- Pediatric Pilot Study, subjects in both the 
placebo and synbiotic groups were asked to continue with the study. Three subjects in 
the placebo group (Cases 1, 3 and 4), one subject (Case 2) that had relapsed (initially in 
placebo group), two subjects (Cases 6 and 7) in the synbiotic group and the open label 
case (Case 9) agreed to continue participation in the study. One subject (Case 10) with 
active UC was newly recruited. Appendix 7 provides a schematic of recruitment. 
The demographic and clinical characteristics of the eight subjects are shown in 
Table 4.3. Six patients are females and two are male. The age of the subjects ranges 
from 9 years, 9 months to 19 years, 3 months. All subjects were initially diagnosed with 
UC through endoscopic and histological evaluation. Six subjects (Cases 2, 4, 6, 7, 9 and 
10) had total/subtotal UC, one subject (Case 1) had proctosigmoid UC and one subject 
(Case 3) had left-sided UC. Six subjects (Cases 2, 3, 4, 6, 7 and 9) were in remission at 
the start of Phase II and two subjects (Cases 1 and 10) had active UC. Cases 6, 7 and 9 
had been receiving the synbiotic therapy for ten months. 
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 Table 4.3 Demographic and Clinical Characteristics of Pediatric Study Subjects 
(Phase II – Pediatric Case Series) 
 
Case 
No. 
Age Gender Location of 
Disease 
Medications Remission Months on 
Synbiotic 
Therapy 
Case  
1 
17 yrs, 
5 mo  
F Proctosigmoid Pentasa® N 0 
Case  
2 
13 yrs, 
5 mo 
M Total/Subtotal Prednisone®, 
Salofalk®
Y 0 
Case  
3 
19 yrs, 
3 mo 
M Left-sided Sulfasalazine® Y 0 
Case  
4 
13 yrs, 
2 mo 
F Total/Subtotal Sulfasalazine® Y 0 
Case  
6 
13 yrs, 
8 mo 
F Total/Subtotal None Y 10 
Case  
7 
17 yrs, 
6 mo 
F Total/Subtotal Sulfasalazine® Y 10 
Case 
9A
9 yrs, 9 
mo 
F Total/Subtotal Pentasa® Y 10 
Case 
10 
12 yrs, 
8 mo 
F Total/Subtotal Salofalk®, 
Salofalk®enemas 
N 0 
AOpen label case. 
 
4.2.2 Clinical Course 
 The clinical course of each subject is presented in Appendix 8.2. Case 1 received 
the synbiotic therapy for a total of 60 days and continued to experience blood and 
mucous in the stool. Case 1 decided to discontinue the synbiotic therapy as it did not 
improve symptoms. Case 2 received the synbiotic therapy for 66 days and subsequently 
went on to have another exacerbation within six weeks of weaning off Prednisone®. The 
synbiotic therapy was discontinued. Case 2 was prescribed Immuran® (100 mg/day) with 
Prednisone® (60 mg/day) to control the UC. He entered remission with this medication 
regime and was able to wean off Prednisone®. Case 2 continues to receive Salofalk® and 
Immuran® to control the UC. 
Case 3 received the synbiotic therapy for 60 days and then decided to discontinue 
the study as the original 12 month commitment was completed. Case 3 did not 
experience severe symptoms while receiving the synbiotic therapy. Within 45 days of 
discontinuation of the study, Case 3 contacted the study coordinator and requested to 
reenter the study, as he was experiencing intermittent abdominal pain and blood in the 
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 stool. Case 3 received the treatment for an additional four months. Following the four 
months, the research coordinator was unable to contact Case 3 and the subject was 
subsequently lost to follow-up. 
Case 4, 6, 7 and 9 reported no severe symptoms of UC while receiving synbiotic 
therapy. Case 6 and 7 participated in the study for approximately 12 months and then 
decided to withdraw from the study. Case 6 and 7 fulfilled the original 12 month 
commitment of the study. The reason the subjects withdrew from the study was not 
requested, as the ethics agreement indicated the subjects could withdraw from the study 
at any point without a reason being provided. 
Case 4 was diagnosed with UC at 10 years, 8 months. Case 4 had never had a 
formed stool since diagnosis and was poorly controlled with standard medical therapy. 
She had trialed Pentasa®, Sulfalsalazine® and Salofalk® but continued to experience 
intermittent symptoms despite the medical therapy. Case 4 entered the study in 
September 2004. One week prior to study initiation, Case 4 had been weaned off 
Prednisone®. Case 4 received the placebo for ten months and the synbiotic therapy for 
14 months. Case 4 has remained in remission for 24 months. Case 9 (open label case) 
received the synbiotic therapy for 26 months and continues to remain symptom-free, 
steroid free and in remission.   
Case 10 entered the study with active UC at the end of March 2006. She was 
experiencing tenesmus, joint pain, four stools during the day plus one at night, all stools 
contained blood and mucous. Medications included Salofalk® (2500 mg/day) and 
Salofalk® enemas (2 g/day). Case 10 returned for a follow-up appointment in April 2006 
and reported 3-4 stools/day, no stools at night and less blood present in the stool and less 
urgency. Case 10 was prescribed 60 mg Prednisone® in attempt to induce remission in 
May 2006. During the month of May 2006, Case 10 was admitted to hospital with 
epigastric pain, diagnosed with esophagitis and treated with Pantaloc®. In June 2006, 
Case 10 was instructed by the pediatrician to begin to wean off Prednisone® and start 
Salofalk®. Case 10 successfully weaned off the Prednisone® and was diagnosed as being 
remission. Case 10 continues to experience blood in her stools despite being in 
remission. Tenesmus and joint pain are no longer present. 
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 4.2.3 Quality of Life 
 The baseline SIBDQ scores ranged from 37 to 65 points (median 58.5 points).  
Following treatment with synbiotic therapy, SIBDQ scores ranged from 43 to 69 points 
(median 59 points). Figure 4.4 shows the changes in total SIBDQ scores for each subject 
treated with synbiotic therapy. Significant differences were found in the SIBDQ scores 
pre-treatment and post-treatment with synbiotic therapy (p= 0.034). 
 Six of the eight subjects SIBDQ scores improved post-treatment with synbiotic 
therapy. The SIBDQ score dropped in one subject (Case 2) while receiving synbiotic 
therapy, as the subject reported decreased quality of life related to side effects from 
Prednisone®. The SIBDQ score for Case 4 remained the same (60 points).  
 
Figure 4.3 Phase II SIBDQ Scores Pre-Treatment and Post-Treatment With 
Synbiotic Therapy (n=8) (p = 0.034)  
 
30
40
50
60
70
SI
B
D
Q
 S
co
re
Ca
se 
1
Ca
se 
2
Ca
se 
3
Ca
se 
4
Ca
se 
6
Ca
se 
7
Ca
se 
9A
Ca
se 
10
Pre-Treatment
Post-Treatment
 
AOpen label case included in synbiotic group. 
 
4.2.4 Symptoms 
 Stool frequency, days with formed stool, days without abdominal pain, days 
without blood or mucous and days feeling well were analyzed for Cases 1, 2 and 4 pre 
and post-treatment with synbiotic therapy (Table 4.4). Pre-treatment was defined as the 
period of time the subjects were on the placebo. The results were not statistically 
significant (p = 0.564). Case 3 was not included in the analysis as the study diary data 
post-treatment was lost by the subject.  
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  Cases 6, 7 and 9 remained well and experienced no severe symptoms of UC 
throughout the study period. Loose stools were reported by Case 6 and 7 in their study 
diaries.  
 Case 10 experienced more symptoms of UC (e.g., increased stools, blood, 
mucous, abdominal pain and increased loose stools) than the other subjects. The 
synbiotic therapy did not improve the symptoms Case 10 was experiencing, thus she 
remained unwell. Case 10 did not enter remission on synbiotic therapy. 
 Although the results are not statistically significant, they are clinically significant 
especially for Case 4 and 9. Case 4 experienced less stools, less blood and mucous, more 
formed stools, and felt better while receiving the synbiotic therapy (14 months) as 
compared to when she was receiving the placebo. Case 4 has been in remission for a 
total of 24 months; previous remission length was six months. Case 9 showed the most 
dramatic improvements in bowel function and symptoms, as Case 9 had remained 
symptom free for 26 months. The longest period Case 9 was symptom free before the 
synbiotic therapy was 4.5 months. 
 
Table 4.4 Comparison of Bowel Function and Symptom Scores For Each Pediatric 
Subject (Phase II – Pediatric Case Series) 
 Case Number 
 1 2 3 4  6 7 9A 10 
Stool frequency (#/day) 
   Pre-treatment 
   Post-treatment 
 
0.9 
0.8 
 
1.0 
1.1 
 
1.0 
  † 
 
2.5 
1.8 
 
 --- 
1.4 
 
 --- 
1.0 
 
 --- 
1.5 
 
 --- 
3.1 
Days with formed stool (%) 
   Pre-treatment 
   Post-treatment 
 
60.3 
64.7 
 
99.0 
93.8 
 
85.9 
   † 
 
61.8 
88.0 
 
 --- 
49.1 
 
 --- 
2.8 
 
 --- 
99.9 
 
 --- 
45.8 
Days without abdominal pain (%) 
   Pre-treatment 
   Post-treatment 
 
 
64.0 
59.6 
 
 
96.0 
98.5 
 
 
87.1 
   † 
 
 
98.6 
98.0 
 
 
 --- 
91.5 
 
 
 --- 
100 
 
 
 --- 
99.1 
 
 
 --- 
80.7 
Days without blood or mucous  
in the stool (%) 
   Pre-treatment 
   Post-treatment 
 
 
68.4 
22.8 
 
 
100 
100 
 
 
93.7 
   † 
 
 
95.8 
98.7 
 
 
 --- 
100 
 
 
 --- 
100 
 
 
 --- 
100 
 
 
 --- 
40.4 
Days feeling well (%) 
   Pre-treatment 
   Post-treatment 
 
12.8 
24.6
 
97.0 
98.5
 
70.6 
   † 
 
89.9 
97.4 
 
 --- 
97.6 
 
 --- 
98.3 
 
 --- 
99.2 
 
 --- 
85.7 
Values are presented as mean. 
AOpen label case included in synbiotic group. 
†Study diary not available. 
*P values were determined using the Wilcoxon signed rank test. P <0.05 were considered to be significant. 
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 4.2.5 Compliance 
 All subjects showed good compliance to the medication. The mean compliance 
rate was 92% for the probiotic capsules and 77.8% for the inulin. Some subjects disliked 
the taste of the beverages when mixed with the inulin. 
 
4.2.6 Safety 
Two subjects reported increased flatulence which was attributed to the inulin. In 
no cases was the gas severe enough to stop the study medication. There were no reports 
of severe adverse events by any of the subjects. 
 
4.3 ADULT CASE SERIES 
4.3.1 Subjects 
Ten adult subjects were referred by three gastroenterologists from the Saskatoon 
Health Region. Three subjects with active UC were deemed eligible to participate in the 
study following extensive chart reviews. The subjects deemed ineligible to participate in 
the study had bowel resections or were on immunosuppressive therapy (e.g., Immuran® 
or Remicade®). 
 
4.3.2 Adult UC - Case Reports 
4.3.2.1 Case A 
 Case A was a 31 year old male with moderate to severe UC. A colonic biopsy in 
March 2005 revealed active UC throughout the colon (total/subtotal UC). He was placed 
on Ascacol® (3.2 g/day) and Prednisone® (30 mg/day) which improved the symptoms 
(diarrhea, blood in stools, abdominal cramping, tenesmus). On attempts at weaning the 
Prednisone® the symptoms returned. The gastroenterologist subsequently prescribed 
Immuran® in October 2005, as Case A had become steroid dependant. Case A trialed the 
Immuran® but developed more diarrhea with its use, so he subsequently discontinued the 
medication. In November 2005, the gastroenterologist suggested that Case A try 
Remicade® to induce remission, but Case A wanted to trial the synbiotic therapy. The 
gastroenterologist referred Case A for entry into the study. 
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 Synbiotic therapy was provided in addition to the Prednisone® (40 mg/day) in 
attempt to induce clinical remission. B. longum R0175 and inulin Frutafit®CLR was 
used as the synbiotic therapy. A dosage of 2.0 x 1010 cfu/day of probiotic bacteria and 15 
g/day of the prebiotic were administered. The short inflammatory bowel disease 
questionnaire (SIBDQ) was performed at baseline and every two months. Case A kept a 
daily record of symptoms (stool consistency, stool frequency, blood and mucous and 
abdominal pain). Case A was asked to report any adverse effects, deterioration of well-
being, increased stool frequency, rectal bleeding or mucous in the stool to the research 
coordinator.  
 The initial SIBDQ score for Case A was 41. A follow-up phone call was placed 
12 days following initiation of synbiotic therapy. Case A reported that his stools had 
increased to between 11 and 24 daily with blood and mucous present. He was 
experiencing severe abdominal pain and felt very unwell. As a result, the research 
coordinator recommended discontinuation of the study medication immediately and 
suggested that the subject seek medical advice as soon as possible. The research 
coordinator also notified the referring physician of the situation. Subsequently, Case A 
went on to receive immunomodulatory therapy (e.g., Remicade®). 
 
4.3.2.2 Case B 
 Case B was a 28 year old female diagnosed with moderate to severe UC. A 
colonic biopsy in September 2005 revealed moderately active UC in the right, transverse 
and sigmoid colon. Initial symptoms included weight loss, tenesmus, 5-30 loose stools 
daily with blood and mucous present. She was treated with Prednisone® (40 mg/day) and 
the symptoms resolved until she began tapering the dosage. She was subsequently 
admitted to hospital in January 2006 with 4-10 bloody stools daily, severe abdominal 
pain, tenesmus, hypoalbuminemia and iron deficiency anemia. In hospital she was 
treated with IV Solumedrol® which induced remission and subsequently was started on 
40 mg/day of Prednisone®. 
 Cased B was referred to the research coordinator and a SIBDQ was completed. 
The score was only 16. The research coordinator, the physician and Case B decided it 
would be prudent to wait to start the synbiotic therapy as Case B was on a high dosage 
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 of Prednisone® (40mg/day). In March 2006, Case B contacted the research coordinator, 
as she wanted to enroll in the study. Case B had recently discontinued Prednisone® and 
was symptom free. A SIBDQ was completed and the score was 33, still indicating poor 
quality of life. The subject was very depressed, but was regularly seeing a counselor. 
 B. longum R0175 and inulin Frutafit®CLR was used as the synbiotic therapy. A 
dosage of 2.0 x 1010 cfu/day of probiotic bacteria and 15 g/day of the prebiotic were 
administered. Standard medications as prescribed by the physician continued (e.g., 
Asacol® 3.6g/day). The SIBDQ was performed on two occasions prior to starting the 
synbiotic therapy in order to obtain baseline data and every two months thereafter. Case 
B kept a daily record of symptoms (stool consistency, stool frequency, blood and 
mucous and abdominal pain). Case B was asked to report any adverse effects, 
deterioration of well-being, increased stool frequency, rectal bleeding or mucous in the 
stool to the research coordinator.  
After one month on the synbiotic therapy, Case B’s symptoms returned and she 
experienced another UC exacerbation. Stool frequency ranged from 5-15 times per day, 
with bleeding, urgency, abdominal cramping and severe flatulence. The flatulence was 
precipitated by the inulin. The physician restarted Prednisone® (30 mg/day) and started 
Case B on Immuran®. Due to the risks of an adverse event occurring with 
immunosuppressive therapy, the research coordinator advised Case B to discontinue the 
study. 
 
4.3.2.3 Case C 
 Case C was a 26 year old male diagnosed with distal colitis by histologic and 
endoscopic evaluation in November 2000. The UC was controlled with Pentasa® 
(2g/day) for approximately four and a half years. During remission, Case C experienced 
intermittent symptoms (i.e., stools that contained blood and mucous and increased 
frequency of stools). In June 2005, Case C presented with large amounts of blood in the 
stool despite being on the Pentasa®. Colonoscopy revealed active UC in the distal colon, 
he was prescribed hydrocortisone enemas for six weeks and the symptoms disappeared. 
In October 2005, the symptoms returned and the gastroenterologist referred Case C for 
entry into the study. 
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 Synbiotic therapy was prescribed in addition to Pentasa® (1000 mg po bid) in 
October 2005. B. longum R0175 and inulin Frutafit®CLR was used as the synbiotic 
therapy. A dosage of 2.0 x 1010 cfu/day of probiotic bacteria and 15 g/day of the 
prebiotic were administered. The SIBDQ was performed on two occasions prior to 
starting the synbiotic therapy in order to obtain baseline data and every two months 
thereafter. Case C kept a daily record of symptoms (stool consistency, stool frequency, 
blood and mucous and abdominal pain). Case C was asked to report any adverse effects, 
deterioration of well-being, increased stool frequency, rectal bleeding or mucous in the 
stool to the research coordinator.  
Case C returned for a follow-up appointment with the gastroenterologist in April 
2006. Medications included the synbiotic therapy and Pentasa® (2g/day). Case C 
complained of blood in the stools for approximately two weeks prior to the appointment. 
The blood in the stool reoccurred following a bout of influenza. The gastroenterologist 
prescribed Cortifoam® enemas twice daily for one week and the symptoms disappeared. 
In May 2006, Case C reported the presence of a small amount of blood upon evacuation 
of his bowels; he was diagnosed with an anal fissure. 
 Figure 4.4 represents the available study diary data for Case C. The blood in the 
stools decreased after 30 days of treatment with synbiotic therapy. The study diary 
indicated that a small amount of blood was present in the stool on three occasions, but 
lasted only 1-2 days since initiation of synbiotic therapy. Stools average 1.3 per day. 
Abdominal pain was absent 94% of the time. The B. longum and inulin were consumed 
98% of the time. 
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   Figure 4.4 Study diary data for Case C 
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* No data available for month 6 and 8 as Case C lost diary. 
 
Figure 4.5 shows the SIBDQ scores of Case C over the course of the study 
period. The baseline SIBDQ scores for Case C were 43 and 48 (completed two weeks 
after first SIBDQ). The SIBDQ scores range from 54 to 64 over the ten months on 
synbiotic therapy (70 indicates best health). No adverse effects were reported.  
 
 
  Figure 4.5 SIBDQ Scores for Case C While Treated With Synbiotic Therapy 
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 CHAPTER 5 
DISCUSSION 
 
 
5.1 Discussion 
 The findings of the current study were fourfold. First, the study demonstrated 
that synbiotic therapy is a safe, adjunct treatment for UC. Second, synbiotic therapy with 
concomitant medical therapy resulted in significant improvements in HRQOL, a 
reduction in severe symptoms (blood and mucous) and reduced relapse rate in pediatric 
subjects with UC in remission. Third, synbiotic therapy provided at the current dosages 
was incapable of inducing remission in the pediatric and adult subjects that entered the 
study with active UC. Fourth, compliance to taking the synbiotic therapy was not an 
issue for the subjects. 
 The results of this intervention are unique because this was the first time 
synbiotic therapy has been investigated for use in pediatric UC. To date, there have been 
no published studies using prebiotic, probiotic or synbiotic therapy for the management 
of pediatric UC. However, a number of studies in adults using probiotics have been 
carried out. One study using synbiotic therapy (B. longum and FOS/inulin mix) was 
carried out by Furrie et al. in 2005, in adults with active UC. These authors reported 
reduced mucosal inflammatory markers (TNF-α and IL-1) and a reduction in colitis at 
both the macroscopic and microscopic level. Previous probiotic studies conducted in 
adults with UC have reported that E. coli Nissle 1917 is as effective as mesalamine for 
maintaining a relapse (Kruis et al., 1997; Kruis et al., 2004). Bifidobacteria fermented 
milk prevented exacerbation of UC symptoms in 73% of subjects versus 10% of subjects 
in the controls (Ishikawa et al., 2003). VSL#3® resulted in a remission rate of 75% in 
subjects that were intolerant or allergic to 5-ASA (Venturi et al., 1999). These studies 
suggest that probiotic preparations have a role in treating quiescent UC and preventing a 
relapse of UC.  
 There are even fewer studies looking at the effects of inulin on UC. Inulin 
prevented mucosal inflammation, as demonstrated by lower colonic lesion scores and 
the release of fewer inflammatory mediators in test rats with distal UC (Videla et al., 
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 2001). Supplementation with 24 g of inulin in patients with ileo-anal pouch anastomosis 
resulted in increased butyrate concentrations, lowered pH, decreased numbers of 
Bacteriodes fragilis, and diminished concentrations of secondary bile acids in feces 
(Welters et al., 2002). Thus, the role of inulin in the management of UC still remains 
very novel. 
 The efficacy of the synbiotic therapy may be related to the increased colonization 
of the protective bacteria, B. longum in the colon. Although not measured in the current 
study, a number of successful clinical trials have demonstrated that Bifidobacteria show 
a high survival rate through the gastrointestinal tract and exhibit probiotic properties in 
the colon (Picard et al., 2005). In addition, B. longum R0175 is resistant to gastric 
acidity, is not degraded by bile salts and colonizes the colon (Institut Rosell’s Probiotic 
Strains, 2002). If the theory that subjects with UC suffer from abnormalities in intestinal 
bacterial content and host-bacterial interaction (Penner et al., 2005) is true, then the 
administration of B. longum, would have helped to normalize the intestinal flora of the 
UC subjects. Supplementation with the inulin likely contributed to this effect, as inulin is 
not only metabolized by the Bifidobacteria, but it supports the growth of the subjects’ 
own resident Bifidobacteria. Thus, increased colonization of probiotic bacteria in the 
colon may be responsible for the improvement in symptoms and HRQOL in the 
pediatric UC subjects. 
 The efficacy for the synbiotic therapy may also be related to increased 
concentrations of short chain fatty acids (SCFA) in the colon as a result of prebiotic 
fermentation. Although not measured in the study, several well-designed studies have 
confirmed that inulin and FOS are highly fermented in the colon, thus produce SCFA 
(Cherbut, 2002). Inulin supplementation is reported to increase fecal butyrate 
concentrations and lower fecal pH in ulcerative colitis subjects with ileal pouch-anal 
anastomosis (Welters et al., 2002). Welters et al. (2002) demonstrated a reduction in 
inflammation of the mucosa of the ileal reservoirs of UC subjects which was confirmed 
endoscopically and histologically. It is also largely accepted that butyrate plays an 
essential role in maintaining colonic mucosa integrity by acting on epithelial cell 
metabolism, proliferation and differentiation (Cherbut, 2002). Therefore, enhancement 
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 of butyrate production via supplementation with inulin may be related to the significant 
improvements noted in the subjects described in this study.   
Endoscopy with histological analysis is the gold standard for the diagnosis of 
clinical activity and assessment of the treatment response in UC (Bremner, Griffiths & 
Beattie, 2004; Chudleigh & Hunter, 2003). The challenge with this procedure is that it is 
invasive and not always readily available in the outpatient setting. In the Saskatoon 
Health Region, endoscopy is completed during exacerbations of UC, and rarely if a child 
is in remission as endoscopy in children involves sedation and admission to hospital. A 
weakness of the current study is that endoscopic and histological analysis was not 
completed due to the nature of the procedure.  
 With the absence of the use of endoscopy and histological analysis, and the lack 
clearly defined definition of relapse provided in the scientific literature, relapse was 
defined in the current study as a drop in SIBDQ score by ≥11.8 points (Jowett et al. 
2001) or the presence of blood or mucous in the stool or admission to hospital for 
management of UC. This definition was problematic, as not all subjects that had a 
relapse of the UC were admitted to hospital or experienced a drop in the SIBDQ scores. 
There were also subjects that had blood present in the stool but were not having a 
relapse. A clearer definition of relapse is required. 
Disease activity indices have been developed to evaluate therapeutic 
interventions for UC (Higgins, Schwartz, Mapili & Krokos, et al., 2005), which all do 
not require endoscopic and histological analysis. The Simple Clinical Colitis Activity 
Index (SCCAI) is one example (Table 2.5) (Walmsley et al., 1998). The SCCAI has 
been validated against the Powell-Tuck and is designed specifically for use in the 
outpatient setting. The advantage to using a disease activity index, such as the SCCAI, in 
the current study is that it would provide a more objective definition of relapse with high 
specificity and sensitivity (Jowett et al., 2003). 
While a limitation of the present study was the absence of a clinical disease 
activity tool, the strength was the inclusion of an instrument that measured quality of 
life. Health related quality of life (HRQOL) is an integral part of the management of UC 
in children (Bremner et al., 2004), as HRQOL is significantly altered when the disease is 
active and when it is in clinical remission and laboratory and endoscopic findings are 
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 essentially normal (Martin et al., 1995). Traditional medical management and follow-up 
of subjects with UC fails to recognize the subjective experiences of the subjects (Martin, 
Leone, Fries & Naccarato, 1995). Chronic and unpredictable gastrointestinal symptoms 
and required treatments impose psychological and social stresses on young patients 
(Griffiths et al., 1999).  
The SIBDQ was specifically designed to measure HRQOL in adult patients with 
IBD (Irvine et al., 1994). Although the SIBDQ was not originally designed for the 
pediatric population, the questionnaire appeared to be sensitive enough to detect changes 
in disease activity. When subjects were experiencing symptoms such as rectal bleeding, 
abdominal pain and increased stool frequency there was a subsequent deterioration in 
SIBDQ scores. The SIBDQ scores were high when the subjects were in remission. As 
patients began to relapse the SIBDQ began to decrease. An additional advantage of the 
SIBDQ was that it was quick and inexpensive to administer. 
An interesting discovery was how UC impacted the different dimensions of 
HRQOL. Our results suggest that the social dimension was least affected by UC as 
compared to the bowel, systemic and emotional dimensions. Other studies have found 
similar results (Casellas et al., 2000). This observation suggests that patients are able to 
participate in social activities, despite their disease state. An unexpected finding was that 
the emotional dimension scored most poorly on the SIBDQ. This finding suggests that 
UC my cause major psychological distress.  
The questions on the SIBDQ were easily answered by the pediatric subjects. The 
readability of the questionnaire was at a grade eight reading level. The majority of the 
subjects in this study were older than grade eight so this was not an issue. Subjects 
younger than grade eight did not appear have any problems interpreting the questions 
either. The question “Overall, in the last two weeks, how much of a problem have you 
had maintaining or getting to the weight you would like to be?” was problematic. The 
question was designed as a systemic measure of HRQOL, where if a patient has active 
disease, they would most likely experience weight loss. In this study, a female teenager 
scored poorly on this question, but when asked if she had lost weight in the past two 
weeks, she indicated she had not but she just wanted to weigh less. As teenagers often 
have body image issues, the way the question is currently worded may not be 
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 appropriate for this population. The question could be reworded to “Overall, in the last 
two weeks, how much of a problem have you had stopping your weight from dropping?”  
The IMPACT is a HRQOL tool, designed for use in the pediatric IBD population 
(Otley et al., 2002). The current study was initiated in 2003, prior to publication of the 
validated questionnaire in 2005(Shepanski et al., 2005). The advantage to using the 
IMPACT is that it incorporates body image issues into the questionnaire, which was a 
limitation of the SIBDQ. The disadvantage to using the IMPACT is that has 36 
questions which is much lengthier than the SIBDQ which has ten questions. It would be 
interesting to assess the reliability and validity of the SIBDQ as disease specific measure 
of HRQOL in pediatric IBD against the IMPACT questionnaire which is specifically 
designed to measure HRQOL in pediatric IBD.  
 A variety of probiotic strains have successfully induced remission in adults with 
active UC (Rembacken et al., 1999, Guslandi et al., 2003, Furrie et al., 2005, Bibiloni et 
al., 2005 & Tursi et al., 2004). In the current study, the adult subjects with active UC did 
not enter remission. Although Case C did not enter remission and have complete 
resolution of symptoms, improved quality of life and reduced symptoms were noted. In 
studies where remission was attained successfully, the dosage of the probiotic ranged 
from 1011 - 1012 cfu/day, where as the current study provided 1010 cfu/day. There is a 
possibility that if the B. longum RO175 were provided at a higher dosage (>1011 cfu/day) 
remission could be attained in these subjects. Furrie et al. (2005) used the B. longum (2.0 
x 1011 cfu/day) and 12 g/day of an inulin/FOS mixture and demonstrated improved 
sigmoidscopy scores and reduced inflammation at both the microscopic and 
macroscopic level in the colonic tissue using this higher dosage.  
 At the present time, no scientific studies have been completed in children that 
use probiotics, prebiotics or synbiotics to induce remission in UC. The current study was 
the first of its kind. The subjects that entered the study with active UC did not enter 
remission while receiving the synbiotic therapy, which was comparable to the adult 
subjects. Despite not attaining full remission, all the pediatric subjects experienced 
improved quality of life and an improvement in symptoms. Again, there is a possibility 
that if a higher dosage of the B. longum was provided to the pediatric subjects, remission 
could be induced.  
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  Experimental studies completed in healthy individuals have shown significant 
increases in Bifidobacteria through supplementation of the diet with 5 to 40 g/day of 
inulin and FOS (Kruse et al., 1999, Bouhnik et al., 1999, Gibson et al., 1995, Klessen et 
al., 1997, Tuohy et al., 2001 and Buddington et al., 1996). The values that are 
recommended as formulation doses for inulin, based on both tests with volunteers and 
the experience of the food industry are 10 g/day (Roberfroid et al., 1993). The daily 
dosage of inulin (15g/day) provided in the current study was higher than recommended. 
The premise for using 15 g/day was based on the belief that compliance may be a 
problem with children especially with a study of such long duration. It was thought that 
even if the subjects were to consume the inulin every second day or half of a package 
daily, the subjects would still receive enough prebiotic to promote the growth of the 
Bifidobacteria. Compliance to taking the inulin proved not to be an issue with the 
subjects.  
 Inulin is also known for its fecal bulking effect and its ability to stimulate bowel 
movements in healthy subjects (Gibson et al., 1995, Kleesen et al., 1997 and Dahl et al., 
2005). In the current study, stool frequency and stool consistency remained unchanged 
in the subjects. Interestingly, Lewis et al. (2005) found similar results when 12 g/day of 
oligosaccharides were provided to elderly individuals that were at risk for AAD. Inulin 
and FOS are mild laxatives but the effect is often small and difficult to detect unless diet 
is controlled. In the current study diet was not controlled, therefore the fecal bulking 
effect and laxation effect may have gone undetected. 
Roberfroid et al. (1993) suggested that individuals can consume up to 10 g/day 
of a non-digestible fermentable carbohydrate without noticeable side effects. There was 
concern that providing over 10 g/day of inulin would cause tolerance issues (e.g., 
increased flatulence or diarrhea) in the subjects. This study was able to demonstrate that 
15 g/day of inulin was safe to administer to children between the ages of 8 -18 years, as 
there were no reports of serious adverse reactions in this population. Two subjects 
reported some flatulence, but after a few days the flatulence subsided, no subjects 
reported diarrhea as a result of the inulin.  
Subjects were recruited through a pediatrician that serves as the gastroenterology 
specialist for Saskatchewan. Attempts at recruiting out of province were unsuccessful as 
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 the pediatric gastroenterologists approached declined participation. Due to the lack of 
success in recruiting pediatric subjects, we decided to recruit additional subjects as 
adults. The physician that referred the majority of potential subjects tends to manage the 
most difficult cases of UC in the Health Region. These subjects were not responsive to 
traditional pharmacological therapies used for UC and went on to require 
immunomodulatory agents such as Immuran® or Remicade® in order to induce 
remission. It is not clear in the scientific literature at this time, if subjects with severe 
UC will respond to synbiotic therapy.  
Overall, it was also difficult to convince the physicians to partake in the study 
despite the potential benefits of prebiotic and probiotic therapy to UC patients. It could 
be that synbiotic therapy is an alternative therapy, and therefore is not part of the 
mainstream medical management of patients with UC. Physicians must practice 
evidence based medicine and unfortunately at this time the area of prebiotics and 
probiotics is still quite novel.  
Although the pediatric subjects were using concomitant medications (e.g., 
Prednisone®, Pentasa®, Salofalk®, Sulfasalazine®) it is unlikely that these medications 
played a significant role in the positive treatment response. The subjects had been on 
these medications for long periods of time prior to starting the study. Intermittent 
symptoms were experienced by the subjects receiving the placebo despite the use of 
standard medications for UC. Case 9 had steroid dependant UC and with the synbiotic 
therapy was able to wean off the Prednisone® successfully. The pediatrician managing 
this case had been considering either immunomodulatory therapy such as Immuran® or 
colectomy. It is not known whether synbiotic therapy will work without concomitant 
medical therapy for UC.  
An important advantage of the synbiotic therapy when provided in combination 
with standard medical therapy is its lack of side effects. No severe adverse effects were 
observed over the course of the study. Two subjects in the current study have received 
the synbiotic therapy in addition to conventional treatment for over two years with the 
absence of any side effects. Furrie et al. (2005) also reported no adverse reactions using 
the B. longum and a FOS/inulin mix in adult UC subjects with active disease. The safety 
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 of Bifidobacteria is supported by the long historical use in fermented milks and its 
GRAS status.  
 There are two major limitations to the current study. First, conducting the study 
open-label for Phase II and III of the study is a major limitation. Without a control 
group, it is difficult to rule out whether a “treatment effect” did occur or rule out a 
placebo response. The second limitation is the small sample size, thus caution must be 
exercised when interpreting the results. Due to the small sample the results cannot be 
generalized to the UC population. Despite this limitation, the study was able to fulfill the 
objectives for the study, therefore providing valuable insight for future research 
direction. 
  
5.2 Conclusion 
 In conclusion, this long term study has provided the first evidence that synbiotic 
therapy may improve HRQOL and symptoms in pediatric subjects with UC in remission. 
In addition, this study demonstrated that synbiotic therapy is also a safe adjunctive 
therapy for the long-term management of UC. Synbiotics have the potential to be 
developed into therapies to help patients suffering from UC.  
 
5.3  Future Research   
 The preliminary results of the current study encourage the development of a 
large randomized control trial with more pediatric subjects to further confirm our results. 
The following changes should be made to enhance a future study: 
? Inclusion of the Simple Colitis Clinical Activity Index to provide a 
clearer and more specific definition of relapse and disease activity. 
? Reduce the inulin to 10 g/day since compliance in the current study was 
better than expected, therefore the higher dosage of 15 g/day is not 
required.  
? To monitor HRQOL, use the IMPACT questionnaire as it is validated for 
use in pediatric IBD. 
Future research will also need to determine if synbiotic therapy will be efficacious 
without concomitant medical therapy for UC. The potential mechanism of action of 
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 Bifidobacteria longum R0175 and inulin in maintaining remission in UC will also need 
to be investigated.
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APPENDIX 1 
 
Recruitment 
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1.1 Telephone Script for Recruitment Purposes 
 
 
Hello, may I speak to the parent or guardian of (insert child’s name here). 
 
My name is Natasha Haskey; I am a Pediatric Dietitian that works at Royal University 
Hospital with Doctor (insert doctor’s name here). Doctor (insert doctor’s name here), 
researchers and myself are doing a research study on how changing the diet may effect 
the symptoms of Ulcerative Colitis. Your child is being invited to participate in this 
research study. Your child’s participation is entirely voluntary, so it is up to you and 
your child to decide whether or not to take part in this study. If you wish to participate, 
we can set up a time to meet at (insert meeting place) to discuss the details of the study.  
If you do not wish to participate, you do not have to provide any reason for your 
decision nor will it affect the medical care of your child now or in the future.       
 
Would you be interested in setting up a time to meet at (insert meeting place) to discuss 
the research study in further detail?  
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1.2 Letter of Recruitment to the Pediatricians 
 
 
 
 
 
Food and Nutrition Services 
Royal University Hospital 
103 Hospital Drive 
Saskatoon SK  S7N 0W8 
Date 
 
Dear (insert doctor’s name here), 
 
I am coordinating a clinical trial with Dr. Garth Bruce MD, Wendy Dahl RD PhD and 
Susan Whiting PhD investigating the effectiveness of low sulfate water, prebiotics and 
probiotics on the length of remission and quality of life in pediatric ulcerative colitis 
patients.  
 
Our research team is currently recruiting pediatric ulcerative colitis patients in clinical 
remission, between the ages of 8-18 years (both male and female), to participate in our 
clinical trial. Patients with non-intact colons and those considered to be immuno-
compromised are excluded from participation.   
 
I am requesting your participation in this clinical trial by providing a confidential list of 
eligible client names, along with their date of birth and health services number, that meet 
the criteria as outlined in the previous paragraph. As the study coordinator, I will contact 
the potential study volunteers to discuss their participation in the study.         
 
The results of this study will be published and if you agree to participate, your name will 
be acknowledged.    
 
A summary of the clinical trial is attached to this letter.   
 
The University of Saskatchewan Biomedical Research Ethics Board has provided ethical 
approval for this study.   
 
I look forward to speaking with you in the near future.  If you have any questions, please 
call me at (306) 655-6512. 
 
Sincerely, 
 
Natasha Haskey RD, Masters student 
Pediatric Dietitian 
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 Royal University Hospital 
103 Hospital Drive 
Saskatoon SK  S7N 0W8 
(306) 655-6512 
natasha.haskey@saskatoonhealthregion.ca 
 
Trial Summary 
An investigation into the effectiveness of low sulfate water, prebiotics and probiotics in 
increasing length of remission and quality of life in pediatric ulcerative colitis patients. 
Summary: A clinical research study for pediatric ulcerative colitis patients that are in 
clinical remission. 
Purpose: This is a research study to determine if low sulfate water, prebiotics and 
probiotics will increase the length of remission and improve quality of life in pediatric 
ulcerative colitis patients.  
Description: This is a 12 month study for pediatric clients between the ages of 8-18 
years of age (male and female), diagnosed with ulcerative colitis, who are in clinical 
remission.  Clients that are immuno-suppressed or have non-intact colons cannot 
participate in the study. Each study volunteer will be randomly assigned into a control or 
treatment group. A capsule and a powder will be provided to both the treatment and 
control groups to be administered on a daily basis. During the 12 months, study 
volunteers will be contacted by telephone interview and monitored bimonthly for 
symptomology by the study coordinator. In addition, study volunteers will be asked to 
keep a diary of their symptoms. The study coordinator will travel to complete chart 
reviews at the initial visit, 6 month and 1 year follow-up visits. All study volunteers, 
family members, researchers and study coordinator will be blinded to the treatment and 
placebo. 
 
Supporting Evidence for the Clinical Trial: Colonic microflora is altered in active 
ulcerative colitis (Fabia et al, 1993), and reduced numbers of Bifidobacteria have been 
found (Edman, 2000). In one uncontrolled study, probiotics maintained clinical 
remission in 75% of patients with mesalamine-intolerant ulcerative colitis (Venturi et al, 
1999). Probiotics have recently been used to successfully prevent the recurrence of 
chronic relapsing pouchitis in patients who have undergone ileoanal pouch anal 
anastomosis due to ulcerative colitis (Gionchetti, 2000). Remission of pouchitis has been 
induced by the administration of certain Lactobacillus species (Kuisma et al, 2003). 
While these studies support the efficacy of probiotics for pouchitis, much more evidence 
is required support the efficacy of probiotic therapy for ulcerative colitis. It is not clear 
whether multiple bacterial strains are required to induce or maintain remission or if 
combination therapy will provide synergistic effect. It is not know if the provision of 
Bifidobacteria will result in improved colonic health and extend the clinical remission of 
ulcerative colitis.  
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Pediatric ulcerative colitis results in poor intake, growth delay and morbidity, therefore, 
aggressive; combination therapy may be indicated to circumvent such drastic treatment 
options as colonic resection. Current nutritional management of ulcerative colitis has 
limited success in maintaining remission (Saskatoon Health Region, unpublished). 
Supplementation of inulin and Bifidobacteria, and sulfate reduction pose no known 
serious risks. We hypothesize that the reduction in sulfate and supplementation with the 
prebiotic, inulin and probiotic, Bifidobacteria will result in a significant increase in 
remission length in pediatric ulcerative colitis patients. 
 
Contact Information: 
 
Natasha Haskey RD, Masters student 
Pediatric Dietitian 
Royal University Hospital 
103 Hospital Drive 
Saskatoon SK  S7N 0W8 
(306) 655-6512 
natasha.haskey@saskatoonhealthregion.ca 
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1.3 Letter of Recruitment to Adult Gastroenterologists 
 
 
 
 
 
Food and Nutrition Services 
Royal University Hospital 
103 Hospital Drive 
Saskatoon SK  S7N 0W8 
Date 
 
Dear (insert doctor’s name here), 
 
I am coordinating a clinical trial with Dr. Garth Bruce MD, Wendy Dahl RD PhD and 
Susan Whiting PhD investigating the effectiveness of low sulfate water, prebiotics and 
probiotics on the length of remission and quality of life in ulcerative colitis patients.  
 
Our research team is currently recruiting ulcerative colitis patients in clinical remission, 
under the age of 40 years to participate in our clinical trial. Patients with non-intact 
colons and those considered to be immuno-compromised are excluded from 
participation.   
 
I am requesting your participation in this clinical trial by providing a confidential list of 
eligible client names, along with their date of birth and health services number, that meet 
the criteria as outlined in the previous paragraph. As the study coordinator, I will contact 
the potential study volunteers to discuss their participation in the study.         
 
The results of this study will be published and if you agree to participate, your name will 
be acknowledged. A summary of the clinical trial is attached to this letter. The 
University of Saskatchewan Biomedical Research Ethics Board has provided ethical 
approval for this study.   
 
I look forward to speaking with you in the near future.  If you have any questions, please 
call me at (306) 655-6512. 
 
Sincerely, 
 
Natasha Haskey RD, Masters student 
Pediatric Dietitian 
Royal University Hospital 
103 Hospital Drive 
Saskatoon SK  S7N 0W8 
(306) 655-6512 
natasha.haskey@saskatoonhealthregion.ca 
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Confirmation of Ethical Approval 
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 2.1 Ethical Approval for Phase I – Pediatric Pilot Study 
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2.2 Ethical Approval for Inclusion of Additional Sites 
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 2.3 Ethical Approval to Increase Recruitment and Increase Treatment Period 
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2.4 Ethical Approval to Increase Recruitment to Include Adult Subjects 
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 APPENDIX 3 
 
Consent Forms 
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 3.1 Written Consent 
3.1.1 Parent/Guardian Information and Consent Form       
PARENT/GUARDIAN INFORMATION AND CONSENT FORM              
 
Natasha Haskey, Pediatric Dietitian, Doctor (insert name here) and researchers in the 
College of Pharmacy and Nutrition, University of Saskatchewan are investigating the 
effect of “health-promoting” bacteria on ulcerative colitis. 
 
Study Title:  An investigation into the effectiveness of low sulfate water, prebiotic and 
probiotics on length of remission and quality of life in pediatric ulcerative 
colitis patients. 
 
Benefits:   There may be no direct benefit to your child for participating in this 
study. Your child is being asked to participate in this study because your 
child has been diagnosed with ulcerative colitis. 
 
Procedures: 
 
 1. Your child will be provided with and asked to consume inulin (or placebo) and 
health-enhancing bifidobacterium (or placebo) for 12 months. You and your 
child will not be told whether you received the placebo or the treatment until the 
conclusion of the study. 
  
 2.  Your child will be expected to consume one capsule of probiotic (or 
placebo)/day and 15 grams of inulin (dissolved in usual beverages) or placebo 
each day for up to one year.   
 
 3.  Every second month you will be called to gain consent to speak with your 
child. If your and your child's consent is gained, your child will be interviewed 
regarding their health using the SIBBQ questionnaire. 
 
 4.  The information regarding whether or not your child received the placebo or 
the treatment is available in the case of an emergency.   
 
Confidentiality:  
 
While absolute confidentiality cannot be guaranteed, every effort will be made to ensure  
that the information you provide for this study is kept entirely confidential. Your name  
and your child's name will not be attached to any information, nor mentioned in any  
study report, nor be made available to anyone except the research team.  
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 Participation is Voluntary: 
 
The participation of your child in this study is entirely voluntary. You and your child 
have the right to refuse to participate and to withdraw from the study at any time, for any 
reason.  Early withdrawal from the study will not result in the loss of health care services 
or result in any sort of penalty. For the telephone survey, your child does not have to 
answer any question that he/she does not want to.  
 
In the event that any new information is available that may affect your decision to allow 
your child's participation, the researchers will advise you. 
 
Potential Risks: 
 
The prebiotic and probiotics to be given in this study may result in changes in bowel 
symptoms including gas and bloating. There is the possibility of unforeseen risks during 
and following the study. 
 
Some of the questions on the SIBBQ telephone survey may be potentially upsetting. If 
responses to the telephone survey indicate that your child is experiencing serious 
difficulties with his/her physical or mental health, the clinical dietitian conducting the 
survey will forward these concerns to the attending physician. 
 
Research Related Injury: 
 
There will be no costs to you for your child's participation in this study. You will not be 
charged for any research procedures. In the event that your child becomes ill or injured 
as a result of participating in this study, necessary medical treatment will be made 
available at no cost to you. 
 
Dissemination of Results: 
 
Data resulting from this information will be submitted for publication in a medical or 
nutrition journal. If you wish, a report of the results of this study will be forwarded to 
you.  
 
Compensation: 
 
You will not receive an honorarium for your child's participation in this study. 
 
Contacts:  
 
If you have any questions with regards to this research project, please do not hesitate to 
contact the researchers below: 
    
Natasha Haskey  306 655 6512 
Wendy Dahl   306 655 1310 
Chris Arnold   306 655 5045  
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If you have any questions about your rights as a research subject, you may contact the 
chair of the Biomedical Ethics Board, c/o the Office of Research Services, University of 
Saskatchewan at (306) 966 4053. 
 
The contents of this consent form have been explained to me. I have been able to ask 
questions about the study and these questions have been answered to my satisfaction. I 
have received a copy of the consent form for my own records. 
 
Signatures: 
 
Parent/Guardian: _________________________ Date: __________________ 
 
Research Coordinator: _____________________ Date: __________________ 
 
Witness: _________________________ 
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 3.1.2 Participant Information and Assent Form  
 
PARTICIPANT INFORMATION AND ASSENT FORM 
   
Title of study:  An investigation into the effectiveness of low sulfate water, 
prebiotic and probiotics on length of remission and quality of life 
in pediatric ulcerative colitis patients. 
 
You are invited to be a volunteer in a project to study how "good bacteria" affect the 
health of people with ulcerative colitis. You are being asked to take part in this study 
because you have ulcerative colitis. 
 
Taking part in this study is not part of your schoolwork. This study is not part of your 
medical treatment. You do not have to take part in this study. If you decide to take part, 
you can quit at any time for any reason. Quitting the study will not result in any penalty 
or loss of health care services. 
 
If you volunteer for this study, 
 
 1.   You will be asked to take a capsule of "good bacteria" everyday for up to one          
  year. 
 2.   You will be asked to eat 15 grams (about one heaped tablespoon) of inulin (a  
  sugary powder made from a root vegetable) each day. The inulin can be mixed 
   with juice, milk, pop or foods.   
 3.   Taking your capsule and inulin will take about 5 minutes each day.  
 4.   You will be phoned by a dietitian about every two months and asked about your  
  how you are feeling. These calls will take about 15 minutes each time. There  
  will be 6 phone calls in one year. 
 
In this study, some of the volunteers will receive "placebos". The placebo capsules and 
inulin will look like the real "good bacteria" capsules and inulin, but will not be the 
good bacteria or the inulin. The placebos will be only a sugar and starch filler. You 
might be chosen for the placebo group. You will not know which group you were in 
until the end of the study.  
 
After eating good bacteria and inulin, you may notice changes in your bowel function. 
You may notice more or less gas and bloating. You may notice changes in your stools. 
You may notice changes in how often you need to pass stools.  
 
Being part of this study will be kept private. No one other than the research people will 
know that you are taking part in this study. No one at your school will be told about the 
study. What you tell the dietitian will also be private. She will not use your name to tell 
the other researchers about how you are feeling.   
 
The information we find out from this study will be used to write a paper for a medical 
or nutrition journal. No names of study participants will be used. 
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This study has been approved by the Biomedical Research Ethics Board (Bio-REB) of 
the University of Saskatchewan. 
 
If you have any questions about this research project, please call: 
 
Natasha Haskey  306 655 6512  
Wendy Dahl   306 655 1310 
Chris Arnold   306 655 5045  
 
If you have any questions about your rights as a research subject, you may contact the 
chair of the Biomedical Ethics Board, c/o the Office of Research Services, University of 
Saskatchewan at (306) 966 4053. 
 
The contents of this consent form have been explained to me. I have been able to ask 
questions about the study and these questions have been answered to my satisfaction. I 
have received a copy of the consent form for my own records. 
 
Signatures: 
 
Study Volunteer: _________________________ Date: __________________ 
 
Research Coordinator: _____________________ Date: _________________ 
 
Witness:_______________________________
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3.2 Verbal Consent to Administer the SIBDQ to Study Participants 
 
 
TELEPHONE SCRIPT FOR ADMINSTRATION OF SIBDQ TO CHILD 
 
Section A 
Hello, may I speak to the parent or guardian of (insert child’s name here). 
 
My name is Natasha Haskey; I am a Pediatric Dietitian that works at Royal University 
Hospital with Doctor (insert doctors name here). I am calling in regards to the research 
study that Doctor (insert doctors name here, researchers and myself are completing on 
how changing the diet may affect the symptoms of Ulcerative Colitis. We are asking for 
consent for your child to participate in a 15-minute telephone questionnaire. The 
questionnaire has been designed to find out how your child has been feeling in the last 
two months as a result of Ulcerative Colitis. Your child will be asked some questions 
about their symptoms related to Ulcerative Colitis, the way they have been feeling in 
general and how their mood has been. 
 
Some of the questions may be potentially upsetting or embarrassing; your child is under 
no obligation to answer these questions. Completion of the telephone questionnaire is 
voluntary and your child may withdraw from the survey at any time without any 
explanation or effect on health care services. Every effort will be made to ensure that the 
information collected today remains confidential. Your child’s name will not be linked to 
any information, nor mentioned in any study report, nor be made available to anyone 
except the research team. 
 
If you have any questions with regards to this project, you may contact 
 
Natasha Haskey 655-6512 
Wendy Dahl  655-1310 
Chris Arnold  655-5045 
 
If you have any questions about your child’s rights as a research subject, you may 
contact the chair of the Biomedical Ethics Board, c/o the Office of Research Services, 
University of Saskatchewan at 966-4053. 
 
Do I have your verbal consent for your child to participate in the telephone 
questionnaire?  
 
If consent provided by parent or guardian, continue to section B. 
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 Section B 
 
Hi, (insert child’s name here) my name is Natasha Haskey; I am a Pediatric Dietitian 
that works at Royal University Hospital with Doctor (insert doctor’s name here). I was 
wondering if I could ask you some questions about how you have been feeling in the last 
2 months as a result of Ulcerative Colitis. It will take about 15 minutes of your time.  
Some of the questions may be upsetting or embarrassing to you. If any of the questions 
make you feel that way; you do not have to answer them. If at any time you do not want 
to continue with the questions, let me know and our conversation can end.  You do not 
have to give me any reason for why you do not want to continue. If you decide to stop, I 
will not be angry or upset with you and you will not be penalized in any way.  The 
information I collect today will remain confidential. It will not be shared with other 
people in the study, parents or teachers. Do you have any questions? Do I have your 
consent to ask some questions?    
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Study Diary
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 APPENDIX 5  
 
The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) 
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 SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE 
This questionnaire is designed to find out how you have been feeling during the last two 
weeks. You will be asked about symptoms you are having as a result of your 
inflammatory bowel disease, the way you have been feeling in general, and how your 
mood has been.  
1. How often has the feeling of fatigue or of being tired and worn out been a problem for 
you during the last two weeks? Please indicate how often the feeling of fatigue or 
tiredness has been a problem for you during the last two weeks by picking one option 
from the following:  (SYSTEMIC) 
? All of the time 
? Most of the time 
? A good bit of the time 
? Some of the time 
? A little of the time 
? Hardly any of the time 
? None of the time 
2. How often during the last two weeks have you had to delay or cancel a social 
engagement because of your bowel problem? Please choose an option from the 
following: (SOCIAL) 
? All of the time 
? Most of the time 
? A good bit of the time 
? Some of the time 
? A little of the time 
? Hardly any of the time 
? None of the time 
 
3. How much of the time during the last two weeks have you been troubled by a feeling 
of having to go to the toilet even though your bowels were empty? Please choose an 
option from the following: (BOWEL) 
? All of the time 
? Most of the time 
? A good bit of the time 
? Some of the time 
? A little of the time 
? Hardly any of the time 
? None of the time 
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 4. How much of the time during the last two weeks have you felt angry as a result of 
your bowel problem? Please choose an option from the following: (EMOTIONAL) 
? All of the time 
? Most of the time 
? A good bit of the time 
? Some of the time 
? A little of the time 
? Hardly any of the time 
? None of the time 
5. Overall, in the last two weeks, how much of a problem have you had passing large 
amounts of gas? Please choose an option from the following: (BOWEL) 
? A major problem 
? A big problem 
? A significant problem 
? Some trouble 
? A little trouble 
? Hardly any trouble 
? No trouble 
6. Overall, in the last two weeks, how much of a problem have you had maintaining or 
getting to the weight you would like to be? Please choose an option from the following: 
(SYSTEMIC) 
? A major problem 
? A big problem 
? A significant problem 
? Some trouble 
? A little trouble 
? Hardly any trouble 
? No trouble 
7. How often during the last two weeks have you felt relaxed and free of tension? Please 
choose an option from the following: (EMOTIONAL) 
? All of the time 
? Most of the time 
? A good bit of the time 
? Some of the time 
? A little of the time 
? Hardly any of the time 
? None of the time 
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 8.  How much difficulty have you had, as a result of your bowel problems, doing leisure 
or sports activities you would have liked to have done over the last two weeks? Please 
choose an option from the following: (SOCIAL) 
? A great deal of difficulty, activities made impossible 
? A lot of difficulty 
? A fair bit of difficulty 
? Some difficulty 
? A little difficulty 
? Hardly any difficulty 
? No difficulty; the bowel problems did not limit sports or leisure activities 
9. How often during the last two weeks have you been troubled by pain in the abdomen? 
Please choose an option from the following: (BOWEL) 
? All of the time 
? Most of the time 
? A good bit of the time 
? Some of the time 
? A little of the time 
? Hardly any of the time 
? None of the time 
10. How often during the last two weeks have you felt depressed or discouraged? Please 
choose an option from the following: (EMOTIONAL) 
? All of the time 
? Most of the time 
? A good bit of the time 
? Some of the time 
? A little of the time 
? Hardly any of the time 
? None of the time 
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 APPENDIX 6 
 
Chart Review Data Collection Sheet
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 CHART REVIEW FORM 
 
Pediatric Ulcerative Colitis Patients  Name:                   
DOB: 
Date Began Study   
Age at Randomization (years/months)   
Sex   
Age at Diagnosis (years/months) 
Date   
Location of the Disease   
Medical Management History    
Current Status   
Current Medication 
  
Date of Last Remission 
  
Length of Last Remission   
Birth Place   
Parent's Birth Place   
Current Dwelling (urban/rural)   
Drinking Water Source   
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Schematic of Recruitment 
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Randomization 
Treatment  
5 subjects 
Placebo 
5 subjects 
Open label case 
study on 
treatment 
1 patient 
dropout 
after 3 
months 
2 subjects 
remission 
2 subjects drop-
out prior to 
starting 
treatment  
3 subjects 
remission with 
intermittent 
symptoms 
2 subjects 
relapse 
Open label case 
study on 
treatment in 
remission 
(10 months of follow-up) 
P
h
a
s
e
 
1 
P
h
a
s
e
 
2
 
&
 
3 
6 pediatric subjects from 
Phase 1 (3 placebo, 1 
from relapse, 2 
treatment) 
Open label case 
study on 
treatment in 
remission 
10 adult subjects with UC 1 pediatric 
patient 
(new) 
Treatment
Relapse: 
2 adult, 2 pediatric 
7 subjects ineligible (5 with 
colectomy, 1 receiving 
Remicade®, 1 physician 
would not approve therapy) 
3 adult 
subjects  
with 
active UC 
Open label case 
study on 
treatment in 
remission 
Remission: 
1 adult, 4 pediatric 
Dropout: 
1 pediatric 
Figure 3.1 Results and Study Design of Phase 1 and 2 of the trial. Phase 1 was a double 
blind placebo controlled randomized trial. Phase 2 & 3 was an open label trial. 
1 subject did 
not attend 
appointments 
  (>24 months follow-up) 
  (>12  months follow-up or relapse) 
16 pediatric subjects with UC in remission (14 
subjects eligible to participate) 
1 pediatric patient with 
active UC 
3 subjects 
did not 
want to 
participate 
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 APPENDIX 8 
 
Clinical Course 
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Appendix 8.1 Clinical Courses in Placebo and Treatment Subjects (Phase I – 
Pediatric Pilot Study) 
 
 
AOpen label case  
†Severe symptoms = presence of blood or mucous in the stool or presence of abdominal pain 
 
Case 1
Case 2
Case 3 
Case 4
Case 5
2 4 8 10 6 
Months 
Case 6
Case 7
Case 8 
 Case 9A
Synbiotic therapy 
Exacerbation 
Discontinued study 
Placebo 
Severe symptoms†
LEGEND: 
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 Appendix 8.2 Clinical Course of Phase II Pediatric Subjects. 
 
 
AOpen label case  
†Severe symptoms = presence of blood or mucous in the stool or presence of abdominal 
pain.
Case 1
Case 2
Case 3 
Case 4
Case 6
2 4 8 10 Months 
Case 7
Case 10
Case 9A
Synbiotic therapy 
Exacerbation 
Discontinued study 
Placebo 
Severe symptoms†
LEGEND: 
6 14 16 12 
14 months
26 months
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